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ABSTRACT OF DISSERTATION

PRIMARY AND SECONDARY PREVENTION OF HEPATITIS C VIRUS AMONG
RURAL APPALACHIAN PEOPLE WHO USE DRUGS
Hepatitis C virus (HCV) remains a major cause of morbidity and mortality worldwide,
with 3% of the global population chronically infected. Clinical impacts in the United States are
projected to increase for two decades, and mortality attributed to HCV now exceeds HIV.
Injection drug use (IDU) is the most common route of transmission in the developed world.
Advances in treatment offer hope of mitigating HCV impacts, but substantial barriers obstruct
people who inject drugs (PWID) from receiving care, particularly in medically underserved
regions including Central Appalachia. This study assessed IDU paraphernalia sharing
longitudinally over 24 months in a sample of 283 rural PWID recruited by respondent‐driven
sampling. Medical follow‐up among 254 seropositive participants was also assessed using
discrete‐time survival analysis.
HCV‐positive screening was associated with reduced IDU sharing frequency 18 months
after testing compared to seronegative participants (adjusted OR [aOR]=1.4, 95% confidence
interval [CI]: 1.0‐1.9), but this effect was not sustained. HCV‐positive participants were less likely
to cease IDU 6 months after testing (aOR=0.4, 95% CI: 0.2‐0.7). Predictors negatively associated
with decreased IDU sharing included recent unprotected sex, sedative use, and frequency of
prescription opioid IDU; protective associations included female gender and religious affiliation.
IDU cessation was negatively associated with ever being incarcerated, recent unprotected sex
with PWID, heavy alcohol use, lifetime use of OxyContin®, and baseline frequency of
prescription opioid IDU; protective associations included number of dependents, receiving
disability payments, and substance abuse treatment. Drug‐specific associations decreasing IDU
cessation included recent illicit use of OxyContin®, other oxycodone, and cocaine.
150 of 254 (59%) seropositive participants saw a clinician after HCV‐positive screening
and counseling, 35 (14%) sought treatment, and 21 (8%) received treatment. Positive predictors
of following up with a clinician following testing and counseling included health insurance,
internet access, past substance abuse treatment, generalized anxiety disorder, and recent
marijuana use. Factors decreasing odds of follow‐up included major depression, lifetime illicit
methadone use, and recent legal methadone. These analyses shed valuable light on
determinants of behavior impacting primary and secondary HCV prevention. Integrated,
multidisciplinary approaches are recommended to meaningfully impact epidemic levels of HCV
among rural PWID in Eastern Kentucky.
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Chapter 1
The Quiet Killer:
Overview of hepatitis C virus

1.1 Introduction
Since its discovery in 1989 (Alter 1999; Houghton 2009; Houghton 2009), hepatitis C
virus (HCV) has emerged as a major global health problem. The virus is prevalent worldwide,
with nearly 200 million individuals now HCV antibody‐positive (Mohd Hanafiah, Groeger et al.
2013), approximately 3% of the human population. Moreover, HCV is the most common blood‐
borne pathogen in the United States (Prevention 2014), where mortality stemming from the
pathological impacts of chronic infection now exceed that of human immunodeficiency virus
(HIV) (Ly, Xing et al. 2012). More ominously, despite declining incidence, the public health
impacts of HCV are projected to worsen for at least the next two decades (Davis, Alter et al.
2010), adding substantially to the already crippling healthcare costs of HCV and demand for liver
transplantation, for which HCV is the number one indication in most developed countries
worldwide, including the United States (Brown and Gaglio 2003; Wiesner, Sorrell et al. 2003).
The estimated incremental cost of HCV infection is over $23,000 annually per individual, and
infection is associated with significantly higher risk of hospitalization, depression, cirrhosis, liver
cancer and transplantation (McCombs, Yuan et al. 2011). The estimated economic impact of
HCV in the United States between 2010 and 2019 is projected at over 190,000 deaths and $10.7
billion in direct medical costs (Wong, McQuillan et al. 2000), while the total global burden of
HCV is now estimated at over 483,000 deaths per year (Lim, Vos et al. 2012) and over 16,000 per
year in the United States (Centers for Disease Control and Prevention 2011), and growing
(Wong, McQuillan et al. 2000). For these reasons, HCV is a major biomedical and public health
challenge on multiple levels: individual, healthcare system, and society as a whole. Thus,
vigorous public health outreach efforts fueled by epidemiological research of high‐risk
populations along with clinical management driven by evidence‐based guidelines are crucial and
ideally, complementary components in the battle to control HCV. With the goal of informing
public health intervention efforts, the data presented in later chapters of this dissertation
address issues specifically related to primary (transmission) and secondary (disease
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manifestations) prevention of HCV in a infrequently studied medically underserved population
in the rural Appalachian region of Eastern Kentucky.

1.2 Virology and taxonomy
(HCV) is a single‐stranded, positive‐sense RNA virus in the genus Hepacivirus of the
family Flaviviridae. HCV’s 9.6‐kilobase viral genome encodes a polyprotein precursor of
approximately 3000 amino acids (Moradpour, Penin et al. 2007) that is subsequently cleaved
into three structural (core, envelope glycoproteins 1 and 2), six non‐structural (NS2, NS3, NS4A,
NS4B, NS5a, NS5b), and several other proteins serving a variety of catalytic and other molecular
functions (Moradpour, Penin et al. 2007; Houghton 2009; Chevaliez and Pawlotsky 2012). In its
infectious form, HCV primarily circulates in serum bound to low‐density lipoprotein (LDL) and
very low‐density lipoprotein (VLDL), although it can also circulate as free virions or bound to
serum antibodies (Andre, Perlemuter et al. 2005). Upon cellular entry, the viral protein capsid
releases its RNA genome into host cytoplasm, which then serves as messenger RNA to code for
the HCV polyprotein (Chevaliez and Pawlotsky 2012). This protein precursor is targeted to the
host endoplasmic reticulum, were it is processed by an assortment of host and viral proteins.
Among the final protein products is NS5B, a viral RNA‐dependent RNA polymerase that lacks a
nucleotide “proofreading” function (Moradpour and Penin 2013). A critical component of HCV
replication, NS5B generates frequent uncorrected errors such as point mutations and inversions
in carrying out its molecular function. In fact, the genetic diversity of HCV is over ten‐fold
greater than that of HIV (Simmonds 2004; Moradpour, Penin et al. 2007) and chronically
infected individuals typically generate and clear upwards of 1012 virions per day with a mean
half‐life of 2.7 hours (Neumann, Lam et al. 1998), warranting multi‐drug treatment regimens to
treat HCV and hindering of research towards a preventive vaccine
This error‐prone replication and rapid mutation result in a highly unstable and
heterogeneous viral genome, even within individuals in the form of multi‐strain superinfection,
or multiple viral genotypes coexisting within an infected individual (Farci, Shimoda et al. 2000;
Moradpour, Penin et al. 2007). Moreover, HCV reinfection among individuals who have cleared
the virus occurs at a rate of 2.4 cases per 100 person‐years among people who use drugs and 6.4
cases per 100 person‐years among people who inject drugs (PWID) (Aspinall, Corson et al. 2013;
Grady, Schinkel et al. 2013), implying that at best there is only partial immunity induced
following viral clearance. HCV’s ability to evade immune recognition have hindered efforts to
2

synthesize an effective vaccine against HCV (Randal 1999; NIH 2002), although a few potential
compounds are in phase 2 clinical trials (Shi and Ploss 2013; Swadling, Klenerman et al. 2013).
Due to this high genetic variability, HCV is often referred to as a “quasispecies.” The
virus has been formally delineated into seven major genotypes “1” through “7”, which vary in
sequence between one another by at least 30%, as well as 67 subtypes delineated by single
lower case letters: a, b,…k and so on (Smith, Bukh et al. 2013). Genotypes vary in prevalence
between geographic regions and have major impact on disease progression, long‐term
prognosis, and efficacy of treatment (Gottwein, Scheel et al. 2009). Genotype 1 is most
prevalent in the United States (Mahaney, Tedeschi et al. 1994), accounting for 73% of a sample
of 6807 chronic HCV (CHC) patients, with the remainder composed primarily of genotypes 2 and
3 (Blatt, Mutchnick et al. 2000). Genotype 3a is common among PWID in Europe and in
individuals infected prior to July 1992 by non‐sterile blood, tissue, and organ donation (Lavanchy
2011; Klevens, Hu et al. 2012). Egypt primarily features genotype 4 and also the highest
prevalence of HCV of any country worldwide, with overall prevalence between 15‐20% (el‐
Sayed, Gomatos et al. 1996; Lavanchy 2011). This is largely due to a long‐term public campaign
to parenterally treat endemic schistosomiasis along the Nile River Valley, which utilized
inadequate sterilization procedures until halted in the 1980s (Frank, Mohamed et al. 2000).
Overall, Central Africa has primarily genotypes 4 and 5, whereas West African features primarily
genotypes 1 & 2 (Lavanchy 2011). In much of Asia and Southeast Asia in particular, genotype 6 is
most prevalent (Li, Chan et al. 2009) along with genotypes 1 and 3, which are widely distributed
worldwide (McOmish, Yap et al. 1994; Lavanchy 2011).
HCV genotype can also have major impact in terms of hepatic disease progression and
long‐term prognosis. Patients chronically infected with genotype 1 are more likely to experience
a more aggressive disease course and poor response to treatment (Nainan, Alter et al. 2006;
Klevens, Hu et al. 2012). Treatment success is defined in terms of sustained virologic response
(SVR), which is the absence of HCV RNA (under detectable limits of 10‐15 international units [IU]
per mL) for at least 6 months following cessation of treatment (Thomas 2013). Regarding
genotype 1, the original interferon‐only treatment protocols featured an SVR rate of less than
15% (Hoofnagle and di Bisceglie 1997). Probability of SVR for genotype 1 patients increased with
the addition of ribavirin to the 48‐week treatment protocol in 1998 (McHutchison, Gordon et al.
1998) and then again in 2001 with the addition of polyethylene glycol to interferon‐α to create
the current form of the drug, peginterferon‐α (Manns, McHutchison et al. 2001). Nonetheless,
3

SVR rates for patients with genotype 1 still lagged behind those with genotypes 2 and 3, and
significant problems with toxicity remained (Manns, McHutchison et al. 2001). In recent years ,
the relatively novel class of direct‐acting antiviral (DAA) drugs such as boceprevir and telaprevir,
specifically targeted to HCV genotype 1, have made great strides in improving probability of SVR
and reducing treatment time in these patients (Casey and Lee 2013). The second generation of
DAAs such as sofosbuvir and ledipasvir will likely enable interferon‐free treatment protocols
with a more benign adverse effect profile in the near future (EASL 2013), as detailed in the
Screening and Disease Management section below. There is significant potential that the
continued advances in HCV drug treatment will enable substantial improvements in treatment
uptake levels and reduced HCV prevalence in the years to come.

1.3 Epidemiology
Upwards of 3% of the world’s population has antibodies to HCV (Shepard, Finelli et al.
2005), a total exceeding 185 million individuals (Mohd Hanafiah, Groeger et al. 2013; Thomas
2013). Although HCV incidence has been stable in the United States since 2004 following a peak
in the mid‐1980s (Armstrong, Alter et al. 2000; Ward 2013), the estimated total with CHC now
exceeds 3 million individuals (1.3% CHC prevalence; 1.6% HCV seroprevalence) (Armstrong,
Wasley et al. 2006). Due to the exclusion of certain high‐risk groups, this figure may
underestimate the total number of individuals with CHC in the United States by up to 2 million,
bringing the number of Americans with chronic infection to over 5.2 million (Chak, Talal et al.
2011). In one study, CHC prevalence in the United States was estimated to have peaked in 2001
with a total of 3.57 million chronically infected individuals (Davis, Alter et al. 2010). As depicted
in Figure 1.1, however, number of reported cases of acute HCV in the United States has increase
since 2009 (Centers for Disease Control and Prevention 2011). Moreover, there remains a major
public health problem with regard to the “baby boomer” cohort born between 1940 and 1965,
which accounts for more than 75% of the population chronically infected with HCV, with the
highest prevalence consistently found among this cohort as they age (Armstrong, Wasley et al.
2006; Rustgi 2007; Davis, Alter et al. 2010; Thomas 2013). Because of this, recommendations
have been amended to promote screening of all individuals born between 1945 and 1965,
regardless of behavioral risk history, in order to address the growing burden of severe liver
disease in the United States (Smith, Morgan et al. 2012; Moyer 2013).
4

Among particular high‐risk groups, HCV prevalence is considerably higher. While many
economically developing nations remain plagued by high rates of HCV infection resulting
primarily from non‐sterile medical procedures, in the United States and most other post‐
industrial countries the primary route of HCV transmission is now injection drug use (IDU). IDU
readily provides the ideal vehicle for efficient transmission of the virus, percutaneous exposure
to infected blood (Amon, Garfein et al. 2008; Thomas 2013). Hyperendemic HCV has been
reported in all previously studied populations of people who inject drugs (PWID), among whom
prevalence is significantly elevated relative to the general population; a global review of findings
published between 1998 and 2005 reported HCV prevalence among PWID exceeding 50% in 49
countries and territories (Aceijas and Rhodes 2007). Another systematic review incorporating 77
nations reported that 60‐80% of PWID were HCV seropositive in 25 countries, and 80% or higher
were seropositive in 12 countries, with a midpoint seroprevalence of 73.4% among PWID
worldwide (Nelson, Mathers et al. 2011).
In the United States, HCV seroprevalence among PWID varies but is consistently
elevated from that of the general population (Alter 2011). Seroprevalences between 35% and
65% were reported in four large cohorts drawn from urban PWID in Baltimore, Chicago, Los
Angeles, and New York City, although prevalence declined among PWID in Los Angeles and
Baltimore between 1994 and 2004 (Amon, Garfein et al. 2008). Nonetheless, sporadic outbreaks
and high regional HCV prevalences have been reported recently in the United States , especially
in suburban and rural areas (Centers for Disease Control and Prevention 2008; 2011; 2012). HCV
seroprevalence in a sample of PWID in Central Appalachian region of eastern Kentucky was
reported to be 54.6% (Havens, Lofwall et al. 2013), and Kentucky has led the nation in cases of
acute HCV in reported annually since 2008 (Centers for Disease Control and Prevention 2011).
For these reasons, Central Appalachia is in need of expanded public health intervention efforts
and focused research to inform such efforts; more detail concerning the Central Appalachian
region and HCV among people who use and inject drugs can be found in the latter sections of
this chapter.

1.4 Clinical course and public health impact
HCV infection is characterized by an insidious clinical course, typically with an
asymptomatic acute phase and a protracted trajectory of chronic infection stretching over two
or three decades before symptoms manifest. Indeed, it has been hypothesized that a foremost
5

selective advantage of HCV is its ability to thrive unnoticed within host hepatocytes, replicating
productively without causing clinical consequences for many years through sophisticated viral
mechanisms to evade or dampen host immune responses (Foy, Li et al. 2005) and induce long‐
term tolerance of CHC until hepatic damage reaches an advanced stage (Thomas 2013). Acute
HCV is defined as occurring within 6 months of viral exposure and is symptomatic in less than
one‐third of individuals (Hoofnagle 1997; NIH 2002), substantially limiting awareness of HCV
status among infected individuals. When symptomatic, acute HCV includes a range of clinical
effects including jaundice, and up to ten‐fold elevation of hepatic aminotransferase enzymes
(Hoofnagle 1997; Alberti, Chemello et al. 1999). Acute HCV spontaneously resolves in 10‐40% of
individuals, resulting in detectable serum antibodies but no long‐term clinical consequences
(Hoofnagle 1997; Lee, Yang et al. 2012).
The majority of serious clinical complications resulting from HCV occur over a 30‐year
period among individuals with chronic infection, which develops in approximately 70‐80% of
those infected with the virus (NIH 2002; Lavanchy 2011; Lee, Yang et al. 2012). Among
individuals chronically infected, approximately 20% progress to serious liver disease including
advanced hepatic fibrosis and cirrhosis, which can eventually progress to decompensated
cirrhosis, particularly among individuals with other risk factors such as moderate to heavy
drinking, comorbid HIV and/or hepatitis B, smoking, obesity and insulin resistance,
schistosomiasis, and iron overload. Modifiable lifestyle factors are crucial determinants of CHC
progression (Missiha, Ostrowski et al. 2008). Patients with decompensated cirrhosis suffer
substantially increased mortality and a constellation of signs and symptoms related to end‐stage
liver failure, including bleeding esophageal and rectal varices, splenomegaly, ascites, hepatic
encephalopathy, asterixis, jaundice, hypoalbumenia, respiratory alkalosis, coagulopathy and
easy bruising. Among these individuals, liver transplantation (LT) is the only remaining
treatment option (NIH 2002; U.S. Department of Veteran's Affairs: National Hepatitis C Program
Office 2007). In addition, an array of extrahepatic manifestations of CHC cause significant
morbidity as well, including mixed cryoglobulinemia vasculitis, membranoproliferative
glomerulonephritis, porphyria cutanea tarda, thyroid disorders, lichen planus, depression and
other psychiatric disorders, and a potential link to type 2 diabetes (Mehta, Brancati et al. 2000;
NIH 2002; Thomas 2013).
Globally, HCV is responsible for an estimated 583,000 deaths per year (Lim, Vos et al.
2012). The majority of CHC‐related mortality is caused by decompensated cirrhosis rather than
6

hepatocellular carcinoma (NIH 2002), and the vast majority of individuals with HCC are also
clinically cirrhotic (El‐Serag 2012). Ultimately, up to 5% of cirrhotic individuals with CHC develop
hepatocellular carcinoma (HCC), the most common form of liver cancer worldwide (Hoofnagle
2002). HCC has among the worst prognoses of all cancers, with 5‐year survival rates under 18%
and relatively poor treatment options, particularly in later stages of disease (Altekruse, McGlynn
et al. 2012; Padhya, Marrero et al. 2013). Although 85% of the cases of liver cancer occur in the
developing world and are caused by hepatitis B virus, in North America HCV is the most common
cause of HCC, which is now among the fastest‐growing of all cancer types (El‐Serag 2012). In the
United States, morbidity and mortality due to CHC are projected to increase over the next two
decades, as the cohort infected between 25 to 45 years old ages (Davis, Alter et al. 2010). This
group accounts for over 75% of CHC in the U.S., and the severe hepatic complications of CHC
most often develop in individuals over 60 years of age (Thomas 2013). For this reason, even
conservative projections indicate the brunt of the HCV‐related healthcare burden in the United
State is yet to come. In 2002, CHC caused an estimated 10,000 to 12,000 deaths in the United
States based on death certificate information (NIH 2002), although this is a moderate estimate.
More recent estimates put the number of deaths in the United States annually due to CHC at
over 15,000 per year (Ly, Xing et al. 2012), with incidence of both decompensated cirrhosis and
HCC predicted to continue increasing for 10 more years. Given current levels of screening,
treatment, and drug efficacy, CHC‐related mortality is projected to peak in the United States in
2022, and 283,378 deaths are estimated between 2020 and 2029 due to serious liver disease
(Davis, Alter et al. 2010). In light of these projections, it is clear that demand for LT will
significantly increase in the decades to come. In the United States, HCV is the most common
cause of LT (NIH 2002), with CHC‐related cirrhosis and/or HCC being the primary indication in
over 30% of individuals on the waiting list for LT procedures (Berg, Steffick et al. 2009). HCV is
the most common cause of LT in many other developed countries as well, along with hepatitis B
virus‐induced cirrhosis and HCC (Perz, Armstrong et al. 2006), which predominates in most Asian
countries (El‐Serag 2012; Liao, Yang et al. 2012).
With regard to mitigating disease progression, several host factors accelerate disease
progression due to CHC. Foremost among these are older age at time of infection, male gender,
alcohol use (particular at levels above 30g/day for men and 20g/day for women), concurrent
HIV, concurrent HBV, and miscellaneous other factors, including iron overload conditions such
as hemochromatosis, non‐alcoholic fatty liver disease, insulin resistance/obesity,
7

schistosomiasis, hepatotoxic drugs, and various environmental toxins (NIH 2002; Missiha,
Ostrowski et al. 2008). As a modifiable behavioral target with robust potential to improve the
long‐term prognosis, alcohol use among individuals with CHC is of particular interest as a form
of secondary disease prevention (Tagger, Donato et al. 1999; Siu, Foont et al. 2009; Drumright,
Hagan et al. 2011). Reducing or eliminating alcohol consumption is included in standard post‐
test counseling materials to be provided to individuals testing HCV‐positive, along with
messages to reduce the likelihood of spreading the virus to others by common routes of
transmission (Ghany, Strader et al. 2009), which are detailed in chapter 2. However, HCV‐
seropositive status disclosure and standard counseling has not been found to reduce alcohol
consumption in most drug‐using samples, and the same held true among HCV‐seropositive
individuals relative to their seronegative counterparts in a rural Appalachian sample of people
who use drugs (Stephens and Havens 2013).

1.5 HCV screening and management
Clinical management of HCV requires individual‐level awareness of HCV infection.
Screening and identifying individuals infected with HCV remains a primary challenge to
mitigating the impact of CHC worldwide. Population‐based studies in the U.S. indicate that less
than 50% of HCV‐positive individuals are aware of their status, and of this subgroup only 3.7%
were tested by a doctor because of their HCV risk profile (Denniston, Klevens et al. 2012). Other
researchers have reported that HCV risk advising (Shehab, Orrego et al. 2003), assessment, and
screening procedures are suboptimal among primary care physicians in the U.S., with screening
rates of only 8% among high‐risk individuals (Almario, Vega et al. 2012), despite long‐standing
national guidelines that individuals with known risk factors for HCV be serotested (Centers for
Disease Control and Prevention 1998; Ghany, Strader et al. 2009). Furthermore, as previously
mentioned, CDC recommendations now formally advise the screening of all individuals born in
the United States between 1945 and 1965, as this birth cohort is likely to experience the
majority of CHC‐related clinical impacts in the decades to come (Davis, Alter et al. 2010; Thomas
2013). The amended guidelines indicating an individual should be screened for HCV antibodies
are summarized below in Table 1.
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Table 1.1
Recommended guidelines indicating individuals should be screened for HCV
 Persons who have ever injected illegal drugs
 Persons who are human immunodeficiency virus (HIV)‐positive
 Persons who have received clotting factor concentrates before 1987
 Persons who received blood from a donor who later tested HCV‐positive
 Persons who received blood or blood component transfusion before July 1992
 Persons who received an organ transplant before July 1992
 Healthcare, emergency medical, and public safety workers following needle stick,
sharps, or mucosal exposure to HCV‐positive blood
 Persons who have ever been on long‐term hemodialysis
 Persons with persistently elevated alanine aminotransferase levels (ALT)
 Children born to HCV‐positive women
 Current sexual partners of HCV‐infected individuals
 Individuals born between 1945 and 1965

Medical assessment and indications for treatment
At the point of receiving medical evaluation after a positive HCV serotest, important
decisions face the patient and physician. Given the substantial cost, time and personal
commitment requirements, and potential adverse effects of HCV pharmacotherapy,
determining patient eligibility for treatment is vital, and approaches vary between medical
cultures and individual clinicians. The initial management step of an HCV antibody‐positive
patient is to assess for active infection via quantification of serum HCV RNA level, typically by
real‐time polymerase chain reaction (RT‐PCR). A genotyping assay should also be performed on
all patients for whom antiviral treatment is being considered, as genotype dictates the therapy
protocols outlined in the following section. Liver biopsy or non‐invasive tests such as FibroSure®
that assess serum biomarkers to determine hepatic fibrosis staging may also be considered for
the purposes of prognostic and treatment determination, at the discretion of the physician and
patient (Ghany, Strader et al. 2009).
Because of the adverse effect profile of many HCV drugs (Casey and Lee 2013) and the
high prevalence (50‐80%) of illicit drug use and IDU among individuals with HCV infection
(Shepard, Finelli et al. 2005; Aceijas and Rhodes 2007), decisions regarding treatment eligibility
can be complex for healthcare providers. There are many potential adverse effects of ribavirin
and pegylated interferon, including anemia and other hematologic disorders (leukopenia,
neutropenia, thrombocytopenia), myalgias, fever, pruritis, rash/dermatitis, flu‐like symptoms,
nausea, weight loss, thyroid disorders, headache, insomnia, anxiety, and depression (NIH 2002;
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Casey and Lee 2013). Moreover, with the addition of the first‐generation direct‐acting antivirals
(DAA) drugs boceprevir and telaprevir to treatment regimens, the degree of hematologic
(particular with boceprevir), dermatologic (including Steven‐Johnson syndrome with telaprevir),
gastrointestinal adverse effects, and drug interactions are substantially increased (Gaetano and
Reau 2013). The second generation of DAAs such as sofosbuvir and ledipasvir featured
significantly increased efficacy and lower toxicity relative to older drugs, although adverse
effects and drug interactions remain an issue, and the cost of HCV treatment has substantially
increased (Thomas 2013; Hoofnagle and Sherker 2014). The formal guidelines for U.S. physicians
emphasize the highly patient‐ and situation‐specific nature of determining treatment eligibility
among CHC patients, summarized by the American Association for the Study of Liver Diseases
(AASLD) as follows (Ghany, Strader et al. 2009):
Treatment decisions should be individualized based on the severity of liver
disease, the potential for serious side effects, the likelihood of treatment
response, the presence of comorbid conditions, and the patient’s readiness for
treatment
With this in mind, specific guidelines with regard to whom treatment is “widely accepted” from
the American Association for the Study of Liver Diseases (AASLD) are summarized below in Table
2.
AASLD guidelines also give individualized recommendations for making the decision to
treat five specific CHC patient subgroups: children and individuals with renal disease, major
depressive disorder, active substance abuse, or HIV coinfection. With regard to patients who are
actively using and/or injecting illicit drugs, the original NIH consensus statement advised
withholding treatment from patients with a history of drug injection until a period of IDU
cessation lasting at least 6 months had occurred (NIH 1997). NIH amended its consensus
statement in 2002, advising individualized assessment of patients currently injecting drugs,
along with an advisory to couple HCV therapy with addiction treatment and opioid substitution
therapy (OST) (NIH 2002). Current AASLD guidelines for HCV management continue to
emphasize a highly individualized approach, reiterating that it remains “important to consider
the individual issues that may affect the risks and benefits of treatment of HCV infection in
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Table 1.2
Characteristics of individuals for whom HCV drug treatment is widely accepted
 18 years of age or older
 HCV RNA detectable in serum
 Liver biopsy showing chronic hepatitis with “bridging” grade fibrosis or higher
 Compensated liver disease (total serum bilirubin <1.5g/dL; INR 1.5; serum albumin
>3.4; platelet count ≥75,000/mm3) without evidence of decompensation (hepatic
encephalopathy or ascites)
 Hemoglobin ≥13g/dL for men or ≥12g/dL for women; neutrophil count ≥155mm3;
creatinine <1.5mg/dL
 Symptomatic cryoglobulinemia
 Willing to be treated and adhere to treatment requirements
 No absolute contraindications (see Table 3)
persons who use illicit drugs, rather than to make categorical recommendations” (Ghany,
Strader et al. 2009). This conservative approach is supported by some studies of HCV treatment
failure among active PWID (Alvarez‐Uria, Day et al. 2009) and to some extent by intuition, with
regard to the unstable lifestyle and inadequate social support resources typical of many people
actively using and/or injecting drugs. Nonetheless, it has been noted that some early
recommendations were not necessarily evidence‐based (Edlin, Seal et al. 2001), and some
researchers consider withholding treatment from people who are actively using drugs to be a
form of clinician bias and considerable barrier to mitigating impact of the HCV epidemic
(Grebely and Dore 2014). Many researchers, particularly those outside of the United States,
have reported that active drug injectors can be equally adherent to treatment regimens and
achieve SVR rates similar to that of other HCV patient groups if treated in a controlled setting in
conjunction with appropriate peer support and addiction services (Robaeys, Van Vlierberghe et
al. 2006; Grebely, Raffa et al. 2007; Bruggmann, Falcato et al. 2008; Melin, Chousterman et al.
2010; Aspinall, Corson et al. 2013; Robaeys, Grebely et al. 2013). Thus, there is some indication
that clinical consensus may be shifting towards specific evidence‐based guidelines with regard
to HCV treatment eligibility among people who use and inject drugs. This shift in medical culture
has considerable implications public health and future cost burdens on healthcare in the United
States, given that PWID have accounted for the vast majority of HCV incidence since safe blood
transfusion procedures were instituted in 1992 (Armstrong, Wasley et al. 2006; Davis, Alter et al.
2010). Absolute contraindications to HCV treatment as published b the AASLD in 2014 are
outlined below in Table 3.
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Table 1.3
Absolute contraindications to drug treatment for HCV










Major uncontrolled depression
Solid organ transplant
Autoimmune hepatitis or other autoimmune condition exacerbated by peginterferon and
ribavirin
Untreated thyroid disease
Pregnant women or women unwilling to comply with contraceptive requirements
Severe hypertension, heart failure, poorly controlled diabetes, or chronic obstructive
pulmonary disease
Less than 2 years of age
Hypersensitivity to HCV drugs

Understandably, there is concern regarding the risk of reinfection among active PWID
(Aitken, Lewis et al. 2008; Grebely, Knight et al. 2010). However, reinfection among PWID have
been shown to be rare in some studies, provided access to OST or sterile syringes is available
(Edlin, Seal et al. 2001; Grady, Vanhommerig et al. 2012; Grady, Schinkel et al. 2013; Robaeys,
Grebely et al. 2013). However, with regard to the setting of the present study, state law in
Kentucky prohibit the services of syringe‐exchange programs (Kentucky Legislative Research
Commission 2010), perhaps fueling provider concerns of HCV reinfection among active drug
injectors in the Central Appalachian region.
In sum, current treatment eligibility guidelines in the United States dictate that
individual clinician judgment remains the most important arbiter of the decision whether to
treat PWID who are diagnosed and seek medical care. Therefore, individual physician
preferences, biases, and variability in medical culture on the regional level factor heavily into
treatment decisions in the frequently stigmatized patient population of drug users and injectors
(Nicklin, Schultz et al. 1999; Treloar, Newland et al. 2010; Cox, Graves et al. 2011; Harris and
Rhodes 2013). One AASLD recommendation for treatment eligibility bears particular relevance
to PWID: “Willing to be treated and adhere to treatment requirements.” Despite rapid
improvements in drug options (Afdhal, Zeuzem et al. 2013) and suggestions of the long‐term
cost‐effectiveness (Martin, Vickerman et al. 2013), HCV treatment remains expensive,
demanding, and relatively lengthy in nature, requiring parenteral administration of interferon,
with a daunting adverse effect profile and total cost of nearly $100,000 in the United States
(Thomas 2013). Therefore, this recommendation is particularly relevant to CHC patients and
their physicians whether or not to undertake treatment of the virus. Of course, individuals with
HCV are screened, diagnosed, and visit a physician for medical evaluation if testing positive,
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although high willingness to be treated has been reported among HCV‐seropositive PWID (Stein,
Maksad et al. 2001), despite low levels of eligibility and treatment initiation (Hagan, Latka et al.
2006). The complex web of patient, provider, and social issues surrounding access to HCV
medical care following a positive serotest are explored in detail in chapter 4.

Treatment guidelines
In the rapidly evolving field of HCV clinical care, new viral targets, novel drugs, and
updated treatment guidelines are emerging on a continual basis. The American Association for
the Study of Liver Diseases (AASLD) regularly updates the treatment guidelines intended to be
used by all specialist physicians currently treating CHC patients in the United States. These
guidelines are genotype‐specific and continually updated as research advanced to reflect the
rapidly changing arsenal of HCV drug agents, including the relatively new direct‐acting antiviral
protease inhibitors specifically targeted to improve the SVR among genotype 1 patients. In
clinical practice, however, the adverse effects of the first‐generated DAAs were often more
severe than anticipated given their promise in clinical trials (Afdhal, Zeuzem et al. 2013; Pollack
2013). Moreover, given the likelihood that all‐oral, interferon‐free and even ribavirin‐free
treatment options are likely to be available in the near future (Everson, Sims et al. 2013; Martel‐
Laferriere, Bichoupan et al. 2013), so many specialists treating HCV are opting to delay
treatment of eligible patients until superior pharmaceutical agents receive FDA approval (Pollack
2013). In short, the field of medical treatment for CHC is in considerable flux. Nonetheless, at
this stage there is reason enough for optimism: recent interferon‐free phase III clinical trials of
sofosbuvir and ledipasvir given effecting SVR in 98‐99% genotype 1 patients, with or without
ribavirin, among both previously untreated individuals receiving 12 weeks of treatment (Afdhal,
Zeuzem et al. 2014) and previously treated patients given 24 weeks of treatment (Afdhal, Reddy
et al. 2014), with no patients in either group discontinuing use of either DAA agent due to
adverse events. Formal practice guidelines are still in the process of being revised at the time of
this publication.
Lastly, it is worth nothing that considerable progress was made with regard to older
treatment protocols using a “personalized medicine” approach predicting treatment outcomes
using genetic sequencing of the promoter site of the cytokine IL‐28B, which has been shown a
robust predictor of HCV treatment success (Estrabaud, Vidaud et al. 2012). This finding has been
consistently reproducible and is often cited as an example of the successful application of
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genome‐wide association scan (GWAS) research techniques to clinical practice (Venegas, Brahm
et al. 2012). However, genotyping the IL‐28B locus is currently recommended in the clinical
management of CHC only if the physician or patient desires additional information regarding
disease progression and probability of achieving SVR (Ghany, Strader et al. 2009; Ghany, Nelson
et al. 2011), and it is likely that variation at the IL‐28B locus will be less important in determining
treatment outcomes in the era of newer anti‐HCV drug agents.

1.6 Injection drug use in rural Appalachia
Non‐medical prescription opioid use (NMPOU) has surged dramatically upwards in the
United States over the last 15 years (Cicero, Surratt et al. 2007; Manchikanti, Helm et al. 2012;
CDC 2013), fueled largely by increases in rural and suburban areas (Havens, Walker et al. 2007;
Okie 2010; Young, Havens et al. 2010; Estep 2011). This trend has been accompanied by a
commensurate rise in IDU, with reports that potent extended‐release painkillers such as
OxyContin® and roxicodone confer high risk of transition to IDU in multiple settings (Hays 2004;
Grau, Dasgupta et al. 2007; Kirsh, Peppin et al. 2012), including rural eastern Kentucky (Young
and Havens 2012). Moreover, the incidence of drug overdose (OD) has increased nearly ten‐fold
since 1999 nationwide, up to a total of 38,329 in 2010 (CDC 2013), a trend that is strongly
associated with per capita sales of prescription opioids (Paulozzi and Ryan 2006). Prescription
drugs account for more than 60% of OD deaths, with three‐quarters of these being due to
prescription opioids (CDC 2013). Moreover, the Central Appalachian region in particular suffers
from among the highest rates drug overdose nationwide (Hall, Logan et al. 2008).
Indeed, widespread NMPOU has been reported in the rural Appalachian area of eastern
Kentucky, particularly with regard to OxyContin® and other prescription opioids containing
oxycodone and hydrocodone (Havens, Walker et al. 2007; Havens, Oser et al. 2010). Rapid
transition to IDU was reported in this population, with a median time of 3 years from first illicit
use to first IDU reported in a sample of 503 PWUD living in the region (Young and Havens 2012).
HCV seroprevalence of 54.6% was discovered among rural PWID in this region (Havens, Lofwall
et al. 2013), affirming that high HCV prevalence among drug injectors in the United States
extends to rural areas. Preliminary analysis from the same study sample reveals high incidence
of HCV as well. Rural Central Appalachia is a largely low‐income region characterized by
considerable socioeconomic distress and generally poor access to hospitals, primary care,
disease screening, and social support services (Stensland, Mueller et al. 2002; Reif, Golin et al.
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2005; Zhang, Infante et al. 2008; ARC 2011), with vital health statistics often comparable to
those of an economically developing country (Murray, Kulkarni et al. 2005; Murray, Kulkarni et
al. 2006). Given that people who use and inject drugs are already subject to a wide variety of
barriers to healthcare and disease screening services (Grebely, Genoway et al. 2008) and HCV‐
infected individuals typically report low rates of screening and treatment (Harris and Rhodes
2013; Thomas 2013), dismal levels of HCV status awareness, healthcare engagement, and
treatment initiation might be expected among rural Appalachian individuals at risk of
contracting HCV. In turn, it is logical to surmise that this combination of frequently undiagnosed
HCV combined with widespread barriers to medical care for HCV will likely be followed by
disastrous elevations in HCV‐related morbidity and mortality in the decades to come, as with
multiple projections for the United States overall (Wong, McQuillan et al. 2000; Davis, Alter et
al. 2010)—a public health burden likely to be crippling for already financially distressed regional
healthcare systems like that of Central Appalachia. A growing body of research indicates that
scaling‐up integrated social services to mitigate the impact of HCV, including education efforts,
substance abuse treatment, opioid substitution treatment, harm reduction programs to reduce
IDU and promote safer injection practices (primary prevention), peer‐driven counseling, and
HCV medical care, are successful in reducing HCV transmission risk (Latka, Hagan et al. 2008;
Turner, Hutchinson et al. 2011). Moreover, treatment of PWID infected with HCV likely to be
cost‐effective in the long run (Martin, Vickerman et al. 2012). At present, however, there are
few integrated programs of this nature for PWID in the United States, and unsurprisingly, none
in Central Appalachia. Moreover, there is little research focused on HCV in rural America or on
factors impacting HCV transmission risk and healthcare engagement in the context of rural
Appalachia, an area where such research is most needed to inform public health intervention
efforts in the years to come.

1.7 Rationale and aims of project
With less than 50% of HCV‐infected individuals in the United States likely to be aware of
their status (Denniston, Klevens et al. 2012), inadequate levels of screening have been reported
as one of the most significant barriers to the control of hepatitis C (Clark and Muir 2012; Ward
2012). In rural populations at risk of acquiring HCV, this proportion is likely to be even lower. For
this reason, assessing the impact of HCV screening among rural individuals who do receive
screening is vital to optimizing this key window of opportunity for prevention in a population
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with little access to other social, substance abuse, or harm reduction services. Understanding
behavior following HCV‐seropositive status disclosure and counseling is crucial to efforts aimed
at reducing the risk of viral transmission, as well as to expanding insight into the convoluted
process of disease management and potential treatment. Successful treatment of HCV can avert
disease manifestations as well as further viral transmission, resulting in HCV prevention on
multiple levels. This “treatment as prevention” benefit has been promoted by several
researchers (Edlin 2011; Page, Morris et al. 2013; Grebely and Dore 2014; Hellard, Doyle et al.
2014) and is likely to substantially improve the cost‐effectiveness of treating people who are
actively using and/or injecting illicit drugs if delivered in a targeted manner in combination with
substance abuse treatment and harm reduction services (Martin, Vickerman et al. 2012; Martin,
Vickerman et al. 2013). Epidemiological research of individual‐level factors affecting primary and
particularly secondary prevention are vital in the era of rapidly improving HCV drug therapies
outlined earlier in this chapters, as well as substantial healthcare changes in the United States
occurring with implementation of the Affordable Care Act.
Because of the protracted clinical trajectory of HCV, the public health impact among
chronically infected individuals in the United States is only beginning to be felt. At current
treatment uptake levels, the impacts on the U.S. economy as well as morbidity and mortality of
the aging population with CHC will be increasingly severe in the coming decades (Davis, Alter et
al. 2010; Thomas 2013). Meanwhile, of course, incident cases of continue to occur, necessitating
interventions that target multiple levels of prevention for meaningful reductions in prevalence
in high‐risk populations (Page, Morris et al. 2013). Thus, this purpose of this dissertation is to
illuminate tractable and pragmatic behaviors related to prevention of HCV transmission and
disease progression: sharing of IDU paraphernalia and following up with a healthcare provider
after receipt of a positive HCV serotest. With the goal of informing public health efforts to
control HCV among rural Appalachian people most at risk of acquiring and transmitting HCV,
the results presented in subsequent chapters focus on the following research questions:
1. Does HCV screening and informational counseling impact behavior promoting primary
prevention of HCV among rural PWID? Which sociodemographic and behavioral
characteristics predict change in injection‐related risk? Relevant prior studies and data from
a cohort of rural Appalachian PWID are explored in the following chapter, Routes of
Transmission.
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2. What proportion of rural Appalachian people who use drugs follow up with a healthcare
provider after receiving a positive HCV serotest and informational counseling? What
characteristics predict healthcare engagement among these individuals? This topic and
relevant findings among rural Appalachian people who use drugs are presented in chapter 4,
Barriers to Care.
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Chapter 2
Routes of Transmission:
Risk factors for the spread of HCV

2.1 Overview
In the human body, HCV exists primarily in the bloodstream and is transmitted almost
exclusively through percutaneous contact with blood and blood products (Seeff 2002). Thus, the
most common modes of HCV transmission are injection‐related: IDU with contaminated needles
and other injection‐related items being perhaps the most well‐known, along with other
percutaneous exposures such as contaminated blood and blood product transfusion. In parts of
the developing world lacking adequate HCV screening protocols, healthcare‐mediated
transmission remains the most common means of HCV incidence (Hauri, Armstrong et al. 2004;
Alter 2011; Thomas 2013). However, other less frequent means of percutaneous exposure to
contaminated blood and have been documented by researchers, including needle‐stick
exposures among healthcare workers (Cainelli 2013; Thomas 2013), non‐sterile tattooing (Ko,
Ho et al. 1992) and piercing (Tohme and Holmberg 2012), organ transplantation (Seem, Lee et
al. 2013), vertical transmission during childbirth (Zanetti, Tanzi et al. 1995; Mast, Hwang et al.
2005), sharing of personal hygiene items such as toothbrushes and razors (Cavalheiro Nde, De La
Rosa et al. 2009), and lastly, invasive medical procedures such as digestive endoscopy
(Karmochkine, Carrat et al. 2006), although other studies have contradicted this finding (Ciancio,
Manzini et al. 2005).
In addition, HCV transmission via permucosal routes has also been reported. As detailed
below, several studies have found the sharing of straws used for intranasal administration
(“snorting”) of illicit drugs to be a risk factor, although this route may in fact represent a
clandestine bloodborne exposure (Allison, Conry‐Cantilena et al. 2012). Despite growing
evidence against heterosexual transmission, sexual transmission of HCV remains somewhat
controversial (Gross 2001; Cainelli and Vento 2002; Alter 2011) and is an occasional source of
incident cases documented among mostly in cases of “rough” sex, men who have sex with men
(MSM), particularly those coinfected with HIV, and in other situations with high risk of mucosal
tearing during intercourse (Alter 2011; Lambers, Prins et al. 2011; Bradshaw, Matthews et al.
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2013; Thomas 2013). Finally, sporadic permucosal transmission has also been reported via
contaminated blood products being splashed into the conjunctiva of the eyes of healthcare
worker (Sartori, La Terra et al. 1993). The primary well‐established routes of HCV transmission
are reviewed in greater detail in the following sections.

Injection drug use
Since the advent of safe screening precautions in the United States in July 1992, the
sharing of syringes, needles, and other injection‐related equipment among PWID has been the
primary mechanism of incident HCV in the United States (Williams, Bell et al. 2011) and in most
developed countries worldwide (Alter 2011; Thomas 2013). As outlined in Chapter 1, HCV
prevalence is high among PWID worldwide, with 49 countries reporting prevalences of at least
50% (Aceijas and Rhodes 2007) and up to 10 million seropositive PWID worldwide (Nelson,
Mathers et al. 2011). Nelson and colleagues (2011) also reported midpoint seroprevalence
among PWID as 67.5% worldwide, with the highest numbers of HCV‐seropositive individuals in
China, Russia, and the United States. In one study, HCV seroprevalence among 5088 PWID aged
18 to 40 years living in 4 major U.S. cities ranged from 35% to 65%, and the odds of testing HCV‐
seropositive increased with years of injection (OR=1.9, 95% CI: 1.7‐2.2) per year. Although HCV
prevalence among PWID in Baltimore and Los Angeles declined between 1994 and 2004 (Amon,
Garfein et al. 2008), there are recent indications that regional prevalences among high‐risk
groups may still be rising in parts of the United States, particularly in suburban and rural areas
(Centers for Disease Control and Prevention 2008; 2011; 2012).
Incidence of HCV among PWID in the United States has been reported between 11.6
(Hagan, Thiede et al. 2004) up to 25.1 (Hahn, Page‐Shafer et al. 2002) and 27.2 cases per 100
person‐years of follow‐up (Cox, Netski et al. 2005), with a median time to seroconversion of 2.1
years in a study of urban PWID (Hagan, Thiede et al. 2004). Importantly, HCV transmission risk
via IDU is not limited to the sharing of contaminated needles and syringes. Several recent
studies have documented an association between incident HCV and the sharing of contaminated
cookers, cotton, and waters used during the preparation of drugs for injection (Thorpe, Ouellet
et al. 2002; Hagan, Thiede et al. 2004; De, Roy et al. 2008), an often overlooked route of
transmission that remains poorly understood in many populations of PWID. Finally,
interventions using a combination of strategies including behavioral intervention, substance‐use
treatment, syringe access and distribution have been shown to be effective in preventing HCV
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infection among PWID (Hagan, Pouget et al. 2011), and several studies have demonstrated the
efficacy of syringe‐exchange programs (SEP) and/or opioid substitution therapy (OST) in
reducing injection‐related HCV transmission (Des Jarlais, Perlis et al. 2005; Turner, Hutchinson et
al. 2011; Iversen, Wand et al. 2013). Unsurprisingly, the prevalence of injection‐related risk
behaviors such as sharing syringes and injecting equipment has been reported to be higher in
areas not offering SEP harm‐reduction programs to reduce the spread of bloodborne infectious
diseases such as HCV and HIV (Neaigus, Zhao et al. 2008), and PWID in New York City who
utilized syringe‐exchange were more likely to inject with a new syringe (Rudolph, Crawford et al.
2010). Kentucky, however—the state in which collection of data analyzed in this dissertation
occurred—is one of 18 states not offering SEP of any kind (Foundation for AIDS Research 2013).

Intranasal drug use
Up to 20% of incident HCV is not explained by the major established modes of
transmission (Centers for Disease Control and Prevention 2011), particularly among HCV‐
positive non‐injection drug users (Tortu, Neaigus et al. 2001; Scheinmann, Hagan et al. 2007),
who typically have higher HCV prevalence than the general population despite denial of past
IDU history (Koblin, Factor et al. 2003). One explanation put forth by some researchers is that
the sharing of straws used for drug snorting such as cocaine and heroin explains some of this
discrepancy (Tortu, McMahon et al. 2004), as blood with HCV RNA has been detected in the
nasal secretions and straws and other intranasal use implements of non‐injecting drug users
(Aaron, McMahon et al. 2008). Koblin and colleagues (2003) found an association of intranasal
administration of heroin and heroin mixed with cocaine with prevalent HCV among non‐
injecting drug users, while Allison et al. (2012) found intranasal use of cocaine in particular to be
a risk factor, conferring an odds ratio of 8.5 in a longitudinal study of 738 blood donors in one
study. As mentioned previously, this heightened risk was suggested to be conferred by
parenteral rather than permucosal transmission, due to frequent epistaxis (nosebleed) during
shared intranasal cocaine use, facilitating blood‐borne transmission (Allison, Conry‐Cantilena et
al. 2012). Macias and colleagues (2008) found a similar pattern (adjusted OR=3.6, 95% CI = 1.3‐
9.8) among non‐injecting drug users who reported sharing straws for the inhalation of crack
cocaine. Nonetheless, the association of intranasal transmission with HCV risk remains less
robust relative to parenteral transmission. Some researchers have found no association with
shared snorting implements (Hermanstyne, Bangsberg et al. 2012), while others have suggested
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that intranasal drug use could in fact confer a protective effect as an alternative route of
administration with regard to HCV transmission risk relative to IDU, conferring multivariate odds
ratios near 0.50 or below for seroprevalent HCV among recent intranasal users of heroin and
heroin‐cocaine mixtures in a sample of prior drug injectors recruited from a detoxification
program in New York City (Des Jarlais, Hagan et al. 2011).

Blood transfusion, transplantation, and other iatrogenic exposures
Iatrogenic transmission of HCV, particularly via transfusion of contaminated blood
products and reuse of non‐sterile medical equipment, remains a serious global health problem
and the most common mode of incident HCV in the developing world (Alter 2011; Thomas
2013). Safe antibody and RNA‐based screening procedures for blood and blood product
transfusion introduced in 1992 have all but eliminated HCV transmission by this route in
economically developed countries (Schreiber, Busch et al. 1996; Busch, Glynn et al. 2005),
although sporadic outbreaks of iatrogenic transmission via errors in tissue transplant testing
have been reported recently in Kentucky and Massachusetts (Centers for Disease Control and
Prevention 2011). Contaminated blood products remain a serious issue in parts of the world
lacking in adequate blood supply and access to advanced HCV screening technology. Moreover,
non‐sterile therapeutic methods including the reuse of syringes for drug and vaccine
administration likely contribute to a substantial portion of incident infections—an estimated 2
million cases worldwide in the year 2000, or 40% of new infections (Hauri, Armstrong et al.
2004). This phenomenon is epitomized by the tragic example of Egypt, where a public
schistosomiasis eradication campaign spanning several decades resulted in the epidemic spread
of HCV genotype 4 described in the chapter 1. However, sporadic outbreaks of HCV in the
iatrogenic setting have also occurred via transfusion and injection in economically developed
countries, resulting from patient‐to‐patient (Perz, Thompson et al. 2010) and transplant‐related
(Centers for Disease Control and Prevention 2011) transmission resulting from breakdowns in
precautionary infection control safeguards. Finally, due to highly efficient rates of infection via
percutaneous exposure , HCV transmission to healthcare professionals via needle‐stick accidents
among healthcare workers has long been observed as a transmission risk factor (Lanphear,
Linnemann et al. 1994) and occurs in 0.9 to 2.2% of exposures to blood from HCV‐infected
patients, a proportion far exceeding the transmission efficiency of HIV (Cainelli 2013).
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Vertical transmission
The risk of transmission from an HCV‐infected mother to newborn falls between 2‐8%
(Syriopoulou, Nikolopoulou et al. 2005; Prasad and Honegger 2013), and this route remains a
significant source of incident HCV in many regions with high prevalence. Unfortunately, unlike
HIV, there is not yet an effective prophylactic treatment to reduce the risk of vertical HCV
transmission, and conventional HCV drug therapy is contraindicated in pregnant women due to
the teratogenic properties of ribavirin and pegylated interferon (Prasad and Honegger 2013).
However, while the impact of newer DAA drugs on the therapeutic options available for HCV‐
infected mothers remains to be seen, there is considerable optimism for substantially reduced
toxicity and amendment of treatment guidelines. Typical risk‐enhancing factors for this mode of
HCV transmission include maternal HIV coinfection, maternal IDU, HCV RNA level (Zanetti, Tanzi
et al. 1995; Syriopoulou, Nikolopoulou et al. 2005), membrane rupture, and internal fetal
monitoring (Mast, Hwang et al. 2005). Breastfeeding has not been found to significantly increase
the risk of vertical HCV transmission, perhaps due to insufficient viral load or inactivation of HCV
in the stomach. CDC recommendations (1998) refer to the data regarding breastfeeding with
HCV as “limited,” and both CDC and the American College of Obstetricians and Gynecologists
advise HCV‐positive mothers without HIV infection to abstain from breastfeeding if nipples are
cracked or bleeding (ACOG 2007).

Tattooing, piercing, and folk medical practices
A few relatively minor but well‐documented sources of incident cases HCV can be
categorized together under various invasive non‐medical procedures practiced without
adequate sanitation precautions, including tattooing, body piercing, and Eastern medical
practices such as acupuncture. Given the efficiency of parenteral transmission of HCV, each has
potential for the viral spread via contaminated blood if needles and other equipment are reused
without recommended sterilization procedures. While most researchers have found little
evidence of transmission risk in establishments following professional sterilization standards,
Howe and colleagues (2005) reported a significant association between HCV‐seropositive status
and receiving a non‐professional tattoo (adjusted OR 3.6, 95% CI: 1.2‐11.3). Similarly, in a meta‐
analysis by Tohme and Holmberg (2012), substantial risk of HCV infection (adjusted odds ratios
ranging from 2.0 to 3.6) was found when tattoos or piercings were received under non‐sterile
conditions, such as in prisons or from friends. The role for piercing as a risk factor is less clear,
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with 5 of 23 studies reporting significant odds ratios from 2.0 up to 7.3 (Tohme and Holmberg
2012). An earlier study found a similar relationship with regard to non‐professional tattooing,
albeit in a small sample of 213 non‐PWID (OR=5.9, 95% CI 1.6‐22.0) (Ko, Ho et al. 1992).
Similarly, Macias and colleagues (2008) reported an OR of 3.5 (95% CI: 1.3‐9.1) for seroprevalent
HCV among 182 non‐PWID undergoing addiction treatment with a history of tattooing, although
other factors, such as a history of incarceration, were possible confounders. Finally, certain non‐
Western medical practices including non‐sterile acupuncture and other procedures have been
reported by some researchers as risk factors for HCV acquisition, particularly in Asian countries
(Kiyosawa, Tanaka et al. 1994; Aikawa and Kojima 2004; Lim 2009).

Sexual transmission and other mucosal routes
The potential role of sexual contact in HCV transmission remains controversial. Data
reported between molecular and epidemiological approaches to the question are conflicting
(Gross 2001; Cainelli and Vento 2002; Alter 2011). Undoubtedly, this mode of transmission is
inefficient relative to direct parenteral exposures such as equipment sharing during IDU and
transfusion of contaminated blood products (Terrault 2002; Cainelli 2013). Several older studies
and case reports have reported that transmission of HCV via sexual contact can occur, albeit
very infrequently (Alter, Coleman et al. 1989; Capelli, Prati et al. 1997; Halfon, Riflet et al. 2001;
Quer, Murillo et al. 2003). Moreover, analysis of 500 HCV‐seropositive individuals who were not
currently injecting drugs and their long‐term heterosexual partners found extremely low
incidence of HCV transmission by sexual contact, with maximum incidence of 0.07% per year
(95% CI 0.01‐0.13%), or one incident case of HCV per 190,000 sexual contacts, after 8,377
person‐years of follow‐up (Terrault, Dodge et al. 2013). Twenty (4%) of the study couples had
evidence of mutual infection via serotesting, among which nine couples had the same genotype
and only three (0.6%) had viral isolates determined to be highly related by genetic sequencing,
indicating very low incidence of sexual transmission. Similarly, a longitudinal study followed a
cohort of 895 monogamous heterosexual partners of HCV‐infected partners for 10 years and
found no evidence of intra‐spousal transmission of HCV via sexual activity using viral sequencing
techniques (Vandelli, Renzo et al. 2004). Researchers suggest that if HCV transmission does
occur among heterosexual partners, it may occur percutaneously via vaginal mucosal tearing or
anal intercourse (Cainelli 2013), shared history of IDU or other surreptitious HCV exposures
(Stroffolini, Lorenzoni et al. 2001), or alternatively, potential permucosal transmission during the
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early (acute) phase of HCV infection, which would explain why transmission among longer‐term
partners is so infrequent (Alter 2011; Thomas 2013).
Among MSM, however, the story of HCV sexual transmission is quite different. Rising
incidence among homosexual men who are not injecting drugs has been documented over the
last decade in many populations (Lambers, Prins et al. 2011; Bradshaw, Matthews et al. 2013).
This trend was first reported in the UK (Browne, Asboe et al. 2004), followed by studies of
similar dynamics in France (Ghosn, Pierre‐Francois et al. 2004), the Netherlands (Gotz, van
Doornum et al. 2005), United States (Luetkemeyer, Hare et al. 2006), and Australia (Matthews,
Hellard et al. 2007). More recently, Witt and colleagues (2013) reported that sexual transmission
of HCV via MSM has been frequent throughout the history of the HIV epidemic, and
unprotected anal sex with more than one male partner was an independent predictor of HCV‐
seropositive status (incidence rate ratio 3.4, p<0.001), as well as HIV, syphilis, or hepatitis B
coinfection, age, and heavy alcohol consumption. As with vertical transmission, HCV incidence
was also predicted by HIV‐positive status and inversely proportional to low‐CD4 count among
participants with less than 500 CD4+ T cells (Witt, Seaberg et al. 2013). A review by Yaphe and
colleagues (2012) affirms this synergy between HIV and incident HCV among MSM, although
they stop short of advising HCV screening for all individuals with a history of MSM, instead
recommending to approach the question on an individualized basis.
Finally, a collection of primarily older studies points to possible permucosal transmission
of HCV through shared use of personal hygiene items including toothbrushes, razor blades,
manicure pliers, and even nail clippers, or so‐called “intrafamilial” or “household” transmission
(Honda, Kaneko et al. 1993; Tibbs 1995; Caporaso, Ascione et al. 1998; Cavalheiro Nde, De La
Rosa et al. 2009). Taken together, the risk of HCV transmission by this route seems to be low
and regionally variable (Ackerman, Ackerman et al. 2000). Nonetheless, a recommendation to
avoid sharing personal hygiene items appears in the post‐test counseling materials issued by
CDC (1998) to be given to all individuals following an HCV‐positive serotest.

2.2 Approaches to prevention
There is a fundamental dichotomy with regard to public health efforts aimed at
mitigating the impact of infectious disease: primary prevention and secondary prevention. With
regard to HCV, primary prevention addresses factors impacting major routes of disease
transmission, whereas secondary prevention focuses primarily on managing existing cases of
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HCV in order to prevent disease manifestations in the years to come (Thomas 2013). Given the
reality of scientific challenges to discovery of an efficacious preventative vaccine (Torresi,
Johnson et al. 2011), biomedical approaches to primary prevention of HCV remain unavailable.
Thus, harm reduction approaches such as SEP, OST, and substance abuse treatment coupled
with efforts to reduce transmission risk via modification of IDU behavior, remain the primary
options available at the present time to reduce incidence of HCV. However, as previously
described, there are no harm reduction programs and a scarcity of substance abuse and related
social services in rural Central Appalachia.
Consensus is lacking regarding the impact of HCV screening on subsequent HCV
transmission‐related risk behaviors among people who use and inject drugs, and this question
has not been previously studied in the rural context. Moreover, there are few prospective
studies examining changes in drug‐related transmission risk behavior in response to HCV
serostatus disclosure over time. Additional longitudinal studies should help solidify public health
understanding of the effectiveness of HCV antibody screening and CDC‐recommended post‐test
counseling materials alone on disease transmission risk. Ultimately, this research question is
highly pragmatic in nature, as HCV screening, when it occurs, is likely to be one of the few
interactions with the healthcare system many members of the rural drug‐using population may
experience. Thus, examining what impact screening may have is vital in rural Central Appalachia,
which as mentioned in chapter 1 features widespread drug injection and inhalation (Young,
Havens et al. 2010), as well as HCV seroprevalence among PWID comparable to urban areas
(Havens, Lofwall et al. 2013). For these reasons, the following chapter focuses on a behavioral
approach to the primary prevention of HCV in medically underserved Eastern Kentucky.
Analyses of transmission‐related IDU risk behaviors among PWID in a rural cohort are presented
before and after HCV serotesting and standard informational counseling.
Chapters 4 and 5, by contrast, focus on secondary prevention of HCV among rural
people who use drugs by describing levels of treatment uptake and exploring key patient‐level
steps in engagement of the healthcare system, specifically the immediate steps study
participants take, or do not take, following receipt of an HCV‐positive serotest result and post‐
test counseling. While ostensibly these chapters are most relevant to the long‐term clinical
prognosis of HCV‐positive individuals, there is important relevance to the prevention of future
HCV transmission as well, as former CHC patients who have achieved SVR can no longer transmit
the virus to others. In other words, successful treatment of CHC can prevent incident infections
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as well as substantially improve the clinical course of individuals already infected (Marinho, Vitor
et al. 2014). In this way, identifying factors predicting healthcare engagement among
seropositive individuals has potential to inform both primary and secondary prevention.
Similarly, effective primary prevention strategies to avoid re‐infection of individuals who have
already achieved SVR are critical for secondary prevention of CHC‐related disease
manifestations to be truly effective. In other words, both approaches to disease prevention are
complementary parts of an effective strategy to containing the impact of HCV on society.
Engagement in HCV management, treatment‐seeking, and treatment uptake among in the rural
Appalachian drug‐using population are explored in more detail in Chapters 4 and 5.
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Chapter 3
Primary Prevention:
HCV screening and transmission risk behavior among rural Appalachian people who inject drugs

3.1 Introduction
As detailed in chapter 1, hepatitis C virus is a major global health challenge with myriad
potential clinical consequences among individuals with chronic infection. HCV is hyperendemic
in a variety of populations of PWID, and IDU is the primary route of transmission in developed
nations worldwide (Hellard, Doyle et al. 2014). HCV screening, including testing and post‐test
informational counseling (T&C), has been proposed as a valuable means of reducing HCV
prevalence among PWID (Clark and Muir 2012; Ward 2013), despite only weak support for the
effectiveness of screening on IDU risk behavior (Chou, Cottrell et al. 2012). However, there are
relatively few studies examining the potential impact of testing and standard counseling might
have on subsequent risk behavior for HCV transmission, particularly within the context of rural
America. Indeed, the impacts of screening and counseling were recently identified as one of six
major areas in need of further study with regard to prevention modalities targeting HCV (Page,
Morris et al. 2013).
Past research yields insight into the interplay of HCV status awareness and IDU risk,
although findings often conflict and previously sampled populations have been primarily from
major urban centers. An early study of 592 PWID in Paris undergoing drug abuse or other
psychosocial treatment compared individuals reporting HCV‐positive status to those reporting
unknown or HCV‐negative status. In a multivariate model, lack of HCV status awareness was
associated with decreased probability of using new IDU equipment of any kind, suggesting
heightened transmission risk among PWID who have not received a serotest for HCV (Vidal‐
Trecan, Coste et al. 2000). Similarly, in one of the first studies to address IDU risk specifically in
relation to HCV‐positive status awareness, Kwiatkowski and colleagues reported on 197 PWID in
Denver, CO in a cross‐sectional analysis. Individuals who were aware of being HCV‐positive
reported a longer duration of IDU but fewer HCV‐related risk behaviors, including IDU with a
used needle, sharing injection paraphernalia (cookers, cotton, or rinse water), and a greater self‐
perception of using “safe” injection techniques (Kwiatkowski, Fortuin Corsi et al. 2002). This
finding contrasts with a recent study from Aspinall (2014) and colleagues reporting no change in
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IDU sharing behavior following positive T&C, although there was a small but significant decline
in overall IDU frequency.
Concordant with the findings of Aspinall, a study of more than 3000 PWID age 15‐30 in
five U.S. cities found that awareness of HCV‐seropositive status was not associated with
decreased sharing of syringes or cotton, nor with decreased syringe‐mediated drug sharing.
Interestingly, however, participants aware of their HCV‐seronegative status were less likely to
reporting recent sharing of a syringe (adjusted OR 0.8, 95% CI: 0.6‐0.9) or filtration cotton (aOR
0.8, 95% CI: 0.6‐0.9) (Hagan, Campbell et al. 2006). Similarly, Korthuis and colleagues (2012)
examined the question cross‐sectionally among PWID in drug treatment, comparing those
aware of their HCV‐positive status to those who were not aware or were HCV‐seronegative. In a
multivariate model, reporting awareness of being HCV‐seropositive was associated with
increased sharing of syringes and needles in the last 6 months (adjusted OR: 2.4, 95% CI: 1.2‐
4.9). Any opioid use, marijuana use, crack use via injection, and female gender were also
associated with increased syringe/needle sharing (Korthuis, Feaster et al. 2012). Norden and
colleagues (2009), however, reported that knowledge of HCV status and awareness of the
personal health consequences of HCV were not associated with significant differences in
prevalence of sharing needles and IDU equipment. Meanwhile, another study by Cox et al.
(2008) used a theoretical approach to investigate correlates to the sharing of syringes and drug
preparation equipment by adapting the AIDS Risk Reduction Model, originally designed to
address HIV sexual risk behavior (Catania, Kegeles et al. 1990). In a multivariate model derived
from 321 PWID in Montreal, lower perceived benefits of safe IDU practices and greater difficulty
in practicing safe injection were associated with greater risk of syringe sharing, while lower
perceived benefits of safe injection and lower self‐efficacy to convince other PWID to inject
safely increased risk of equipment sharing (Cox, De et al. 2008). Similarly, a study from Budapest
found IDU equipment‐sharing was associated with lower self‐efficacy for the use of safe
injecting procedures and higher peer pressure to share equipment, along with higher perceived
susceptibility to HIV/AIDS and having a criminal record (Racz, Gyarmathy et al. 2007). However,
the cross‐sectional design of these studies limits causal interpretation of these findings,
although it is probable that HCV infection and serotesting preceded most reports of drug
injecting behavior as measure of recent sharing (last 3‐6 months) were utilized.
In the first prospective study to address the question of transmission risk‐related
behavioral change among PWID, Ompad and colleagues (2002) interviewed 106 young PWID in
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Baltimore six months after HCV serotesting. As with the majority of cross‐sectional studies, no
significant differences between individuals receiving HCV‐positive T&C versus individuals with a
negative result or no awareness of their status with regard to the sharing of syringes, needles,
and other IDU‐related paraphernalia (Ompad, Fuller et al. 2002). However, this analysis was
bivariate in nature and did not control for potential confounders, such as demographic factors,
illicit drug use patterns, and prior HCV status knowledge at baseline in particular. In another
prospective study, Tsui and colleagues (2009) followed 112 initially PWID in San Francisco who
seroconverted and received post‐test counseling during the course of a 12‐month study period.
Incidence of IDU and sharing injection equipment decreased among all study participants,
regardless of serotest result and counseling received. In a multivariate model, non‐injection
drug use decreased significantly among HCV seroconverters relative to HCV‐negative
participants immediately after status disclosure and counseling (OR 0.4, 95% CI: 0.2‐0.8),
although this decline was not sustained over 6‐ and 12‐month follow‐ups; no significant
differences were observed between HCV groups with regard to IDU sharing. Thus, as with the
above studies of Hagan, Aspinall, and Ompad, risky IDU practices did not seem to be affected by
HCV seroconversion and brief counseling, and the initial decrease in non‐IDU was not detected
after 12 months of study (Tsui, Vittinghoff et al. 2009).
Although not specific to the impact of screening, PWID‐targeted HCV interventions such
as peer‐driven counseling and integrated harm reduction programs have been shown to be
highly effective among PWID. A systematic review of HCV primary prevention studies assessed
the impact of targeted behavioral interventions on HCV incidence (3 studies) and IDU‐related
risk behaviors (6 studies). Of these latter studies, two reported significant decreases in IDU risk
behavior, although disparities in study design and primary outcome measures prevented pooling
of data (Sacks‐Davis, Horyniak et al. 2011). A meta‐analysis examining the impact of harm‐
reduction programs in the United Kingdom found that combined syringe‐exchange and opioid
substitution programs reduced needle sharing by 48% (adjusted OR=0.52, 95% CI: 0.32‐0.83)
and mean IDU frequency by 20.8 occasions per month (95% CI: 14.4‐27.3). In addition,
significant decreases in HCV incidence were reported for both SEP and OST programs, with an
impressive 80% reduction in new cases observed among “full harm reduction” recipients in
combined programs (aOR=0.2, 95% CI: 0.1‐0.5). Finally, a small number of studies indicate that
analysis of social network‐level variables can be predictive of syringe, needle, and equipment
sharing among PWID. These factors include measures of network structure, such as density and
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turnover, along with compositional attributes including individual network member centrality
and dyadic characteristics, behavioral norms, and local drug use patterns (De, Cox et al. 2007;
Shaw, Shah et al. 2007).
Taken together, the majority of past research suggests that HCV screening and brief
post‐test counseling alone are unlikely to substantially reduce transmission‐related risk among
PWID. In fact, there is some evidence that awareness of HCV‐positive serostatus may even
increase IDU risk behavior. However, even more targeted educational and counseling
interventions may be of limited benefit unless implemented in a multi‐component fashion with
integrated focus to education and as well as opioid addiction treatment , harm reduction
programs, and accessible options for CHC medical care and treatment (Birkhead, Klein et al.
2007; Sacks‐Davis, Horyniak et al. 2011; Page, Morris et al. 2013; Grebely and Dore 2014). This
research question is particularly relevant to the unique setting of rural Appalachia, where public
health efforts to address the burgeoning HCV crisis are almost non‐existent and few local
healthcare providers or hospitals (Stensland, Mueller et al. 2002; Zhang, Infante et al. 2008).
Furthermore, as the state of Kentucky prohibits syringe‐exchange programs (Kentucky
Legislative Research Commission 2010), the region might be expected to feature particularly
high rates of injection‐related risk behavior among PWID (Vlahov and Junge 1998; Neaigus, Zhao
et al. 2008). Finally, as expanded upon in later chapters, medical management of HCV is
characterized by a variety of challenges on virological, individual, healthcare provider, and
societal levels, so optimizing primary prevention strategies are particularly important.
Therefore, the purpose of this study was to longitudinally assess whether HCV screening and
counseling impacts IDU risk behavior among PWID in rural Central Appalachia.

3.2 Methods
Sampling
Data analyzed here were collected at the first four study occasions (baseline, 6‐months,
12‐months, and 18‐months) during the ongoing longitudinal cohort study, Social Networks
among Appalachian People (SNAP; R01DA024598 and R01DA033862), principal investigator
Jennifer R. Havens. This purpose of this study was study epidemiology and risk factors of HCV,
HIV, and herpes simplex virus type 2 (HSV‐2) among people who use illicit drugs in the Central
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Appalachian region of rural Eastern Kentucky. Individuals were eligible for enrollment in the
study if they met the following criteria:





18 years of age or older at the time of enrollment
Resident of a rural Appalachian county of Kentucky
Used one or more of the following drugs to get high in the past 30 days: prescription
opioids, heroin, cocaine or crack, or methamphetamine.
Not currently receiving treatment for illicit drug use or other addiction problems
A storefront location in Hazard, KY (Perry County) was established for the purposes of

recruitment and data collection. A baseline sample of 503 study participants was recruited
between November 2008 and August 2010 using respondent‐driven sampling (RDS). This
sampling technique has been shown to be useful in the recruitment of difficult‐to‐access or
“hidden” populations, such as drug users in both urban (Abdul‐Quader, Heckathorn et al. 2006;
Des Jarlais, Arasteh et al. 2007) and rural settings (Falck, Siegal et al. 2005; Frost, Brouwer et al.
2006; Wang, Falck et al. 2007). The RDS protocol developed and refined by Heckathorn offers
substantial advantages over other techniques such as “snowball” sampling, which tend to be
highly biased by non‐random recruitment (Heckathorn 1997; Heckathorn 2002; Heckathorn
2007).
The recruitment process utilized informational flyers posted in public locations around
Hazard, KY (Perry County, pop. 28,241) to collect an initial group of study “seeds,” who were
screened for eligibility and enrolled in the study if meeting eligibility requirements. This initial
group was screened for eligibility as described above with the additional requirement that they
had injected drugs with a needle in the past 6 months; this was confirmed by asking a set of
detailed questions regarding specific injection techniques and performing a physical
examination for evidence of track marks or other evidence of recent injection. Initial recruits
were given three study coupons to recruit potentially eligible members of their drug use
network (without the requirement of recent IDU), and later compensated $10 for each
additional eligible study participant who enrolled. This secondary wave of new recruits was
subsequently screened for eligibility, enrolled in the study if appropriate, and then given
another set of coupons to initiate the recruitment of a third wave of potential study
participants, and so on. This recruitment cycle continued until the sample reached the size
determined to be necessary for adequate study power. 107 initial study seeds in total recruited,
resulting in a final baseline sample of 503 participants. For each dependent measure assessed,
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RDSAT software, version 7.1 (Ithaca, NY) was used to correct for residual non‐randomness in the
sample recruited during the course the RDS recruitment protocol. RDSAT yields individualized
statistical weights for each study outcomes via 25,000 bootstrap iterations and enhanced data
smoothing to appropriately adjust for potential bias and artificially induced sampling
homogeneity (homophily) among recruitment chains, which can be introduced by the RDS
protocol and result in inappropriately narrow confidence intervals (Heckathorn 2002; Volz and
Heckathorn 2012; Volz, Wejnert et al. 2012). Participants were compensated $50 for their time
in completing interviews, $20 for serotesting, and $20 for returning to receive serotest results.
Study recruitment, serotesting procedures, pre‐ and post‐test counseling, and interviewing
procedures were approved by the University of Kentucky College of Medicine Institutional
Review Board and a Certificate of Confidentiality was obtained. All study participants granted
informed consent in order to participate.

HCV serotesting and data collection
All SNAP participants were tested at baseline and every subsequent 6‐month visit for
serum antibodies to HCV by trained study personnel using the Home Access® Hepatitis C Check
serotest (Home Access Health Corporation, Hoffman Estates, IL). This test utilizes dried blood
spot specimens collected by finger‐stick and a 3rd‐generation enzyme immunoassay (EIA) to
detect antibodies to HCV in serum. Sensitivity and specificity of this test are 98.2% and 99.6%,
respectively (US Food and Drug Administration 1999), and accuracy exceeds 99% (O'Brien,
Kruzel et al. 2001). Four results are possible with this serotest (Home Access Health Corporation
2008):





HCV‐seropositive
HCV‐seronegative
Indeterminate (antibodies but not necessarily specific to HCV)
Result not available (inadequate blood volume/poor sample); participant retested

Participants were asked to return to the study site in approximately two weeks to receive their
test results; if unable to return in person, participants were informed of their test result and
counseled as described below by telephone. Participants with indeterminate or “reactive” test
results were counseled as if testing seropositive (described below). Individuals testing
seropositive or reactive were categorized as negative if they did not receive test results at least
30 days before subsequent interviewing. HCV status was then positive at the next interview with
more than 30 days between HCV+ status disclosure and counseling. If participants received a
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Table 3.1
Guidelines for pre‐test counseling of individuals receiving an HCV antibody test
 Exposures associated with the transmission of HCV, including behaviors or exposures that
might have occurred infrequently or many years ago
 Test procedures and the meaning of test results
 Nature of hepatitis C and chronic liver disease
 Benefits of detecting infection early
 Available medical treatment
 Potential adverse consequences of testing positive, including disrupted personal
relationships and possible discriminatory action (e.g., loss of employment, insurance, and
educational opportunities)
seronegative test after a previously reactive test, HCV status was amended to negative at the
time the negative result was received to reflect the most recent counseling messages received.
Pre‐test counseling messages were administered to all study participants, as advised by
CDC guidelines (1998) and presented in Table 3.1 above. Post‐test counseling and printed
informational materials were given simultaneously with serotest results and tailored to
individual serotest results. Table 3.2 below summarizes the recommendations from CDC (1998)
for individuals testing HCV‐seropositive. While these guidelines do not specifically address IDU
behavior, AASLD guidelines published in 2009 include the recommendation that HCV‐
seropositive individuals stop using illicit drugs and avoid any sharing of syringes, needles, and
injecting equipment including cookers, rinse water, spoons, or cotton filters. Trained SNAP study
personnel advised participants accordingly regarding the risk of sharing syringes and injection
equipment, and printed materials included specific statements regarding the high risk of HCV
transmission through the sharing of any IDU paraphernalia (needles, syringes, and ancillary
equipment) and a statement to always use one’s own injecting equipment to eliminate the risk
of HIV, HBV, and HCV transmission via IDU. Pamphlets with illustrated instruction were also
distributed with information regarding “safe” methods of cleaning all IDU equipment using the
“3x3” technique with bleach, including ancillary equipment, and to always use a new cotton
filter and water. Finally, the standard counseling information for those testing positive for HCV
included a list of local community clinics and hospitals offering further testing, physician
assessment, and potential treatment options for HCV. This list included the Appalachian
Regional Health Center hospital (Hazard, KY) and four additional nearby clinics located in Perry
County, Kentucky.
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Table 3.2
Guidelines for post‐test counseling of individuals testing HCV‐seropositive
• To protect their liver from further harm, HCV‐positive persons should be advised to:
‐ Not drink alcohol
‐ Not start any new medicines, including over‐the‐counter and herbal medicines,
without checking with their doctor
‐ Get vaccinated against hepatitis A if liver disease is found to be present
• To reduce the risk for transmission to others, HCV‐positive persons should be advised to:
‐ Not donate blood, body organs, other tissue, or semen
‐ Not share toothbrushes, dental appliances, razors, or other personal‐care articles
that might have blood on them
‐ Cover cuts and sores on the skin to keep from spreading infectious blood or
secretions
• HCV‐positive persons with one long‐term steady sex partner do not need to change their
sexual practices. They should:
‐ Discuss the risk, which is low but not absent, with their partner (If they want to
lower the limited chance of spreading HCV to their partner, they might decide to use
barrier precautions [e.g., latex condoms])
‐ Discuss with their partner the need for counseling and testing
• HCV‐positive women do not need to avoid pregnancy or breastfeeding.
• Other counseling messages
‐ HCV is not spread by sneezing, hugging, coughing, food or water, sharing eating
utensils or drinking glasses, or casual contact
‐ Persons should not be excluded from work, school, play, child‐care or other settings
on the basis of their HCV infection status
‐ Involvement with a support group might help patients cope with hepatitis C
• HCV‐positive persons should be evaluated for presence or development of chronic liver
disease including:
‐ Assessment for biochemical evidence of chronic liver disease
‐ Assessment for severity of disease and possible treatment according to current
practice guidelines in consultation with, or by referral to, a specialist knowledgeable
in this area
‐ Determination of need for hepatitis A vaccination
A detailed questionnaire was administered at baseline and subsequent follow‐up
interviews (approximately every six months) by specially trained SNAP personnel at the study
site in Hazard. Participants’ responses were directly entered into a touch screen laptop using
computer‐assisted personal interviewing (CAPI) software (Questionnaire Development System,
Nova Research Company, Bethesda, MD). Trained interviewers in the SNAP study all resided in
the target rural area around Perry County, KY, and all were certified as HIV counselors who had
undergone a thorough training program in the standardized interviewing procedures used
throughout the study. Standard sociodemographic data including participant gender, race, age,
education level (including classroom/academic settings and technical training), income (with
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illegal sources specified), marital status, sexuality, religion, transportation status (access to
vehicle and possession of driver’s license), access to the internet, pattern of employment history
were collected at baseline, along with participant responses to the MINI neuropsychiatric
interview, version 5.0.31 (Sheehan, Lecrubier et al. 1998), to assess for symptoms of psychiatric
disorders including major depressive disorder (MDD), generalized anxiety disorder (GAD), post‐
traumatic stress disorder (PTSD), and antisocial personality disorder (ASPD). Participants who
met the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM‐
IV) for any of these four psychiatric diagnoses were given a standardized information sheet with
detailed information on mental health resources available in the region. Finally, previous receipt
of a positive test for HCV, hepatitis B virus, HIV, or HSV‐2 from a healthcare professional was
also asked at each interview.
A battery of time‐varying measures were collected at each interview as well, including:
health insurance status (dichotomized as no insurance or any insurance including private
insurers, Medicaid, or Medicare), lifetime and recent incarceration, self‐reported health status
and frequency of health‐related problems, substance abuse treatment, use in the last 30 days
and 6 months of: alcohol (including to intoxication), legal and illegal methadone and
buprenorphine, lifetime and recent illicit drug (including prescription opioids such as OxyContin®
and other oxycodone ‐containing formulations, heroin, sedatives and tranquilizers, cocaine,
crack, methamphetamine, oral amphetamines/prescription stimulants, barbiturates,
hallucinogens, marijuana, and simultaneous use of multiple substances. Illicit use of prescription
opioid was defined in concordance with the National Survey on Drug Use and Health (NSDUH) as
use within the previous 6 months for the purpose of experiencing euphoria, or use of a
prescription opioid not prescribed to the participant (SAMHSA 2003). Data on injection drug use
including drugs injected, frequency of IDU, and year of first IDU, were collected at baseline and
all subsequent interviews. Lifetime drug use history measures were also collected for reach
substance above. Detailed questions regarding participants’ recent HCV transmission risk via
drug use behaviors, including sharing of syringes, needles, cottons, cookers, rinse water, were
asked at all interviews. Sexual risk behavior was collected in the form of recent unprotected sex,
recent unprotected sex with PWID, and recent unprotected transactional sex (for drug, money,
or gifts). In addition, the following 6 true‐false questions were asked at baseline to assess level
of participant HCV knowledge:
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There is treatment for hepatitis C.
Hepatitis C is passed from one person to another by sharing needles or syringes.
Hepatitis C is passed from one person to another by sharing other injection equipment
(cookers, cotton, etc.).
Hepatitis C is passed from one person to another by coming into contact with infected
blood.
Hepatitis C is passed from one person to another through infected food or water.
Hepatitis C is passed from one person to another by tattooing or body piercing
instruments.

Lastly, a series of questions concerning HCV‐seropositive individuals obtaining medical follow‐
up, seeking and obtaining HCV treatment from a healthcare professional were asked at the 6,
12, and 18‐month interviews. These measures are described in detail in chapter 5.

Analysis
For the purposes of the specific analyses specific to this chapter (described below), a
subsample of n=291 individuals returning for another interview after baseline HCV serotesting
and reporting IDU in the past 6 months at any interview between 6 and 24 months and were
included for analysis of IDU sharing (needles, syringes, and ancillary equipment, including
cookers, cotton filters, and rinse water). For analysis of IDU cessation, included participants
reported IDU at any time point between baseline and 18 months and must have returned for at
least one interview between 6 and 24 after initial report of recent IDU to enable longitudinal
analysis of IDU cessation, yielding a sample size of n=324. 22 recent PWID were excluded under
these criteria. These individuals and any participants missing any interview between 6 and 24‐
month study occasions were assessed for significant differences with regard to major
sociodemographic or time‐invariant measures reported at baseline.
The primary dependent measure in this analysis was sharing of syringes, needles, and/or
any other ancillary IDU equipment (cookers, cotton filters, or rinse water) in the 30 days
preceding each 6‐month interview. Thus, in order to capture the effect of HCV testing and
counseling over time independent of baseline sharing habits, a binary change variable was
created indicating decreased frequency of IDU sharing relative to baseline levels reported by
each participant. A corresponding variable capturing increased IDU sharing frequency was also
created to capture deleterious effects. In addition, any engagement in IDU during each 6‐month
intervals following was also assessed in a secondary analysis of IDU cessation during the study
period. In addition, descriptive statistics for IDU sharing and IDU frequency in the last 6 months,
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sources of needles and syringes, and syringe cleaning using bleach were also calculated at
baseline and compared at 6 months by HCV serotest results for select variables.
In light of the research question, receipt of HCV test results and counseling were
considered for inclusion in all multivariate models. Other covariates listed above were
considered in a bivariate screening step for potential inclusion in multivariate modeling as
outlined below. Potential associations between each covariate and the outcome of interest
were assessed in a bivariate manner using generalized estimating equations (GEE; described
below), with an unstructured specifications of covariance considered as described below.
Covariates found to be associated with an outcome at the p<0.10 level of significance were
considered for inclusion in the multivariate modeling procedures described in the following
section. The main effect of time and standard sociodemographic measures including sex, age,
race, education, and income were also considered in all multivariate models and retained if
coefficients for significant independent measures changed by 10% or more (Hosmer and
Lemeshow 1989).
Longitudinal data are characterized by within‐subject correlation between data
collection occasions, violating the assumption of independent observations key to conventional
statistical techniques within the framework of generalized linear models. Failing to account for
this within‐subject correlation across observations can result in misleading statistical inferences
stemming from overestimation of sampling variability, inflating standard error and 95%
confidence intervals, and limiting meaningful statistical inference (Hardin and Hilbe 2003;
Fitzmaurice, Laird et al. 2004). For this reason, statistical methodologies designed to account for
within‐subject correlation in data are required. Since informing pragmatic public health
strategies at the level of the sampled population is the primary objective of this study,
generalized estimating equations (GEE) were used for bivariate and multivariate analysis of the
outcomes described above. Proposed in 1986 as an extension of generalized linear models, GEE
accounts for within‐subject correlation over time by explicitly modeling pairwise covariance
structures as exchangeable, autoregressive, unstructured, and so on. Unstructured and
autoregressive covariance structures were considered in this analysis, although GEE is relatively
robust to misspecification of covariance (Fitzmaurice, Laird et al. 2004) and offers significant
relaxation of conventional generalized linear model assumptions that would otherwise restrict
analysis of longitudinal data. However, use of GEE remains subject to a few important
assumptions, namely: log‐odds of the dependent variable is linearly related to the predictors,
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total count of clusters (individuals in this case) is relatively high (>30), and between‐cluster
observations are independent (Hardin and Hilbe 2003; Ghisletta and Spini 2004). Importantly,
GEE yields population‐averaged (“marginal”) coefficients for independent variables, meaning
that inferences are applicable to the background population sampled via the RDS protocol
described above (Liang and Zeger 1986; Zeger, Liang et al. 1988; Fitzmaurice, Laird et al. 2004).
Regression parameters in the GEE modeling were derived using robust (“sandwich”) standard
error estimates and Wald tests with a significance threshold of p<0.05. To assess model fit and
compare nested multivariate models in a hierarchical fashion, the quasi‐Akaike Information
Criterion (QIC), a quasi‐likelihood‐based score test which balances goodness‐of‐fit with
parsimony by penalizing each additional regression parameter, was used select the model with
optimal goodness‐of‐fit and parsimony using the qic add‐on algorithm for Stata (Pan 2001; Cui
2007). Again, as the GEE modeling procedure yields only population‐averaged inferences,
regression parameters are not appropriate for individual‐specific inferences among participants
within a study sample (Hardin and Hilbe 2003). Stata, version 13.1 (College Station, TX) was used
for all statistical analyses.
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Table 3.3
Drug‐related behavior and baseline HCV test result and counseling received (T&C) among recent
PWID (n=288)
Behavior
Overall
HCV+ T&C
HCV‐ T&C
p‐value
sample
n=154
n=134
n (%)
n (%)
n (%)
IDU sharing (last 30d): Baseline
Any paraphernalia
115 (39.9)
67 (43.5)
48 (35.8)
0.184
Needles/syringes
65 (22.6)
42 (27.3)
23 (17.2)
0.041
Other IDU equipment
103 (35.8)
60 (38.9)
43 (32.1)
0.225
IDU sharing (30d): 6m after test (n=267)1
Any paraphernalia
46 (17.2)
33 (22.4)
13 (10.8)
0.012
Needles/syringes
23 (8.6)
18 (12.2)
5 (4.2)
0.0272
0.020
Other IDU equipment
42 (15.7)
30 (20.4)
12 (10.0)
181 (67.8)
117 (79.5)
64 (53.3)
<0.0001
IDU 6 months after HCV test (n=267)1
IDU frequency (last 6m): Before test
Less than once per month
66 (22.9)
19 (12.3)
47 (35.1)
<0.0001
1‐3 times per month
50 (17.4)
17 (11.0)
33 (24.6)
0.002
1‐6 times per week
70 (24.3)
42 (27.3)
28 (20.9)
0.208
26 (19.7)
<0.0001
Daily or more
102 (35.4)
76 (49.7)
81 (44.8)
61 (52.1)
20 (31.3)
0.007
Daily or more IDU: 6m after test (n=181)3
Days of Rx opioid IDU (30d):
Before test ‐ mdn (IQR)
7 (1‐25)
20 (2‐30)
2 (0‐10)
<0.0001
15 (1‐30)
2 (0‐20)
0.004
6 months after test (n=181)3 – mdn (IQR) 10 (0‐30)
Drugs injected (6m): Before test
0.219
Prescription opioids
266 (92.4)
145 (94.2)
121 (90.3)
0.826
Heroin
31 (10.8)
16 (10.4)
15 (11.1)
0.0812
Sedatives/tranquilizers
13 (4.5)
4 (2.6)
9 (6.7)
5 (3.7)
0.4792
Methamphetamine
8 (2.8)
3 (1.9)
0.2712
4 (3.0)
Prescription stimulants
13 (4.5)
9 (5.8)
3
Drugs injected (6m): After test (n=181)
Prescription opioids
172 (95.0)
114 (97.4)
58 (90.6)
0.044
Heroin
9 (5.0)
7 (6.0)
2 (3.1)
0.3982
0.2862
Sedatives/tranquilizers
3 (1.7)
1 (0.9)
2 (3.1)
0.3482
Methamphetamine
5 (2.8)
2 (1.7)
3 (4.7)
0.3542
Prescription stimulants
1 (0.6)
0 (0)
1 (1.6)
Primary needle source: Before test
Pharmacy or clinic
13 (4.5)
8 (5.2)
5 (3.7)
0.551
Drug dealer/street
53 (18.4)
33 (21.4)
20 (14.9)
0.155
Family member
33 (11.5)
11 (7.1)
22 (16.4)
0.014
Friend/acquaintance
93 (32.3)
46 (29.9)
47 (35.1)
0.346
Diabetic
93 (32.3)
54 (35.1)
39 (29.1)
0.281
0 (0)
1.0002
Syringe exchange program
1 (0.3)
1 (0.6)
No source given
2 (0.7)
1 (0.6)
1 (0.7)
1.0002
Cleaned syringes with bleach (6m):
Before test
96 (33.3)
60 (39.0)
36 (26.9)
0.030
56 (30.9)
42 (35.9)
14 (21.9)
0.051
6 months after test (n=181)3
232 (80.6)
120 (77.9)
112 (83.6)
0.226
Straw sharing (6m): Before test
148 (55.4)
75 (51.0)
73 (60.8)
0.109
Straw sharing (6m): 6m after test (n=267)1
1
n=267 PWID interviewed after 6 months (147 HCV+, 120 HCV‐)
2
Fisher’s exact test
3
n=181, excluding missing participants and those denying recent IDU at 6 months (117 HCV+, 64 HCV‐)
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3.3 Results
Description of IDU risk behavior
Of 503 individuals interviewed and serotested for HCV at baseline, participant follow‐up
rate was 94.4% (n=475) after 6 months, 93.2% (n=469) after 12 months, 95.0% (n=478) after 18
months, and 86.5% (n=435) after 24 months. Table 3.3 on the preceding page describes IDU
habits and risk behavior among all study participants reporting recent (past 6‐month) IDU at
baseline (n=288) compared by HCV test result and counseling received. Note that serotest result
and counseling received can differ from actual HCV serostatus, as some seropositive participants
did not receive their test result at least 30 days prior to 6 month interviewing and were
categorized as negative with regard to testing and counseling. 40% of PWID were sharing any
IDU equipment at baseline and 35% reported injecting daily or more often in the last 6 months.
After testing, overall proportion sharing any IDU paraphernalia had declined to 17% of the 267
individuals who returned after 6 months. Of note, despite an overall decline in IDU over the 6
month period, receiving HCV‐positive T&C at baseline was associated with reporting continued
IDU at 6 months in bivariate chi‐squared analyses. 80% of those receiving HCV‐positive T&C at
baseline continuing to inject after 6 months, compared to just 53% of PWID receiving negative
T&C (p<0.0001).
IDU sharing overall as well as sharing of ancillary equipment displayed similar patterns
of increased risk following a positive test and counseling, although sharing of needles and
syringes was significantly higher in the positive T&C group before testing as well (p=0.041). Daily
IDU among active injectors (n=181 at 6 months) was associated with HCV‐positive T&C both
before (p<0.0001) and after testing (p=0.007), as was number of days of prescription opioid IDU
out of the last 30 (p<0.0001 and p=0.004, respectively). The primary sources of needles and
syringes at baseline were friends or acquaintances (32%) and diabetics (32%), which included
diabetic acquaintances as well as study participants themselves. A smaller proportion of
participants receiving HCV‐positive T&C reported obtaining needles and syringes from family
members (7.1%) relative to the HCV‐negative group (16.4%; p=0.014), although baseline
associations are not temporally ordered with regard to assessing impact of T&C. Finally, a
greater proportion of participants testing HCV‐positive reported cleaning used syringes with
bleach before T&C (39% vs. 27%, p=0.030), whereas the proportion cleaning with bleach 6

40

50.0
Overall sample
HCV+ T&C

% Reporting Any IDU Sharing

40.0

HCV‐ T&C
30.0

*

20.0

*
10.0

0.0

0

6

12

18

24

30

36

Months
Figure 3.1: RDS‐adjusted population estimates and 95% confidence intervals for proportion of
PWID sharing any IDU paraphernalia. HCV serotest results and post‐test counseling were
received at least 30 days prior to interviews, with the exception of 0 months (*p<0.05)
months after HCV‐positive T&C was higher as well but of only marginal significance (36% vs. 22%
of HCV‐negative; p=0.051).
288 (57.3%) participants reported IDU in the 6 months preceding baseline, and 283 of
these individuals (98.3%) returned for at least one interview after baseline. Figure 3.1 depicts
RDS‐adjusted population estimates of proportion of PWID sharing any IDU paraphernalia over
time compared by results of HCV status from previous screening and post‐test counseling. Time
since study enrollment is represented continuously as the mean number of months between the
five interviews. An overall decline in IDU sharing was observed between baseline (35.5%) and 18
months (8.6%) among baseline PWID regardless of HCV status, followed by an overall increase at
24 months (12.2%) driven by rising absolute risk among individuals receiving HCV‐positive T&C
between baseline and 18 months. Despite insignificant differences before serotesting (p=0.25),
IDU sharing prevalence between HCV groups differed significantly after 6 and 12 months (20.3%
of HCV‐positive vs. 9.5% of HCV‐negative and 12.1% of HCV‐positive vs. 4.5% of HCV‐negative,
respectively; p<0.05). Sharing prevalence at 18 months was nearly identical in the two groups
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Table 3.4
Baseline sample characteristics of recent PWID and RDS‐adjusted bivariate associations with any
IDU sharing (n=283)
Characteristic

% IDU Sharing
(95% CI)
50.4 (40.1‐60.6)
93.4 (86.2‐97.0)
32.7 (31.0‐34.4)
32.7 (24.0‐42.7)
20.6 (13.1‐30.8)
12.2 (7.2‐20.1)
0.7 (0.5‐0.9)
11.7 (11.3‐12.1)
1267.2 (901.6‐
1632.8)
37.0 (27.6‐47.5)
37.0 (27.3‐47.7)
29.8 (21.5‐39.7)
32.8 (24.2‐42.8)
33.3 (24.6‐43.4)
13.6 (8.4‐21.2)
39.1 (29.3‐49.8)
71.1 (61.3‐79.2)
94.4 (88.4‐97.4)
98.2 (93.2‐99.6)
22.4 (15.2‐31.7)
49.4 (39.2‐59.7)
5.6 (3.7‐7.6)
33.9 (24.7‐44.6)
23.3 (15.3‐33.9)
4.5 (2.0‐10.2)
15.1 (9.3‐23.5)
4.8 (2.1‐10.7)
6.0 (2.9‐11.9)

% Not Sharing
(95% CI)
60.1 (51.4‐68.2)
94.8 (89.8‐97.4)
32.6 (31.2‐34.1)
21.2 (15.5‐28.2)
24.8 (18.6‐32.3)
6.0 (3.2‐11.1)
1.1 (0.8‐1.3)
11.6 (11.2‐11.9)
1278.0 (970.6‐
1585.3)
25.9 (19.1‐34.0)
33.8 (26.1‐42.5)
25.8 (19.1‐33.8)
28.4 (21.0‐37.3)
34.5 (26.8‐43.1)
11.2 (7.1‐17.3)
15.4 (10.2‐22.6)
59.5 (50.9‐67.5)
89.7 (83.5‐93.7)
95.3 (91.1‐97.6)
35.1 (27.4‐43.8)
40.2 (32.3‐48.5)
5.3 (3.8‐6.9)
32.0 (24.7‐40.4)
27.5 (20.6‐35.7)
17.0 (11.7‐24.1)
8.3 (5.0‐13.4)
6.0 (3.3‐10.8)
9.7 (5.9‐15.7)

p‐value

Most often unemployed (last 3 years )
Driver’s license and vehicle
Major depressive disorder
Generalized anxiety disorder
Antisocial personality disorder
Post‐traumatic stress disorder
Received HCV+ test prior to study
HCV+ serotest at baseline
≥5 of 6 general HCV questions correct
3 of 3 HCV transmission questions correct
Health insurance coverage
“Poor” to “fair” health status
Days with health problems1 ‐ mean (SD)
Reported chronic medical condition
Taking legally prescribed medication
Receiving physical disability pension
Substance use treatment (last 6m)
Legal methadone use (last 6m)
Recent incarceration1

Sample total
n (%)
167 (59.0)
265 (93.6)
32.7 (7.9)
81 (28.6)
68 (24.0)
27 (9.5)
1.0 (1.4)
11.7 (2.4)
1340.5
(2014.0)
84 (29.7)
93 (32.9)
77 (27.2)
84 (29.0)
97 (34.3)
39 (13.8)
63 (22.3)
171 (60.4)
257 (90.8)
271 (95.8)
85 (30.0)
127 (44.9)
5.8 (10.1)
91 (32.2)
72 (25.4)
35 (12.4)
33 (11.7)
17(6.0)
25 (8.8)

Lifetime behaviors
Incarceration
Substance abuse treatment
Drug overdose
Years of IDU ‐ mean (SD)
Heroin use
Illicit methadone use
Legal methadone use
Illicit buprenophine use
Legal buprenorphine use
OxyContin® use
Other oxycodone use
Any other prescription opioid use
Sedative, hypnotic, or tranquilizer use
Barbiturate use
Crack use
Cocaine use
Methamphetamine use

241 (85.2)
186 (65.7)
104 (36.8)
8.0 (7.0)
123 (43.5)
261 (92.2)
45 (15.9)
201 (71.0)
41 (14.5)
272 (96.1)
273 (96.5)
231 (81.6)
246 (86.9)
31 (11.0)
212 (74.9)
267 (94.4)
128 (45.2)

83.1 (71.0‐90.8)
63.9 (53.4‐73.3)
37.2 (28.1‐47.4)
8.3 (6.7‐9.9)
47.3 (37.2‐57.6)
93.5 (86.0‐97.1)
15.1 (9.4‐14.8)
80.3 (71.3‐87.0)
18.0 (11.0‐28.2)
96.3 (91.3‐98.5)
96.7 (91.0‐98.8)
80.9 (71.9‐87.6)
93.7 (87.4‐97.0)
9.0 (4.6‐16.6)
76.1 (65.6‐84.1)
95.6 (89.4‐98.2)
49.4 (39.2‐59.7)

82.3 (74.0‐88.3)
68.3 (59.8‐ 75.8)
34.1 (26.6‐42.6)
7.7 (6.6‐8.9)
37.0 (29.5‐45.3)
91.0 (85.1‐94.7)
14.8 (10.0‐21.3)
65.3 (56.6‐73.0)
11.6 (7.4‐17.9)
97.1 (92.9‐98.8)
96.8 (92.9‐98.6)
80.3 (71.9‐86.7)
84.2 (77.5‐89.2)
13.0 (8.2‐19.8)
74.9 (67.0‐81.4)
94.5 (90.0‐97.1)
38.2 (30.4‐46.5)

0.895
0.499
0.628
0.547
0.122
0.493
0.951
0.013
0.186
0.701
0.949
0.913
0.019
0.344
0.842
0.694
0.095

Male
White
Age (years) ‐ mean (SD)
Any religious affiliation reported
Married
Bisexual or homosexual
Number of dependents ‐ mean (SD)
Education (years) ‐ mean (SD)
Monthly income (US $) ‐ mean (SD)
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0.155
0.662
0.944
0.042
0.468
0.789
0.012
0.665
0.965
0.078
0.639
0.492
0.486
0.855
0.563
0.0001
0.069
0.170
0.185
0.038
0.169
0.853
0.768
0.499
0.002
0.080
0.676
0.262

Prescription stimulant use
Marijuana use
Hallucinogen use
Inhalant use
Multiple substance use

110 (38.9)
276 (97.5)
142 (50.2)
59 (20.9)
264 (93.3)

44.0 (34.3‐54.3)
96.2 (80.8‐99.4)
56.6 (46.0‐66.6)
21.2 (14.2‐30.5)
94.1 (87.1‐97.4)

33.3 (25.7‐41.9)
97.6 (94.1‐99.1)
38.4 (30.8‐46.6)
17.6 (12.5‐24.1)
93.8 (89.2‐96.5)

0.105
0.639
0.007
0.463
0.912

Recent risk behaviors (last 6m unless noted)
231 (81.6)
Unprotected sex1
102 (36.0)
Unprotected sex with PWID1
18 (6.4)
Unprotected transactional sex1
Drug overdose
8 (2.8)
Alcohol use to intoxication
58 (20.5)
101 (35.7)
Daily or greater IDU frequency
12.4 (11.8)
Days of IDU1 ‐ mean (SD)
Heroin use
48 (17.0)
Heroin IDU
31 (11.0)
Illicit methadone use
212 (74.9)
OxyContin® use
268 (94.7)
Other oxycodone use
242 (85.5)
Any other prescription opioid use
278 (98.2)
Any prescription opioid IDU
262 (92.6)
12.1 (11.9)
Days of opioid IDU1 ‐ mean (SD)
Sedative, hypnotic or tranquilizer use
272 (96.1)
Sedative, hypnotic or tranquilizer IDU
13 (4.6)
Barbiturate use
12 (4.2)
Crack use
92 (32.5)
Cocaine use
158 (55.8)
Cocaine IDU
112 (39.6)
Methamphetamine use
37 (13.1)
Methamphetamine IDU
8 (2.8)
Prescription stimulant use
47 (16.6)
11 (3.9)
Prescription stimulant IDU
Marijuana use
204 (72.1)
Hallucinogen use
19 (6.7)
Multiple substance use
268 (94.7)
1
Last 30 days

84.9 (76.2‐90.7)
56.8 (46.6‐66.5)
3.7 (1.5‐8.6)
4.3 (1.8‐9.8)
11.3 (6.8‐18.2)
51.5 (41.2‐61.7)
17.4 (14.9‐20.0)
15.3 (9.7‐23.4)
9.9 (5.5‐17.4)
65.0 (53.6‐74.9)
97.4 (89.6‐99.4)
91.9 (85.4‐95.6)
98.0 (92.1‐99.5)
93.9 (85.7‐97.6)
17.1 (14.5‐19.6)
97.4 (89.6‐99.4)
5.7 (2.7‐11.8)
2.4 (0.5‐9.7)
32.5 (24.0‐42.4)
56.4 (45.9‐66.3)
39.1 (29.4‐49.7)
12.5 (7.5‐20.2)
2.5 (0.9‐7.0)
18.0 (11.6‐26.9)
2.1 (0.6‐6.9)
73.3 (62.5‐81.9)
8.9 (4.8‐15.9)
90.8 (80.1‐96.0)

79.8 (72.3‐85.7)
27.5 (20.5‐35.8)
5.8 (3.2‐10.3)
0.8 (0.2‐3.3)
25.4 (18.4‐34.0)
26.4 (19.7‐34.3)
9.7 (7.9‐11.6)
14.3 (9.6‐20.8)
9.3 (5.6‐15.1)
76.5 (68.6‐82.9)
93.5 (88.8‐96.3)
80.3 (72.5‐86.4)
98.0 (93.5‐99.4)
91.4 (85.7‐94.9)
9.6 (7.7‐11.4)
94.5 (89.1‐97.3)
3.3 (1.2‐8.6)
5.1 (2.6‐9.7)
25.7 (19.5‐33.1)
52.4 (43.8‐60.9)
40.8 (32.7‐49.5)
10.5 (6.7‐16.0)
1.9 (0.7‐5.4)
12.9 (8.6‐18.9)
3.9 (1.9‐8.0)
70.4 (62.3‐77.3)
4.2 (2.1‐8.3)
94.7 (88.2‐97.7)

0.323
<0.0001
0.389
0.029
0.005
0.0001
<0.0001
0.824
0.863
0.074
0.219
0.009
0.996
0.499
<0.0001
0.340
0.370
0.331
0.240
0.562
0.801
0.597
0.735
0.257
0.384
0.640
0.106
0.345

(8.8% of HCV‐positive and 8.1% of HCV‐negative; p=0.844), and while sharing among PWID
counseled as HCV‐positive began to rise during the final study interval (14.1%), this proportion
was not significantly different from the HCV‐negative group (8.0%; p=0.127).

Correlates of IDU sharing at baseline
Table 3.4 above describes sociodemographic and baseline behavioral characteristics of
the 283 recent PWID who returned for at least one interview and were eligible for longitudinal
analyses. Participants predominantly male (59%), white (94%), single (76%), uninsured (70%
uninsured at baseline; 51% reported no insurance throughout the study), with a mean age of

43

32.7 years. Of 171 (60%) total seropositive tests, 151 participants (53%) received positive test
results and post‐test counseling at least 30 days before 6‐month follow‐up; by the end of 18‐
month serotesting, 195 participants had tested positive at any study visit (68%). 241 participants
(85%) had a lifetime history of incarceration and 104 (37%) had ever experienced a drug
overdose. Over 96% reported having ever used either OxyContin® or another form of oxycodone
non‐medically, and the mean duration of IDU in the cohort was 8 years. 93% of participants
reported injecting any prescription opioid over the course of the study, and the mean number of
days of opioid IDU out of the last 30 was 12 over the course of the study. 113 participants
(39.9%) reported sharing IDU needles, syringes, or other equipment in the 30 days preceding
baseline interviews. 63 participants (22%) reported receiving an HCV‐positive test prior to study
enrollment, a characteristic strongly associated with IDU sharing in the 30 days preceding
baseline (39% of HCV+ versus 15% of HCV‐; p<0.0001). Other significant negative associations
with IDU sharing at baseline included number of dependents (p=0.012), having any form of
health insurance coverage (p=0.038), receiving a physical disability pension (p=0.002), and
recent alcohol use to intoxication (p=0.005). Measures significantly associated with increased
IDU sharing included prior HCV‐positive testing (p=0.0001), recent unprotected sex with PWID
(p<0.0001), lifetime history of using buprenorphine (p=0.013), prescription sedatives (p=0.019)
or hallucinogens (p=0.007), recent drug overdose (p=0.029), recent non‐medical use of
oxycodone formulations aside from OxyContin® (p=0.009), and both measures of recent IDU
frequency: daily IDU during the last 6 months (p=0.0001) and days injecting during the last 30
days (p<0.0001).
An RDS‐adjusted multivariate logistic model for independent associations with recent
IDU sharing reported at baseline is presented below in Table 3.5. A positive HCV test prior to
study entry tripled the odds of reporting recent IDU sharing (95% confidence interval [CI]: 1.4‐
6.2), while recent unprotected sex with PWID conferred a 6.4‐fold increased risk of IDU sharing
95% CI: 3.9‐10.4). Reporting more dependents (adjusted OR [aOR]=0.7 per individual, 95% CI:
0.6‐0.9) and receiving a pension for disability (aOR=0.2, 95% CI: 0.1‐0.6) were negatively
associated with IDU sharing. Illicit drug use measures increasing risk of IDU sharing included
lifetime history of using sedatives (aOR=2.9, 95% CI: 1.1‐7.2) or hallucinogens (aOR=2.8, 95% CI:
1.5‐5.2), recent use of non‐OxyContin® forms of oxycodone (aOR=2.9, 95% CI: 1.1‐7.5), and
frequency of IDU during the last 30 days (4% increased odds per day, 95% CI: 1.0‐1.1). Of note,
recent drug
44

Table 3.5
Baseline correlates of IDU sharing among recent PWID (n=283)1
Characteristic
Adjusted
Odds Ratio
Received HCV+ test prior to study
2.97
Number of dependents (per individual)
0.74
Currently receiving pension for physical disability
0.20
Unprotected sex with PWID (last 30 days)
6.36
Ever used sedatives, hypnotics, tranquilizers (lifetime) 2.86
Ever used hallucinogens (lifetime)
2.78
Oxycodone use of other than OxyContin® (last 6m)
2.87
Days of IDU out of last 30 (per day)
1.04
1

95% CI

p‐value

1.43 – 6.21
0.60 – 0.91
0.07 – 0.58
3.89 – 10.41
1.13 – 7.22
1.50 – 5.16
1.11 – 7.45
1.01 – 1.07

0.004
0.004
0.003
<0.0001
0.026
0.001
0.030
0.001

Logistic regression model adjusted for RDS

overdose was also predictive of IDU sharing if included in the model, but the low number of
participants reporting an overdose in the last 6 months (n=8) severely impacted the precision of
this estimate (95% CI: 2.4‐77.0), so the measure was dropped from the multivariate model. This
change in model specification resulted in little apparent impact on goodness‐of‐fit (BIC=339.6
with recent drug overdose measure vs. 340.8 without). Logistic regression diagnostics were
performed using the linktest command in Stata, which rebuilds the model using the linear
predicted value squared to indicate potential errors in specification of predictors or link
function. No significant errors in specification or with regard to omitted variables were detected
in this diagnostic test (p=0.682), and the mean variance inflation factor (VIF) for this model
calculated using Stata’s collin command was 1.05, indicating no issues with regard to
multicollinearity in this model.

Predictors of change in IDU sharing frequency
Table 3.6 summarizes sample characteristics and bivariate population‐averaged
associations with improved risk of HCV transmission risk parameterized as decreased frequency
of IDU sharing following HCV test result disclosure and counseling. In light of the robust bivariate
association of receiving an HCV+ test prior to study entry with decreased sharing among
baseline PWID (OR=3.1, 95% CI: 1.8‐5.6), participants reporting previous receipt of a positive
test were excluded from analysis of the dependent change variable of interest in order to
improve inferences regarding the potential effect of HCV screening on decreased IDU sharing
frequency, resulting in a sample of 220 baseline PWID with no prior knowledge of HCV‐positive
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Table 3.6
Description of sample and population‐averaged bivariate associations with decreased IDU
sharing among recent PWID with no previous HCV+ test (n=220)1
Characteristic
Time‐invariant
Received HCV+ test prior to study2
Male
White
Age (years) ‐ mean (SD)
Any religious affiliation reported
Married
Bisexual or homosexual
Number of dependents ‐ mean (SD)
Education (year) ‐ mean (SD)
Monthly income (per $100 US) ‐ mean (SD)
Most often unemployed (last 3y)
Transportation
Major depressive disorder
Generalized anxiety disorder
Antisocial personality disorder
Post‐traumatic stress disorder
≥5 of 6 general HCV questions correct
3 of 3 HCV transmission questions correct
Time‐varying
HCV+ T&C at any study visit (0‐18m)
Study occasions since HCV+ T&C:
1
2
3
4
Followed up with clinician after HCV+ test
Sought treatment after HCV+ test
Received HCV treatment after HCV+ test3
Health insurance coverage
“Poor” to “fair” health status
Days with health probs4 ‐ mean (SD)
Reported chronic medical condition
Taking legally prescribed medication
Receiving physical disability pension
Substance use treatment (last 6m)
Legal methadone use (last 6m)
Legal buprenorphine use (last 6m)
Incarceration4
Lifetime behavior
Incarceration
Substance abuse treatment
Drug overdose
Years of IDU ‐ mean (SD)
Heroin use
Illicit methadone use
Legal methadone use
Illicit buprenophine use

Sample total
n (%)

Odds
Ratio

95% CI

p‐value

63 (22.3)
134 (60.9)
205 (93.2)
32.5 (8.2)
55 (25.0)
74 (25.4)
20 (9.1)
0.9 (1.3)
11.7 (2.5)
1250.4 (1832.9)
63 (28.6)
70 (31.8)
57 (25.9)
57 (25.9)
78 (35.5)
33 (15.0)
196 (89.1)
209 (95.0)

3.13
0.56
1.33
1.00
1.93
0.63
3.13
0.80
1.07
0.99
1.77
1.01
1.27
1.53
1.14
2.30
1.59
2.27

1.76 – 5.57
0.30 – 1.07
0.41 – 4.31
0.96 – 1.05
1.01 – 3.70
0.26 – 1.55
1.20 – 8.19
0.62 – 1.02
0.95 – 1.21
0.98 – 1.01
0.94 – 3.36
0.50 – 2.05
0.65 – 2.49
0.76 – 3.08
0.60 – 2.18
1.04 –5.12
0.58 – 4.37
0.46 – 11.18

<0.0001
0.079
0.639
0.832
0.048
0.317
0.020
0.074
0.237
0.399
0.079
0.971
0.483
0.237
0.694
0.041
0.369
0.312

134 (60.9)
107 (48.6)
120 (54.6)
128 (58.2)
134 (60.9)
74 (33.6)
11 (5.0)
8 (3.6)
109 (49.6)
127 (57.7)
5.1 (7.9)
109 (49.6)
104 (47.3)
59 (22.7)
64 (29.1)
24 (10.9)
31 (14.1)
87 (39.6)

1.12
0.93
0.94
1.17
0.81
1.08
0.95
n/a
0.94
1.03
0.99
0.99
0.83
0.99
1.07
1.12
0.89
1.08

0.91 – 1.38
0.81 – 1.07
0.81 – 1.08
1.00 – 1.36
0.64 – 1.03
0.94 – 1.24
0.92 – 0.98
n/a
0.84 – 1.05
0.90 – 1.18
0.99 – 1.00
0.75 – 1.22
0.61 – 1.14
0.87 – 1.13
0.87 – 1.32
0.87 – 1.44
0.75 – 1.04
0.92 – 1.26

0.288
0.302
0.356
0.047
0.081
0.257
0.001
0.054
0.283
0.683
0.228
0.965
0.253
0.860
0.512
0.380
0.144
0.335

184 (83.6)
141 (64.1)
73 (33.2)
7.6 (7.0)
89 (40.5)
201 (91.3)
32 (14.6)
153 (69.6)

1.26
0.74
1.00
1.02
1.50
2.26
0.77
1.90

0.44 – 3.60
0.58 – 2.13
0.95 – 1.05
0.98 – 1.06
0.80 – 2.81
0.66 – 7.69
0.31 – 1.91
0.95 – 3.83

0.670
0.752
0.999
0.348
0.209
0.192
0.571
0.071
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Legal buprenorphine use
25 (11.4)
0.93
0.35 – 2.47
0.891
0.209
Illicit OxyContin® use
209 (95.0)
0.43
0.12 – 1.60
0.871
Other illicit oxycodone use
211 (95.9)
0.88
0.20 – 3.87
0.668
Any other prescription opioid use
180 (81.8)
1.20
0.53 – 2.73
0.015
Sedative, hypnotic, or tranquilizer use
187 (85.0)
4.15
1.32– 13.11
0.120
Barbiturate use
21(9.6)
0.39
0.12 – 1.28
0.825
Crack use
159 (72.3)
1.08
0.54 – 2.15
0.472
Cocaine use
205 (93.2)
0.65
0.20 – 2.10
0.216
Methamphetamine use
93 (42.3)
1.48
0.80 – 2.75
0.267
Prescription stimulant use
85 (38.6)
1.43
0.76 – 2.70
0.270
Marijuana use
215 (97.7)
3.51
0.38 – 32.65
0.039
Hallucinogen use
110 (50.0)
1.96
1.03 – 3.75
0.417
Inhalant use
47 (21.4)
1.35
0.65 – 2.81
0.276
Multiple substance use
202 (91.8)
0.55
0.18 – 1.62
Recent risk behavior (last 6m unless indicated)
Recent unprotected sex4
200 (90.9)
0.75
0.59 – 0.95
0.016
82 (37.3)
0.72
0.51 – 1.00
0.053
Recent unprotected sex with PWID4
7 (3.2)
0.98
0.93 – 1.04
0.605
Recent unprotected transactional sex4
0.348
Drug overdose
14 (6.4)
1.72
0.55 – 5.33
0.118
Alcohol use to intoxication
142 (64.6)
0.87
0.74 – 1.03
98 (44.6)
0.77
0.58 – 1.01
0.060
Daily or greater IDU frequency
11.6 (10.5)
0.99
0.98 – 1.00
0.017
Days of IDU4 ‐ mean (SD)
0.983
Heroin use
25 (11.4)
1.00
0.68 – 1.46
0.322
Heroin IDU
14 (6.4)
0.79
0.50 – 1.25
0.766
Illicit methadone use
172 (78.2)
0.97
0.81 – 1.17
0.153
Illicit buprenorphine use
159 (72.3)
0.85
0.67 – 1.06
189 (85.9)
0.87
0.75 – 1.01
0.183
OxyContin® use5
0.035
Any other oxycodone use
208 (94.6)
0.89
0.80 – 0.99
0.653
Any other prescription opioid use
192 (87.3)
0.96
0.82 – 1.13
0.036
Any prescription opioid IDU
162 (73.6)
0.78
0.62 – 0.98
6.5 (8.4)
0.99
0.98 – 1.00
0.017
Days of opioid IDU4 ‐ mean (SD)
0.028
Sedative, hypnotic or tranquilizer use
187 (85.0)
0.84
0.72 – 0.98
0.453
Sedative, hypnotic or tranquilizer IDU
5 (2.3)
0.58
0.14 – 2.38
0.218
Barbiturate use
19 (8.6)
0.97
0.93 – 1.02
0.187
Crack use
57 (25.9)
0.90
0.78 – 1.05
0.347
Cocaine use
107 (48.6)
0.90
0.71 – 1.13
0.152
Cocaine IDU
56 (25.5)
0.57
0.26 – 1.23
0.484
Methamphetamine use
36 (16.4)
0.89
0.65 – 1.23
0.399
Methamphetamine IDU
11 (5.0)
0.55
0.14 – 2.20
0.149
Prescription stimulant use
67 (30.5)
0.81
0.62 – 1.08
0.663
Marijuana use
181 (82.3)
1.05
0.83 – 1.35
0.440
Hallucinogen use
16 (7.7)
0.97
0.91 – 1.04
0.140
Multiple substance use
203 (92.3)
1.09
0.97 – 1.23
1
GEE models with unstructured correlation, adjusted for RDS
2
n=283 (participants who reported IDU in the 6 months preceding baseline and returned after 6 months
3
GEE did not converge; zero PWID with reduced IDU sharing received HCV treatment compared to 8
(5.5%) reporting no treatment (p‐value via Fisher’s exact test)
4
Last 30 days
5
Includes original and abuse‐deterrent formulations
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status. Sample proportions for time‐invariant measures are reported from baseline data
collection. Sample totals for time‐varying measures reflect proportion of participants reporting
any occurrence between 6 and 24 months for dichotomous variables; means for reported
continuous measures were calculated for the same period. Similar to the previous analysis
including all baseline PWID (Table 3.4), the 220 participants included in this analysis were again
largely male (61%), white (93%), single (75%), and uninsured over the course of the study (50%).
Prescription sedatives and opioids were the most commonly reported drugs used illicitly during
the last 6 months across all time points, with 85% reporting sedative use, 86% OxyContin®, 95%
other forms of oxycodone, and 87% other prescription opioids. 162 participants (74%) reported
prescription opioid IDU over the course of the study, compared to lower proportions of those
reporting recent IDU of cocaine (26%), heroin (6%), methamphetamine (5%), sedatives (2%), and
the one participant reporting prescription stimulant IDU (0.5%; not shown).
74 individuals in this sample (33.6%) reported decreased IDU‐related equipment sharing
at any interview between 6 and 24 months. In bivariate GEE analyses specifying unstructured
covariance, decreased IDU sharing was associated with HCV‐positive T&C 18 months after
receipt of test results and counseling (OR=1.2, 95% CI: 1.0‐1.4), but there were no significant
associations at any other time point or with overall HCV T&C received at any point during the
course of the study. Participants reporting any religious affiliation were more likely to report
decreased IDU sharing (OR=1.9, 95% CI: 1.0‐3.7), as were those reporting bisexuality or
homosexuality (OR=3.1, 95% CI: 1.2‐8.2), ever having used prescription sedatives (OR=4.2, 95%
CI: 1.3‐13.1) or hallucinogens (OR=2.0, 95% CI:1.0‐3.8), and those meeting the DSM‐IV criteria
for PTSD (OR=2.3, 95% CI: 1.0‐5.1). Variables negatively associated with decreased IDU sharing
included seeking treatment after testing HCV‐positive (OR=0.95, 95% CI: 0.92‐0.98), recent
unprotected sex (OR=0.8, 95% CI: 0.6‐1.0), IDU frequency in the last 30 days (OR=0.99 per day,
95% CI: 0.98‐1.00), recent non‐medical use of any oxycodone formulation except OxyContin®
(OR=0.9, 95% CI: 0.9‐1.0) or sedatives (OR=0.8, 95% CI: 0.7‐1.0), and frequency of prescription
opioid IDU in the last 30 days (OR=0.99, 95% CI: 0.98‐1.00). No other IDU measures had negative
associations with decreased IDU sharing.
Table 3.7 presents adjusted odds ratios for decreasing IDU sharing from a multivariate
GEE model with unstructured covariance specified. This model was statistically weighted to
adjust for RDS and incorporated time elapsed since HCV‐positive test disclosure and counseling
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Table 3.7
Predictors of decreased IDU sharing among recent PWID with no previous HCV+ test (n=220)1
Characteristic
Adjusted
95% CI
p‐value
Odds Ratio
Male
0.38
0.19 – 0.75
0.006
Number of dependents (per individual)
0.73
0.55 – 0.97
0.029
Any religious affiliation
2.63
1.32 – 5.22
0.006
0.291
0.87 – 1.58
1.17
Study intervals since HCV+ test & counseling: 1
0.152
0.92 – 1.73
1.26
2
0.042
1.01 – 1.92
1.40
3
0.72 – 1.43
1.01
4
0.940
Unprotected sex (last 30 days)
0.82
0.67 – 0.99
0.043
Sedative, hypnotic or tranquilizer use (last 6m)
0.81
0.70 – 0.95
0.007
Days of prescription opioid IDU (last 30 days)
0.99
0.97 – 1.00
0.026
1

GEE model with unstructured correlation, adjusted for RDS

in discrete study intervals along with other significant covariates. Having previously received an
HCV+ test before study enrollment was not significant at any time except 3 study intervals
(approximately 18 months) after serotesting (aOR=1.4, 95% CI: 1.0‐1.9). Men were 62% less
likely to decrease their IDU sharing (95% CI: 0.2‐0.8). Reported number of dependents was
negatively associated with improvements in sharing behavior in this population (aOR=0.7 per
individual, 95% CI: 0.6‐1.0), whereas having a religious conferred more than 2.5 times the odds
of decreasing IDU sharing over the course of the study (aOR=2.6, 95% CI: 1.3‐5.2). Those
reporting unprotected sex in the last 30 days were 18% less likely to reduce IDU sharing during
the same period (95% CI: 0.7‐1.0). Recent of frequency prescription opioid IDU also had a
harmful effect on IDU sharing (aOR=0.99 per day of IDU, 95% CI: 0.97‐1.0) independent of
overall IDU frequency, which was not significant and dropped from the model. Finally, recent
non‐medical users of sedatives, hypnotics, or tranquilizers were nearly 20% less likely to report a
reduction in frequency of IDU sharing (95% CI: 0.7‐1.0).
The above model assumed an unstructured (US) specification for the covariance matrix
quantifying within‐subject correlation, with a quasi‐Akaike information criteria (QIC) measure of
goodness‐of‐fit of 1700.5. Given the nature of longitudinal data, an autoregressive (AR)
covariance structure was also considered for the final model, as presented in the Appendix
(Table A3.1). Because missed “middle” interviews are restricted from models specifying
autoregressive covariance, the sample size for this alternative model was n=203. Number days
of prescription opioid IDU was not significant and replaced with any prescription opioid IDU in
the last 6 months (aOR=0.8, 95% CI: 0.6‐1.0). As with the unstructured correlation model, HCV‐
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positive T&C conferred higher likelihood of decreasing sharing after 3 study intervals (aOR=1.2,
95% CI: 0.9‐1.4), but the effect was of marginal significance in the autoregressive model
(p=0.068). Because the QIC value for this reduced autoregressive model suggested no
improvement in goodness‐of‐fit (QICAR=1775.5 versus QICUS=1700.5), the unstructured
specification presented above was selected as the final model. Mean VIF for final predictors in
the unstructured model was 1.21, indicating no issues with multicollinearity.
To investigate potentially deleterious changes in IDU sharing frequency over time, a
multivariate GEE model for increased IDU sharing in the last 30 days is presented in Table 3.8. As
summarized in the Appendix in Table A3.2, receipt of an HCV‐positive test prior to study
enrollment was not significantly associated with risk of increased IDU sharing in bivariate
analyses (OR=1.1, p=0.85), thus these 63 participants were included in this analysis. 55 study
participants reporting recent baseline IDU (19.4%), or an RDS‐adjusted population estimate of
18.1% (95% CI: 13.7‐23.6), increased their frequency of IDU sharing between 6 and 24‐month
interviews. HCV‐positive T&C had statistically marginally negative associations with increased
IDU risk only in the HCV‐positive T&C had statistically negative associations with increased IDU
risk only in the third and fourth study intervals (p=0.062 and p=0.079, respectively). Length of
time in the study was positively associated with increasing IDU sharing frequency (aOR=1.04 per
month, 95% CI: 1.01‐1.07), as recent unprotected sex with a PWID (aOR=5.2, 95% CI: 2.8‐9.4),
illicit use of prescription stimulants (aOR=3.3, 95% CI: 1.5‐7.6), and frequency of prescription
Table 3.8
Predictors of increased IDU sharing among recent PWID (n=283)1
Characteristic
Adjusted
Odds Ratio
Time since study enrollment (per month)
1.04
Monthly income (per $100)
0.97
1.38
Study intervals since HCV+ test & counseling: 1
1.04
2
0.38
3
0.31
4
Unprotected sex with PWID (last 30 days)
5.17
Ever used marijuana (lifetime)
0.40
Prescription stimulant use (last 6m)
3.31
Days of prescription opioid IDU in last 30 days (per day) 1.09
1

GEE model with unstructured correlation, adjusted for RDS
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95% CI

p‐value

1.01 – 1.07
0.95 – 1.00
0.58 – 3.28
0.44 – 2.46
0.14 – 1.05
0.08 – 1.14
2.84 – 9.42
0.19 – 0.87
1.45 – 7.58
1.07 – 1.11

0.013
0.032
0.465
0.923
0.062
0.079
<0.0001
0.021
0.005
<0.0001

opioid IDU (aOR=1.09 per day, 95% CI: 1.07‐1.11). The unstructured covariance model fit equally
as well as the autoregressive model (n=264) presented in Appendix Table A3.3, with QIC values
of 588.9 for both models and similar magnitudes and directions of associations and levels of
significance for all independent measures in the multivariate models. Finally, mean VIF with the
unstructured specification was 1.22, suggesting no multicollinearity between predictors in the
final model.

Predictors of IDU cessation
In light of the association of HCV‐positive T&C with increased frequency of IDU after 6
months observed among baseline PWID (Table 3.5) and the nested nature of injection drug
paraphernalia sharing within IDU itself, a secondary analysis of injection cessation over time was
undertaken to further explore this protective behavior. Receiving an HCV‐positive test prior to
study enrollment was negatively associated with IDU cessation in the bivariate analyses
presented in Table A3.4 among the 283 baseline PWID, thus analysis of this outcome was
undertaken excluding the 63 individuals reporting a prior positive test. 166 of these 220
participants (75.5%) reported at least one 6 month break from IDU between 6 and 24‐month
interviewing. Bivariate GEE analysis adjusted with RDS weights also appears in Table A3.4 of the
Appendix. Given the high prevalence of IDU as a preferred route of drug administration in this
sample and the robust correlation observed between IDU and illicit drug use during the same
study interval, two multivariate models are presented with regard to IDU cessation over the
course of the study: one excluding recent illicit drug use to assess non‐drug‐related time‐varying
measures, and another including significant recent illicit drug use measures in order to
differentiate drug‐specific associations with likelihood of IDU cessation. Of note, inferences
regarding the principal research question of interest (impact of HCV screening on IDU cessation)
were similar between these two model specifications.
Table 3.9 presents a multivariate GEE model with an unstructured covariance
specification and recent illicit drug use measures excluded (n=220). HCV‐positive testing and
counseling conferred a 40% reduction in odds of IDU cessation during the interval following
serotesting (aOR=0.6, 95% CI: 0.4‐1.0). The most robust predictor of reporting continuous IDU at
each interview was recent unprotected sex with PWID, which was associated with an 84%
decrease in odds of cessation (95% CI: 0.1‐0.3). Other independent predictors of increased odds
of IDU cessation included receiving substance abuse treatment in the last 6 months (aOR=2.2,
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Table 3.9
Predictors of IDU cessation among recent PWID, excluding recent illicit drug use measures
(n=220)1
Characteristic
Adjusted
95% CI
p‐value
Odds Ratio
0.049
0.35 – 1.00
0.59
Study intervals since HCV+ test & counseling: 1
0.111
0.90 – 2.84
1.60
2
0.210
0.80 – 2.71
1.48
3
0.097
0.89 – 4.23
1.94
4
Number of dependents
1.31
1.09 – 1.56
0.004
Lifetime history of incarceration
0.23
0.10 – 0.53
0.001
Currently receiving disability pension
2.86
1.63 – 5.02
<0.0001
Substance abuse treatment (last 6m)
2.23
1.22 – 4.04
0.009
Unprotected sex with PWID (last 30d)
0.16
0.09 – 0.30
<0.0001
Alcohol use to intoxication (last 6m)
0.64
0.43 – 0.96
0.029
Ever used illicit OxyContin® (lifetime)
0.24
0.09 – 0.62
0.003
Days of Rx opioid IDU in last 30d (per day)2
0.93
0.91 – 0.95
<0.0001
1
2

GEE model with unstructured correlation, weighted for RDS
At baseline

95% CI: 1.2‐4.0), number of dependents reported (aOR=1.3 per individual, 95% CI: 1.1‐1.6), and
current receipt of a pension for physical disability (aOR=2.9, 95% CI: 1.6‐5.0). Lifetime histories
of incarceration (aOR=0.2, 95% CI: 0.1‐0.5) and non‐medical OxyContin® use (0.2, 95% CI: 0.1‐
0.6) decreased the likelihood of IDU cessation, as did frequency of prescription opioid IDU in the
30 days preceding baseline (aOR=0.93 per day, 95% CI: 0.9‐1.0) and recent alcohol use to
intoxication (aOR=0.6, 95% CI: 0.4‐1.0). Table A3.5 in the appendix presents a GEE model with
autoregressive covariance specified (n=203). The QIC value of this alternative model suggested
marginal improvement in goodness‐of‐fit (QICAR=1746.1 vs. QICUS=1753.3). The significance and
direction of associations agreed in both models with the exception of recent use of alcohol to
intoxication, which was dropped from the autoregressive model. Associations of all other
covariates were of the same direction and similar in magnitude between the two models.
Finally, Table 3.10 below summarizes multivariate odds ratios for IDU cessation
including recent illicit drug use measures with an unstructured covariance matrix for GEE.
Directions and magnitude of associated covariates were unaffected with the exception of recent
alcohol use to intoxication and substance abuse treatment, which were dropped from the
recent illicit drug use model. Unprotected sex with PWID in the last 30 days remained the
strongest predictor of continuous IDU, conferring an 80% reduction in odds of IDU cessation
(95% CI: 0.1‐0.4), largely in agreement with the recent drugs‐excluded model in Table 11. Drug‐
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Table 3.10
Predictors of IDU cessation among recent PWID, including recent illicit drug use measures
(n=220)1
Characteristic
Adjusted
95% CI
p‐value
Odds Ratio
Time since study enrollment (per month)
0.98
0.95 – 1.00
0.086
0.003
0.21 – 0.73
0.40
Study intervals since HCV+ test & counseling: 1
0.747
0.60 – 2.02
1.10
2
0.882
0.53 – 2.08
1.05
3
0.827
0.49 – 2.42
1.29
4
Number of dependents (per individual)
1.29
1.05 – 1.57
0.015
Lifetime history of incarceration
0.23
0.11 – 0.50
<0.0001
Currently receiving disability pension
2.66
1.46 – 4.83
0.001
Unprotected sex with PWID (last 30d)
0.20
0.11 – 0.37
<0.0001
Days of Rx opioid IDU in last 30d (per day)2
0.93
0.91 – 0.95
<0.0001
Illicit OxyContin® use (last 6m)
0.22
0.13 – 0.39
<0.0001
Other oxycodone use (last 6m)
0.33
0.20 – 0.54
<0.0001
Cocaine use (last 6m)
0.48
0.28 – 0.81
0.006
1
2

GEE model with unstructured correlation, weighted for RDS
At baseline

specific illicit use in agreement with the recent drugs‐excluded model in Table 3.9. Drug‐specific
illicit use measures independently associated with decreased likelihood of IDU cessation in this
model were OxyContin® (aOR=0.2, 95% CI: 0.1‐0.4), other formulations of oxycodone (aOR=0.3,
95% CI: 0.2‐0.5), and cocaine (aOR=0.5, 95% CI: 0.3‐0.8). The QIC value for this model was
1498.02, suggesting superior fit to the model without recent illicit drug use measures in Table
3.9 (QIC=1753.3), as expected given the strong correlation between recent illicit drug use and
IDU in this sample. Regarding the independent measure of interest, HCV‐positive T&C at the
previous study visit was again associated with decreased odds of IDU cessation during the
subsequent interval (aOR=0.4, 95% CI: 0.2‐0.7). An alternate GEE model specifying an
autoregressive covariance structure (n=203; see Table A3.6 of Appendix) resulted in no changes
of significance or direction of any associations, with adjusted odds ratios similar in magnitude
and no improvement in goodness‐of‐fit (QICAR=1506.7 vs. QICUS=1498.0). Therefore, the
unstructured covariance specification in Table 3.10 was selected as the final model for statistical
inference.
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3.4 Discussion
This study is the first to examine longitudinal patterns of IDU risk behavior in a rural
population of PWID, and among the first to assess the impact of drug‐specific illicit use.
Consistent themes emerged across various metrics of IDU behavior pursuant to assessment of
impact of screening and counseling on risk behaviors for HCV transmission. In concordance with
the majority of previous studies addressing this question, HCV testing and post‐test counseling
had minor apparent positive impact on IDU‐related risk behavior in this rural Appalachian
population, with mixed findings among individuals testing positive in particular. At time of study
enrollment, prior HCV‐positive status awareness was strongly associated with sharing any IDU
paraphernalia in the past 30 days. Because this association held true for two other measures of
IDU behavior (decreased IDU frequency and IDU cessation), 63 participants reporting a previous
HCV‐positive test were excluded from multivariate analyses of these outcomes to enhance
inferences regarding HCV testing and counseling received specifically during the course of this
study. Following suggestions of a trend at 6 and 12‐month interviews, a modest positive
association with decreased frequency of IDU sharing was observed among individuals testing
positive 18 months previously. This effect was transient, however, and no significant effect of
HCV‐positive T&C detected at the following interview. Similarly, HCV‐positive T&C did not
significantly impact on increased IDU sharing during any study period, although marginally
protective associations (p<0.10) were observed 18 and 24 months after serotesting. However, it
is important to bear in mind that these results reflect change in IDU frequency, and a nominally
higher proportion of HCV‐seropositive individuals were sharing IDU paraphernalia at every study
occasion, with significantly higher proportions at 6 and 12 months. Moreover, with regard to
IDU continuity regardless of sharing patterns, positive T&C had a clear harmful effect in the
short term, with a significant reduction in odds of IDU cessation seen in both the drug‐excluded
and recent drug use‐specific longitudinal models. This effect was also transient, however, and
no associations with the occurrence of IDU were significant beyond 6 months. In sum, these
results suggest that HCV screening and brief post‐test counseling has modest impact on IDU risk
in the setting of rural Appalachia. However, the behavioral changes observed were not
sustained over time and may be unlikely to significantly reduce HCV incidence among rural
Appalachian PWID in the absence of further intervention.
Cross‐sectional associations with lower risk of IDU sharing at baseline included number
of dependents reported and receipt of a disability pension. Interestingly, while these factors also
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emerged as protective in longitudinal analysis as significant predictors of IDU cessation, number
of dependents was negatively associated with reporting a decreased frequency of IDU sharing,
suggesting a complex role of family‐related financial obligations in risk calculation among rural
PWID. In addition to HCV‐positive status awareness, measures associated with increased IDU
sharing at baseline included recent unprotected sex with a drug injector and various illicit drug
use measures, including lifetime use of sedatives and hallucinogens, recent use of oxycodone‐
containing prescription opioids, and frequency of recent opioid IDU. Of these, unprotected sex
with another PWID and frequency of prescription opioid IDU were repeatedly associated with
greater IDU risk quantified as sharing and continuous injection in longitudinal analyses, whereas
recent non‐medical use of OxyContin® and other oxycodone‐containing drugs predicted
diminished likelihood of IDU cessation only.
Of the sociodemographic factors were associated with changes in IDU behavior, gender
was the most notable. Men were significantly less likely to decrease IDU sharing over the course
of the study, suggesting that women could be more responsive targets of IDU risk reduction
education efforts, regardless of HCV serostatus. Moreover, interventional efforts may need to
consider gender‐specific approaches and focus particular attention to IDU risk behavior among
men. Of note, this finding is in direct contrast to other studies of IDU sharing behavior, which
have reported women being more likely to share injection paraphernalia (Evans, Hahn et al.
2003; Korthuis, Feaster et al. 2012). Reported number of dependents exhibited a negative
association with decreasing IDU sharing, whereas those reporting any religious affiliation were
more likely to reduce IDU sharing over the course of the study. These findings are novel in the
field of IDU risk behavior research, and the latter association is of particular interest given the
importance of religion in Appalachian culture (Pew Forum on Religion & Public Life 2008) and
the key role of altruism among HCV‐positive PWID who elect to reduce IDU risk behavior.
Moreover, religion‐based public health interventions (Studts, Tarasenko et al. 2012; Schoenberg,
Bundy et al. 2014) have been effective in rural Appalachia, although 75% of individuals in this
sample reported no religious affiliation. In addition, while income was not associated with IDU
risk reduction in this population, higher income did significantly reduce risk of increased IDU
sharing, a finding supported by the sharing‐protective association reported in a French sample
of HCV‐seronegative PWID (Vidal‐Trecan, Coste et al. 1998). Other sociodemographic measures
had little impact on IDU sharing, including age, despite previously reported protective
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associations (Norden, Saxon et al. 2009; Korthuis, Feaster et al. 2012) and education, although
Korthuis et al (2012) reported a protective effect of higher education.
Recent unprotected sex with another PWID displayed robust risk associations across
metrics of IDU risk, including a strong positive association with increased frequency of IDU
sharing and decreased likelihood of IDU cessation. Similarly, any unprotected sex in the last 30
days was negatively associated with reducing IDU sharing frequency. The influence of sexual risk
on IDU behavior has been reported in previous studies, with increased risk of IDU sharing among
individuals reporting transactional sex (Wood, Li et al. 2005), sex partners who currently inject
(Shaw, Shah et al. 2007), and among women, recent sex with PWID (Evans, Hahn et al. 2003).
Furthermore, Evans et al. (2003) also reported that recent sexual contact with PWID explained
concomitant IDU risk better than gender alone. Despite very low risk of transmission by sexual
contact (Terrault, Dodge et al. 2013), risky sexual behavior such as transactional sex (Hahn,
Page‐Shafer et al. 2002; Ward 2013) is a commonly associated with HCV infection, suggesting
correlation between sexual and IDU risk behaviors given the very low likelihood sexual
transmission. The robust association in this population between IDU sharing and unprotected
sex with partners known to be injecting further supports this connection.
In one of the few studies to report associations of using specific drugs with IDU sharing,
Korthuis et al. (2012) reported that use of any opioid, marijuana, and crack via IDU were
positively associated with IDU sharing. In this analysis, frequency of injecting prescription
opioids in particular conferred greater risk of IDU sharing, independent of overall IDU frequency,
whereas recent crack IDU had no significant associations and lifetime marijuana users were
actually less likely to increase sharing. Moreover, recent non‐medical use of prescription
stimulants predicted increased IDU sharing, whereas non‐medical sedative uses were less likely
to decrease sharing frequency. However, non‐medical use of prescription OxyContin® and other
oxycodone formulations, particularly via IDU, was consistently associated with elevated IDU risk
quantified as either increased or decreased sharing frequency. As with IDU cessation, this
further attests to the unique behavioral risk relationships of non‐medical prescription drug use
in general and prescription opioid IDU in particular among rural Appalachian PWID relative to
their urban counterparts (Young, Havens et al. 2010; Havens, Oser et al. 2011; Havens, Lofwall
et al. 2013).
Previous studies have suggested “breaks” from IDU to be effective as a pragmatic
approach to reducing HCV incidence in high‐risk populations, even if only in the short‐term
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(Hahn, Page‐Shafer et al. 2002; Evans, Hahn et al. 2009; Page, Morris et al. 2013). A recent
longitudinal study reported a small but significant decrease in IDU frequency among PWID
testing HCV‐positive (Aspinall, Weir et al. 2014). Among rural PWID in this study, by contrast,
HCV‐positive T&C reduced the likelihood of taking a break from IDU in the short‐term. This also
implies that receiving a negative HCV test result may have a beneficial effect on IDU cessation in
the 6 months following testing. However, this pattern was not sustained over time, implying
that the impact of testing and counseling alone is transient regardless of serostatus, and that
focused multidisciplinary interventions with peer‐driven approaches are more likely to effect
lasting decreases in IDU risk (Latka, Hagan et al. 2008). Although there were no significant
associations between alcohol use and IDU sharing as reported in other studies (Vidal‐Trecan,
Coste et al. 1998; Le Marchand, Evans et al. 2013), recent alcohol use to intoxication was a risk
factor for continuous IDU. This finding echoes previous research (Shah, Galai et al. 2006; Evans,
Hahn et al. 2009), suggesting that IDU is best reduced via complete abstinence from any drug
use, whether illicit or legal in nature. Incarceration also substantially reduced the likelihood of
IDU cessation in this population, similar to findings in an urban population of PWID in Baltimore
(Galai, Safaeian et al. 2003) and related to prior associations with both IDU sharing (Wood, Li et
al. 2005) and hepatitis C itself (Neff 2003; Larney, Kopinski et al. 2013). Lower IDU frequency
was another key predictor of cessation reported by Evans et al. (2009), and in this cohort
baseline IDU frequency of prescription opioids in particular was negatively associated with IDU
cessation, whereas overall IDU frequency was not significant. Similarly, while heroin use also
predicted decreased chance of cessation among urban PWID in San Francisco (Evans, Hahn et al.
2009), OxyContin® and oxycodone were important predictors of continuous IDU in the rural
population studied here. This finding reinforces important differences in IDU preference
between urban and rural populations as reported in previous research of Appalachian PWID
(Young, Havens et al. 2012). Finally, illicit benzodiazepine use was negatively associated with IDU
cessation in the urban San Francisco cohort (Evans, Hahn et al. 2009), while in this population
recent non‐medical use of sedatives decreased the likelihood of reducing IDU sharing frequency,
but had no apparent impact on occurrence of IDU itself.
Less than a third of this study sample reported receiving substance abuse treatment
during any study interval. Encouragingly, however, recent substance abuse treatment in this
population decreased risk of engaging in IDU, supporting arguments to expand access such
programs in the rural Appalachian region and reiterating reports from Galai (2003) and Evans et
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al. (2009). As with baseline prevalence of IDU sharing, receiving a disability pension again
conferred a protective effect. Whether this association resulted from substance abuse
treatment and support structure of this government program, habitual reporting bias stemming
from program eligibility criteria, or associated drug testing is unknown. Furthermore, although
no previous studies have investigated the impact of government support such as disability
insurance program on IDU risk, the protective association observed here is striking given that
nearly a quarter of this population reporting receiving disability over the course of the study,
and Appalachian Kentucky has among the highest proportions of disability recipients nationwide
(Flippen 2014). Echoing the findings of Shah and colleagues (2006), risky sexual relationships
with PWID were a robust predictor of continuous IDU in this population. As with IDU sharing as
discussed above, this further suggests considerable overlap of injecting and sexual risk
relationships in this population and supports the application of network‐based approaches to
the study of IDU among risk rural PWID. Finally, an association between number of dependents
and increased likelihood of IDU cessation was observed, independent of recent illicit drug use.
This finding implies that family responsibilities could be important points of social leverage with
regard to targeting and implementation intervention efforts aimed at diminishing IDU risk
behavior in Central Appalachia.
Prior research of HCV prevention modalities often refers to the hypothesis that
increasing HCV screening reduces injection risk behavior among PWID (Page, Morris et al. 2013),
although the strength of evidence that HCV screening reduces transmission risk behaviors was
rated “low” in a comparative effectiveness review from the Agency for Health and Research
Quality (Chou, Cottrell et al. 2012). Furthermore, it has been noted that HCV testing and
counseling creates opportunities to decrease IDU risk behavior on two levels: 1. individual,
among those testing HCV‐negative; 2. population, or the network of PWID connected via IDU to
those testing positive (Hagan, Campbell et al. 2006). If the concept of risk is defined as “the
chance you take of becoming injured by a hazard” (Norden, Saxon et al. 2009), then PWID
already infected with HCV receive no primary preventive benefit in reducing IDU‐related risk
behavior. Thus, population‐level primary prevention is optimized only if HCV‐positive PWID
place value in reducing or eliminating IDU sharing behavior. However, concordant with another
study of PWID in substance abuse treatment reported an association of HCV‐positive status
awareness (Korthuis, Feaster et al. 2012), HCV‐positive status awareness conferred increased
risk of IDU sharing in cross‐sectional cross‐sectional analysis (Table 3.5), and the magnitude of
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association was similar between the studies, with multivariate odds ratios of 3.0 in this sample
and 2.4 in the Korthuis (2012). By contrast, a recent study of HCV seroconverters reported no
change in frequency of injecting with used equipment among PWID recently acquiring
antibodies to HCV, although overall frequency of any IDU did show a modest decrease (Aspinall,
Weir et al. 2014). Another major study differentiated risk behaviors on the basis of HCV‐positive
awareness versus HCV‐negative awareness in a cross‐sectional analysis, acknowledging that HCV
“risk” has distinctly different meanings between HCV‐seropositive and HCV‐seronegative
PWID—specifically, infection versus disease manifestation, respectively. Using this approach,
Hagan and colleagues (2006) reported that PWID who were aware of their HCV‐negative status
were less likely to share syringes or cotton filters. Related patterns of increased risk among HCV‐
seropositive PWID aware of their status have been reported in cross‐sectional analysis (Norden,
Saxon et al. 2009). By contrast, other researchers have found no effect of HCV screening and/or
seropositive status on IDU risk (Ompad, Fuller et al. 2002; Miller, Mella et al. 2003; Tsui,
Vittinghoff et al. 2009), whereas just two have reported decreased IDU sharing among HCV‐
seropositive PWID (Vidal‐Trecan, Coste et al. 2000; Kwiatkowski, Fortuin Corsi et al. 2002),
implying that the net population‐level effect of HCV screening and post‐test counseling with
regard to primary prevention behaviors among seropositive PWID is most often null or even
potentially negative in the absence of further interventional effort, but these negative effects
can be offset by prevention “reminders” among seronegative PWID (Hagan, Campbell et al.
2006).
Overall, findings from the rural population studied here suggest a similar pattern, with
HCV‐positive testing and counseling weakly associated with reduced injecting risk behaviors or
of null effect and short‐term tendency among those testing seronegative to cease IDU. This
implies there could be modest population‐level benefit to screening among HCV‐seropositive
PWID, as suggested by Kwiatkowski (2002) and Vidal‐Trecan (2000), and a short‐lived individual‐
level effect among HCV‐seronegative PWID with regard to IDU cessation. However, as all
apparent benefits were ephemeral in nature, the overall preventive gains of screening are likely
minimal or null in this population, in agreement with the preponderance of conclusions from
other longitudinal studies (Ompad, Fuller et al. 2002; Tsui, Vittinghoff et al. 2009; Aspinall, Weir
et al. 2014). In this analysis, sharing proportions presented in Figure 4.1 became nearly identical
between HCV groups after 18 months, when a beneficial effect of positive T&C on IDU sharing
become significant, but this preventive gain was not sustained. This trajectory suggests that the
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entire sample substantially decreased IDU sharing after baseline regardless of serostatus, but
individuals testing negative were somewhat less likely to decrease sharing relative to those
testing positive 18 months previously. Moreover, this preventive benefit was not sustained
beyond 18 months, and the proportion of HCV‐seropositive individuals sharing IDU
paraphernalia at the final study occasion showed signs of increase from the preceding visit.
Furthermore, individuals testing HCV‐positive were more likely to report continuing to engage in
IDU in the 6 months following their serotest. Thus, while HCV‐positive testing and counseling
had a potentially beneficial effect on IDU sharing frequency in this population, these behavioral
gains may be offset by a concomitant tendency to continue injecting 6 months after positive
screening. Moreover, no associations in IDU risk behavior were observed beyond 18 months,
although there was marginally significant trend among individuals who received HCV‐positive
T&C to cease IDU 24 months or more following serotesting. Regardless, HCV screening was not
clearly effective in decreasing IDU risk in this population, and as suggested in other studies
among PWID, more intensive targeted interventions are likely required to meaningfully
decrease HCV incidence via behavior change.
The study of primary HCV prevention is predicated on understanding the concept of
“risk” among seropositive PWID—individuals with substantial IDU risk who are likely infected
with HCV. Risk perception and aversion theory offers valuable insight into the culture of HCV risk
and IDU behavior among injectors. In the first application of psychometric scaling methods
(Slovic, Fischhoff et al. 1985) to a drug‐using sample, Marsch and colleagues (2007) found the
three most significant components impacting risk perception among PWID to be (ranked in
descending order of importance in accounting for perception variance): 1. potential severity of
consequences related to the risk; 2. degree of certainty with regard to experiencing potential
consequences of risk; and 3. extent to which consequences of risk are delayed versus
immediate. In theory, HCV screening and counseling should ameliorate both factors 1 and 2,
first by reducing the uncertainty of future consequences by providing status awareness, and
second by educating PWID with regard to the potential severity of untreated HCV in the long
term—namely, morbidity and mortality due cirrhosis and HCC, as well as extrahepatic morbidity.
However, the third component in this model of risk perception is largely unaffected by HCV
testing and counseling. Moreover, HCV risk would presumably rank very low in this category
regardless of serostatus, given that the disease manifestations of CHC take upwards of two
decades to manifest, if symptoms appear at all. It is logical to surmise that many PWID are likely
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concerned with the more immediate consequences of IDU‐related risk, namely managing the
symptoms of opiate addiction, maintaining adequate food and shelter, avoiding incarceration
and other legal concerns, and more rapidly progressing health problems caused by IDU.
Furthermore, among individuals already infected with HCV, the notion of risk compensation
becomes relevant, given that these individuals’ “risk” of acquiring HCV is effectively negated,
eclipsed perhaps by other more clear and present medical risks of IDU, such as drug overdose
and infective endocarditis, although it has been reported that the health risks of IDU are not
high‐priority concerns of daily life among most PWID (Miller 2005). Even among seronegative
individuals, the threat of HCV acquisition may seem minor compared to other risks routinely
faced by PWID. HCV has been referred to as “ordinary” and “ubiquitous” by PWID (Rhodes,
Davis et al. 2004; Rhodes and Treloar 2008), to the extent that HCV has assumed a normative
status in many communities of injectors (Davis, Rhodes et al. 2004; Treloar and Rhodes 2009).
Many PWID and even some public health officials regard HCV as an “inevitable” consequence of
IDU not worth the effort of preventing (Page, Morris et al. 2013). Moreover, “hepatitis” as a
potentially hazardous construct was ranked only intermediate in a scale of perceived risk among
PWID: position 20 out of 53, just ahead of “police work,” “barbiturates,” and “motorcycles,” but
behind “dynamite,” “terrorism,” and “nuclear power,” with HIV and AIDS ranked first and
second (Marsch, Bickel et al. 2007). This further suggests that the potentially severe, but very
gradual health threats that affect “only” 1 out of 4 individuals with CHC are not sufficient to
substantially deter injection‐related risk among PWID after basic screening without more
focused intervention.
Despite this low HCV risk perception, the modest effect of screening observed in this
Appalachian cohort suggest that scaling up of HCV screening and counseling among rural PWID
do offer a moderate benefit to behavioral targets of primary prevention. Perhaps reflective of
the poor access to healthcare and disease screening services characterizing Central Appalachia,
it appears that any intervention is likely better than none with regard to HCV risk among rural
PWID. However, many researchers suggests that one intervention in isolation—even those
requiring significant government or other financial support such as syringe exchange and opioid
substitution programs)—are unlikely to significantly reduce high HCV incidence among PWID
(Page‐Shafer, Hahn et al. 2007; Rhodes and Hedrich 2010; Hagan and Schinazi 2013; Grebely and
Dore 2014; Hellard, Doyle et al. 2014). By contrast, combined interventions incorporating
integrated addiction treatment, focused counseling, peer support, opioid substitution, syringe
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exchange, and convenient medical care for HCV have been demonstrated to effect sustained
decreases in IDU risk behavior and HCV transmission (Wright and Tompkins 2006; Birkhead,
Klein et al. 2007; Latka, Hagan et al. 2008; Zule, Costenbader et al. 2009; Vickerman, Martin et
al. 2012; Martin, Hickman et al. 2013). Meta‐analysis of SEP and OST in the UK reached the same
conclusion, finding that combined OST and high‐coverage SEP together resulting in a 48%
reduction in needle sharing and an 80% reduction in odds of acquiring HCV (Turner, Hutchinson
et al. 2011). The superiority of combined interventions seems likely to hold true in rural
Appalachia as well, though unfortunately both the funding and political will to support
implementation of such programs in the Central Appalachian region is unlikely in the
foreseeable future. As was noted earlier, Kentucky is one of 18 states in the U.S. without SEPs
(Foundation for AIDS Research 2013), as such programs are prohibited by state law (Kentucky
Legislative Research Commission 2010). Thus despite the tremendous economic burden
projected from public health impacts of HCV (Davis, Alter et al. 2010), a pragmatic approach to
prevention such as the scaling‐up of existing HCV testing options, expanded access to substance
abuse therapy and mental health services, and invigorated public health education campaigns
are likely the most realistic hope to contain HCV in rural Appalachia, barring substantial changes
in political culture and availability of funding.
Although this study provides important insights into the nature of injection‐mediated
HCV transmission risk among rural PWID, there are limitations to consider. First, while the data
are longitudinal in nature, some covariates do not temporally precede the dependent variables
assessed. Collection of time‐invariant data including sociodemographic measures and lifetime
behavioral and drug use measures preceded assessment of IDU sharing at each time point, as
did HCV testing and potential post‐test counseling. However, other time‐varying measures
including self‐reported health‐related measures, illicit drug use during the last 6 months, and so
on, were analyzed concurrently with the reported outcome (IDU sharing), limiting causal
inference. Nonetheless, this strategy was deemed appropriate in light of these measures
reflecting conditions closer to the outcome of interest. Moreover, IDU sharing was assessed in
the last 30 days, lending support to causal inferences made from behaviors covering the entire
6‐month study interval and diminishing recall bias with regard to the primary outcome.
Assessing IDU sharing within the last 30 days also reduced the influence of HCV test result
disclosure date variance between participants, as the Home Access serotest used between
baseline and 18 months came before the era of instant point‐of‐case testing such as the
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OraQuick® “instant” serotest (implemented at 24 months in this cohort), requiring instead 2
weeks or more before test results were available and potential counseling received, dependent
upon participant’s return for test results and patterns of attrition. In addition, a choice was
presented between assessing sharing of needles/syringes, ancillary IDU equipment (cookers,
cotton filters, water, spoons), or a combination of both. In light of considerable research
demonstrating the importance of so‐called “indirect” sharing of equipment and syringe‐
mediated sharing in HCV transmission (Hagan, Thiede et al. 2001; Thorpe, Ouellet et al. 2002;
Pouget, Hagan et al. 2012) and widespread awareness of HCV risk via needles/syringes as well as
ancillary equipment sharing methods in this cohort at baseline (99.7% and 97.2% respectively),
combining sharing of any IDU equipment was deemed justifiable and most physiologically
relevant with regard to HCV transmission. Furthermore, as described in chapter 2, the study
survey instrument captured baseline status awareness among participants testing HCV‐
seropositive, but not among those testing negative. Although there was no apparent impact of
baseline status awareness among seropositive participants, it is unknown whether previous
awareness of HCV‐negative status might have influenced IDU sharing and continuity at later
study occasions. Finally, lifetime and recent behavioral measures used in this analysis relied on
self‐report from study participants, potentially subjecting the data to reporting, social
desirability, and recall biases. Nonetheless, self‐reported risk behavior from PWID was
determined to be a reliable indicator of actual behavior in a comprehensive review (Weatherby,
Needle et al. 1994; Darke 1998), and the possibility recall bias was minimized by the primary use
of 6‐month measures of drug use and 30‐day for the primary outcome measured concerned IDU
sharing.
The data presented here illuminate several important pathways for future research of
HCV risk in this population. Given the dynamic interplay of sexual and injection behaviors
reported here, one avenue for further study in this population is to incorporate dyadic and
sociometric network measures in relation to IDU risk behavior over time. Moreover, while this
analysis accounts for awareness of one’s own HCV status in impacting future risk behavior, it
does not assess whether an individual’s awareness of serostatus of other members in an IDU
network may influence risk behavior. Network‐oriented analysis and modeling of HCV risk has
produced important insights with regard to HCV transmission, treatment, and reinfection (Rolls,
Sacks‐Davis et al. 2013) and HIV risk behavior and norms (Latkin, Forman et al. 2003; Latkin,
Kuramoto et al. 2010), including demonstrated efficacy of network‐based risk reduction
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interventions (Latkin, Donnell et al. 2009; Latkin, Donnell et al. 2013). However, there have been
relatively few studies examining network factors and network‐oriented interventions on IDU risk
behavior in populations with high HCV prevalence, although the impact of social network factors
on both IDU risk behavior (De, Cox et al. 2007; Shaw, Shah et al. 2007) and HCV transmission
(Sacks‐Davis, Daraganova et al. 2012) has been substantial in past research. Finally, there have
been no longitudinal studies of straw‐sharing during inhalational drug use, specifically what
impact HCV testing and counseling might have on straw sharing over time. In light of the finding
that intranasal administration is higher among rural Appalachian prescription opioid users
relative to urban users (Young, Havens et al. 2010), sharing of straws used for drug inhalation
could represent an important mode of viral transmission in this population and another viable
target for intervention.
In sum, the results from this sample build upon most previous studies of the topic
suggesting that HCV screening and post‐test informational counseling in isolation are unlikely to
have a strong lasting effect on IDU risk behavior among PWID in most settings, including that of
rural Central Appalachia. On the other hand, screening for HCV may have a positive short‐term
effect on maintaining “safer” IDU behaviors among seronegative PWID, and modest
improvement in IDU sharing frequency were observed among those receiving a positive test and
counseling. Moreover, the opportunities for promotion of secondary prevention via lifestyle
modification (particularly reduction of alcohol intake) and medical management and potential
treatment of HCV are substantial (Marinho, Vitor et al. 2014). As discussed in the following
chapters, widespread HCV treatment uptake targeted to the right individuals has considerable
potential to act as a cost‐effective means of primary prevention (Martin, Pitcher et al. 2011;
Martin, Vickerman et al. 2011; Hagan, Wolpe et al. 2013; Grebely and Dore 2014). Rapidly
evolving and potent drug agents specifically targeting HCV are increasingly likely to result in viral
clearance in the form of SVR, which in turn represents a vital isthmus between primary and
secondary HCV prevention. Thus, regardless of impact on transmission risk behavior, HCV
screening has potential benefit among high‐risk populations if only to increase the probability of

chronically infected individuals engaging the healthcare system to receive active clinical
management of CHC. Of course, individuals infected with HCV must first know their disease
status in order to seek care from a healthcare provider, and the newest drug agents do not
come without a hefty a price tag for those eligible to be treated. In the following chapter, the
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many challenges, barriers, and clinical issues marking the path to medical care and treatment
among individuals with CHC are explored in detail.
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Chapter 4
Secondary Prevention:
Factors impacting progression of chronic HCV

4.1 Overview
Once hepatitis C establishes chronic infection in the liver of an exposed individual, the
virus induces a nonspecific immune response resulting in chronic hepatic inflammation, high
levels of oxidative stress, and variable degrees of fibrosis (Feld and Liang 2006). A body of
research also indicates the virus is also likely responsible for direct activation of hepatic stellate
cells, apoptosis, and oncogenic activity mediated primarily by the viral core protein (Okuda, Li et
al. 2002; Chou, Tsai et al. 2005). Beyond the increasingly efficacious drug treatment options, an
array of biological, behavioral, and environmental factors are known to dictate progression of
hepatic fibrosis, development of hepatocellular carcinoma (HCC), and long‐term clinical
prognosis of patients with CHC. Age is perhaps the most important non‐modifiable predictor of
CHC progression, with age at time of infection robustly predicting rate of hepatic fibrosis, even
controlling for the effect of duration of infection and exceeding the impact of viral genotype
(Poynard, Bedossa et al. 1997). This pattern is reflected in concerns among public health officials
as the American “baby boomer” cohort born between 1945 and 1965 advances in age and the
clinical impacts among individuals infected with HCV expand (Davis, Alter et al. 2010). The
pathological mechanism at play between aging and HCV remain uncertain, although hypotheses
include declining immune function, loss of mitochondrial capacity, and reduced vascular
perfusion (Missiha, Ostrowski et al. 2008). Similarly, male sex has also been reported as a
predictor of accelerated progression to cirrhosis in many studies (Poynard, Bedossa et al. 1997;
Wright, Goldin et al. 2003), doubling the rate of fibrosis progression in one study even
controlling for other established factors impacting disease progression (Ratziu, Munteanu et al.
2003). Higher rates of HCC among men as well as greater numbers of liver transplantations are
also observed. This gender differential risk is mediated primarily by protective effects of
estrogen, although important gender differences in IL‐10 and IL‐6 expression have also been
reported (Missiha, Ostrowski et al. 2008). Some evidence also indicates that race impacts the
likelihood and rate of CHC progression, particularly with regard to U.S. studies demonstrating
increased risk of HCC (El‐Serag 2004) and poor response to conventional HCV treatment (Muir,
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Bornstein et al. 2004) among African‐American patients. Surprisingly, however, this trend
among Black patients with CHC has not translated to increased risk of cirrhosis, perhaps instead
indicating poor access to medical care among African‐Americans (Nguyen, Segev et al. 2007). In
addition, sporadic data indicate accelerated progression among American Latinos (Bonacini,
Groshen et al. 2001), whereas Native Americans have exhibited higher rates of spontaneous
viral clearance (Scott, McMahon et al. 2006). Other potential non‐modifiable factors include
source of infection and a variety of host genetic polymorphisms detected via genome‐wide
scanning (Missiha, Ostrowski et al. 2008). Although viral genotype exerts well‐established
effects on sustained virologic response (SVR) in response to conventional ribavirin‐interferon
treatment regimes, particularly with regard to genotype 1, reports of accelerated fibrosis among
patients with genotypes 1 and 3 have been largely discredited (Missiha, Ostrowski et al. 2008).
Nonetheless, genotype 3 has been positively associated with spontaneous clearance of acute
infection in the absence of treatment in (Lehmann, Meyer et al. 2004).
An important and frequently overlooked aspect of HCV management is that many
severe manifestations of chronic hepatitis C are strongly correlated to patient behavioral factors
and other modifiable characteristics. Foremost among these behaviors is alcohol consumption
among individuals with CHC. Over 20 years of research have unequivocally demonstrated a
deadly synergy between alcohol consumption and HCV, with clearly elevated rates of hepatic
fibrosis, cirrhosis, and HCC among individuals who consume alcohol after infection (Hutchinson,
Bird et al. 2005; Mallat, Hezode et al. 2008), even at moderate levels (Khan and Yatsuhashi
2000). Of note, receiving an HCV‐positive serotest and post‐test counseling did not significantly
reduce frequency of alcohol consumption 6 months after testing among baseline drinkers in the
cohort studied in this report, suggesting that more intensive interventions are needed in the
setting of rural Appalachia (Stephens and Havens 2013). In addition to alcohol, smoking tobacco
is another well‐established risk factor for HCC (Mori, Hara et al. 2000) and potentially
accelerated fibrosis (Missiha, Ostrowski et al. 2008) among CHC patients, and marijuana
smoking has been reported to increase risk of steatosis and potentially fibrosis (Hezode, Roudot‐
Thoraval et al. 2005; Hezode, Zafrani et al. 2008; Mallat, Hezode et al. 2008). Hepatic iron levels
have also been established as an important predictor of liver disease progression (Shedlofsky
1998; Fujita, Sugimoto et al. 2007). Therapeutic phlebotomy is effective in the management of
CHC for hemochromatosis patients and the 30‐40% of HCV‐infected individuals who become
iron overloaded (Yano, Hayashi et al. 2002). Proposed histopathological mechanisms for iron’s
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deleterious effect include increased inflammation and viral‐mediated changes in iron trafficking
(Missiha, Ostrowski et al. 2008). Next, with particular relevance to the medical setting of Eastern
Kentucky, a variety of interrelated metabolic factors including obesity, insulin resistance, and
non‐alcoholic steatohepatitis exhibit strong associations with advanced liver disease among CHC
patients (Fierro, Gonzalez‐Aldaco et al. 2014; Huang, Yang et al. 2014); interestingly, these
appear to be HCV genotype‐specific. Finally, an array of co‐infections can substantially
accelerate disease progression, including hepatitis B, HIV, and schistosomiasis, with the latter
pathogen being particularly relevant to the epidemic levels of HCV in the developing world
(Missiha, Ostrowski et al. 2008). The pathological synergy observed with regard to HIV stems
from viral suppression of CD4+ T‐cells, leading to attenuated cell‐mediated immunity and
elevated HCV viral loads among co‐infected individuals.

4.2 HCV treatment and barriers to care
Along with the modifiable and non‐modifiable factors impacting disease progression
described above, medical treatment holds substantial power to avert severe clinical
manifestations of CHC. This is increasingly true as new all‐oral, interferon‐free and potentially
ribavirin‐free treatment options make impressive strides in terms of vastly increased efficacy
and decreased toxicity. However, HCV presents obstacles to effective disease management at
multiple levels: molecular, individual (patients and their physicians), and at the macro scale of
the healthcare system and society itself (Morrill, Shrestha et al. 2005; Thomas 2013; Treloar,
Rance et al. 2013). Once chronic infection has been established, as is the case in approximately
75% of exposed individuals (NIH 2002), the virus can obscure its presence from the host immune
response for decades and even actively downregulate signaling process of host cell machinery
(Foy, Li et al. 2005) that would otherwise have resulted in viral eradication. Similarly, in most
individuals with CHC, symptoms are subtle and rarely recognized—if symptoms are present at all
(NIH 2002; Seeff 2002). Even among those individuals who are diagnosed with HCV and seek
medical care, the many contraindications outlined in Table 1.3 coupled with physician‐level
barriers can block the path to treatment and viral eradication, despite rapid advances in HCV
pharmacotherapy. However, most of the reasons to delay or withhold care have been reported
as perceived at the patient‐level, including concerns of non‐adherence, psychiatric comorbidity,
toxicity, threat of reinfection, and inability to afford treatment, along with numerous
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organizational/institutional obstacles, (Edlin, Seal et al. 2001; McGowan, Monis et al. 2013;
Robaeys, Grebely et al. 2013). Furthermore, it is worth noting that in McGowan and colleagues’
(2013) survey of 697 physicians in 29 countries, reported reasons for deferring treatment among
physicians varied substantially between geographic regions.
Thomas (2013) suggested that all necessary virologic and therapeutic factors for HCV
eradication are present: HCV can be effectively cleared from infected individuals, transmission
can be controlled by behavioral modification and harm‐reduction policies, and HCV does not
have a non‐human reservoir, which prevents the complete elimination of some other
pathogens. Moreover, treatment of a sufficient number of individuals with CHC could reduce
the exclusively human‐borne reservoir for HCV to the point that, in theory, the HCV epidemic
could be brought to an end. However, inadequate investment in public health intervention
efforts, insufficient financial resources to subsidize the expense of treatment, prevention and
harm reduction programs, and a general lack of socioeconomic and political will in many parts of
the world obstruct widespread eradication of the virus at present (Thomas 2013).
Largely because of the insidious clinical course fostering low status awareness combined
with marginalized social status of many individuals with CHC (Conrad, Garrett et al. 2006), most
previously reported HCV treatment uptake rates in the general population have been very low.
For instance, rates worldwide have varied from 16% in France to less than 1% in Romania,
Poland, Greece, and Russia (Lettmeier, Muhlberger et al. 2008). The United States falls in the
middle of this spectrum, with one study finding 11.6% of 99,166 veterans with CHC initiating
treatment, but only 6.4% of them completing it (Kramer, Kanwal et al. 2012), despite this
patient population having essentially free access to medical care for HCV. A sobering model
predicting the impact of HCV treatment on health outcomes in the United States estimated that
just 14% of future mortality due to progressive hepatic disease resulting from CHC will be
prevented by drug therapy at current levels of treatment uptake (Volk, Tocco et al. 2009).
As for status awareness among individuals with CHC, population‐based data in the U.S.
indicate that HCV screening and treatment uptake are relatively low across multiple
socioeconomic strata. In an analysis of 170 HCV‐seropositive individuals recruited from those
participating in the National Health and Nutrition Examination Survey (NHANES) between 2001
and 2008, just 49.7% were aware of the HCV‐positive serostatus before being notified by
NHANES, although 80% of these individuals had seen a doctor after receiving their initial positive
HCV test result. Unfortunately, data on seeking or receiving treatment were not reported.
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Notably, participants 40‐59 years of age, non‐Hispanic whites, and those who reported seeing a
physician following status disclosure also scored higher on a survey assessing their knowledge
level of HCV (Denniston, Klevens et al. 2012). Volk and colleagues (Volk, Tocco et al. 2009)
reported data from a subsample of 133 HCV‐infected respondents taken from NHANES (2003‐
2008), 11 individuals (sampling weight‐adjusted proportion: 12%, 95% CI: 4‐19%) were treated
for HCV. The most frequently cited reasons for not receiving treatment were as follows: 69
(adjusted 49%, 95% CI: 39‐60%) were unaware of their HCV‐seropositive status prior to NHANES
participation, 33 (adjusted 24%, 95% CI: 15‐33%) were advised by their physician not to be
treated, 12 (adjusted 9%, 95% CI: 3‐16%) did not follow‐up with a physician following status
disclosure, and 8 (adjusted 6%, 95% CI: 1‐9%) refused treatment. Unsurprisingly, poor access to
healthcare and lack of insurance emerged as major barriers to HCV status awareness and
treatment, with sampled individuals lacking any form of health insurance more likely to be
unaware of their HCV status (OR 4.8, 95% CI: 1.8‐12.7) and marginally less likely to receive
treatment (OR 0.3, 95% CI: 0.03‐2.6). Moreover, NHANES participants without a usual source of
medical care were more likely to be unaware of their status (OR 19.0, 95% CI: 2.4‐148.1), and
none of these respondents had received treatment for HCV (Volk, Tocco et al. 2009).
Other studies reiterate low rates of treatment uptake across multiple settings. In a study
of 2118 residents of inner‐city Vancouver, Canada, just 15 of 1360 (1.1%) of HCV‐seropositive
individuals had initiated treatment between January 2000 and December 2004—an alarming
proportion in a population with access to government‐sponsored healthcare (Grebely, Raffa et
al. 2009). A retrospective analysis of 196 Irish patients receiving opioid substitution therapy
found that 151 (77%) had been previously screened for HCV, and of these HCV seroprevalence
was 69%. 24 (23%) of the 104 individuals with a positive test result had followed up with a
physician and just 3 (3%) had received HCV treatment (Cullen, Stanley et al. 2007). This
represents a somewhat anomalous pattern, in that a large proportion of individuals in this
sample were screened and aware of their HCV status, yet very few of those testing positive had
followed up with a physician or received treatment. In a non‐population‐based sample, Morrill
and colleagues (2005) investigated barriers to care among 208 HCV RNA‐positive patients under
the care of a primary physician in community health centers. 57 (27.4%) individuals had
undergone treatment, with individual‐level and physician‐level barriers cited, as outlined in the
following sections.
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People who use and/or inject drugs face additional barriers to care relative to the
general population (Grebely, Genoway et al. 2008) and are generally characterized by lower
levels of treatment uptake for CHC relative to the general population. Australian health
researchers in one study found treatment uptake among HCV‐positive PWID to be just 4%
(National Centre in HIV Epidemiology and Clinical Research 2009). Other researchers in Australia
reported an increase from the proportion of 9478 PWID who had received treatment from 3.4%
to 8.6% between 1999 and 2001 (Iversen, Grebely et al. 2013), though it is worth noting that
Australian public health and government officials have been aggressively confronting the HCV
epidemic among PWID. Another study of 597 PWID living in Baltimore reported treatment
initiation rates of just 6%, with 22% aware that HCV was curable, and only 21% reporting that
they had received evaluation by a healthcare provider and discussed treatment (Mehta,
Genberg et al. 2008). Similarly, Strathdee and colleagues (2005) found that just 27% of PWID
aged 18‐35 years in three U.S. cities had followed up with a healthcare provider following the
disclosure of their HCV‐seropositive status.
In light of these data, there are barriers to HCV medical care for infected individuals
across multiple levels: the often asymptomatic nature of acute and early chronic HCV, the
perceptions and preferences of individuals infected with the virus, and the attitudes and clinical
judgment of clinicians providing care for HCV‐positive individuals, who are in turn subject to
complex contraindications to treatment along with restrictions and financial constraints of the
overall healthcare system, although vast differences can exist both within and between
countries (McGowan, Monis et al. 2013). Finally, society itself presents many obstacles to HCV
eradication, including social stigmatization and discrimination with regard to HCV‐positive
individuals and PWID in particular (Zacks, Beavers et al. 2006; Treloar, Rance et al. 2013), as well
as a general lack of resources and energy allocation for effectively managing a global public
health crisis caused by what theoretically should be an eradicable disease agent (Thomas 2013).

Individual‐level
Data presented in chapter 5 are principally focused on individual‐level barriers to HCV
care, specifically those with potential to influence the decision to seek medical care after being
diagnosed HCV‐seropositive and receiving informational post‐test counseling. As reported in
many prior studies (Fraenkel, McGraw et al. 2005; Khokhar and Lewis 2007; Nguyen, Dore et al.
2007; Swan, Long et al. 2010), fear of treatment adverse effects and lack of concern for the
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potential long‐term health consequences of CHC were suggested as the most pressing personal
concerns with regard to initiating HCV treatment in a sample of 120 HCV‐positive individuals. By
contrast, physician recommendations were cited as a common motivating factor (Fusfeld,
Aggarwal et al. 2013). Race has also been suggested to be an important effect modifier in the
decision to begin treatment (Khokhar and Lewis 2007), although as yet this question remains
inadequately studied in minority populations (Borum, Igiehon et al. 2009). Morrill et al. (2005)
found that single individuals, women, current heavy alcohol users, and patients with low
attendance to appointments with their physician were less likely to receive treatment for HCV; a
positive association with declining therapy among women was also suggested in another study
(Khokhar and Lewis 2007). By contrast, in a study of HCV‐positive individuals in Australia, Stoove
and colleagues (2005) found the opposite association with regard to gender and HCV specialist
referral; female gender conferred increased likelihood of referral, along with a longer period of
time since HCV diagnosis, longer consultation times at diagnosis, and the experiencing of HCV‐
related symptoms. In a multivariate model, absence of current IDU and seeing a general
practitioner specifically for HCV care were strongly associated with referral to a specialist for
HCV treatment, whereas current IDU was associated with diminished probability of receiving
treatment. Thus, current IDU was negatively associated with both HCV specialist referral and
subsequent treatment (Stoove, Gifford et al. 2005).
As these previous findings from Stoove and colleagues suggests, among active PWID,
healthcare barriers are likely to be more pronounced and potentially distinct from those faced
by the general population, although much overlap exists given the high prevalence of IDU in the
HCV‐positive population (Grebely, Genoway et al. 2008). In a qualitative study, Treloar and
colleagues (2010) examined patient‐level barriers to care and treatment initiation in a small
sample (n=27) of HCV‐infected PWID receiving opioid substitution therapy (OST) in Australia.
Among the factors OST clients reported were competing responsibilities such as caring for
children, concerns regarding adverse effects of treatment, perceived low efficacy of HCV drug
therapy, homelessness and unstable living arrangements, medical and psychiatric comorbidities
including HIV, stroke, myocardial infarction, diabetes, epilepsy, hepatitis B, depression, and
antisocial behavior. In a related quantitative study, younger age (adjusted OR=0.9, 95% CI: 0.9‐
1.0), higher formal education (aOR=7.8, 95% CI: 1.6‐37.7), and participation in opioid
substitution therapy (aOR=4.5, 95% CI: 2.2‐8.2) were independently associated with receiving
medical assessment for potential HCV treatment in a cross‐sectional analysis of Australian PWID
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(Treloar, Hull et al. 2012). Swan and colleagues (2010) qualitatively explored barriers to HCV
care among Irish PWID in a variety of settings, finding that several patient perceptions and
characteristics inhibited access to HCV care, including the notion that HCV is a benign disease,
fear of invasive tests and treatments, lack of symptoms, and a general perception of HCV drug
therapy as undesirable circulated in the form of negative anecdotes through peer networks.
Other life responsibilities also competed with treating participants HCV infection, such as
keeping a job and housing, attaining education, and addiction problems, whereas experiencing
HCV symptoms, having obligations to children, and expressing the desire to quit using illicit
drugs were all commonly reported as factors motivating HCV treatment initiation (Swan, Long et
al. 2010). The demotivating impact of CHC’s often asymptomatic course was also reported in
another qualitative study of 95 racial minorities who use drugs, in addition to reluctance from
physicians to initiate treatment and recommendations against treatment from both healthcare
providers and peer networks. Moreover, low HCV knowledge levels were reported among study
participants with regard to the meaning of a positive HCV serotest, the long‐term health
implications of CHC, the necessity of clinical follow‐up and active HCV monitoring, and the
availability of efficacious treatment (Jordan, Masson et al. 2013).
The individual‐level barriers above are repeated across many studies in the field. Among
216 treatment‐naïve PWID in 3 U.S. cities, researchers found that higher levels of awareness of
the threat of advanced liver disease, having a regular source of healthcare, absence of alcohol
dependency, and higher levels of readiness to quit drug use were associated with greater
interest in initiating HCV drug therapy. Moreover, PWID who had been told by a healthcare
professional that they were at risk for cirrhosis or liver cancer had seven‐fold greater levels of
interest in HCV treatment (Strathdee, Latka et al. 2005), suggesting the priority of physician‐
level advocacy for treatment of eligible patients, as described in the following section. In
qualitative assessment of participants the large Australian Trial in Acute Hepatitis C (ATAHC)
study, treatment toxicity, current substance use, mental health contraindications were reported
as common barriers to HCV treatment among active drug injectors, but financial and
transportation problems, lack of social support, and legal system difficulties (criminalization of
IDU) also emerged as frequently cited barriers to medical care and treatment adherence
(Nguyen, Dore et al. 2007). A later analysis from the same study found a treatment uptake level
of 76% (111 of 146) in this highly interventional setting, with HCV RNA level and duration of HCV
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infection being independently associated with treatment uptake, while current IDU was not
(Grebely, Petoumenos et al. 2010).
Finally, by using Geographic Information Systems (GIS) software technology, distance of
residence from available HCV care facilities has recently been shown to be strongly associated
with HCV diagnosis and status awareness in French PWID (Monnet, Collin‐Naudet et al. 2006;
Monnet, Ramee et al. 2008). Thus poor geographic access might also be expected to impact
access to HCV care and treatment‐seeking, particularly in the rural setting. In a related study
controlling for the system‐level factor of healthcare resource deprivation, the same association
was suggested in a model for PWID in the United States, although this finding was specific to
PWID with a history of receiving OST (Astell‐Burt, Flowerdew et al. 2011).

Healthcare provider‐level
In light of the complex set of contraindications, the lengthy and demanding nature of
the treatment, and many adverse effects surrounding treatment, it is inherent to the nature of
HCV pharmacotherapy that the decision between a patient and physician to initiate therapy is
difficult and beset with potential barriers, even among individuals who are aware of their status
and seek medical care. However, adherence to basic HCV screening guidelines among physicians
was found to be poor in a sample of 154 U.S. physicians, with numerous barriers at the level of
clinician knowledge and attitudes (Southern, Drainoni et al. 2013), potentially exacerbating what
is already a cumbersome and challenging process in terms of medical management. With a
regard to initiation of HCV treatment, McGowan and colleagues (2013) found in a global review
of 697 physicians in 29 countries that patient‐level issues were the most commonly reported
barriers to care, including concerns regarding toxicity, duration of treatment, and cost of
therapy, as alluded to in the previous section. However, in this study physician knowledge of the
principles of HCV treatment was again found to be deficient across healthcare settings, with less
than 50% of providers providing correct responses to questions covering treatment paradigms
such as treatment stoppage in responses to HCV RNA levels at various stages of therapy and the
impact of patient fibrosis staging and HCV viral load (RNA titer) on the probability of achieving
SVR. Commonly cited barriers at the healthcare provider‐ and system‐levels included insufficient
reimbursement for services, lack of access to necessary medications and labs, lack of
administrative and office support to treat patients, insufficient training lack of referral from
other physicians, and limitation of HCV treatment to government‐controlled centers (McGowan,
74

Monis et al. 2013). In addition, in Morrill and colleagues’ retrospective analysis (2005),
reluctance among physician to treat patients with a history of substance abuse was reported as
a provider‐level barrier, along with other typical patient‐related factors such as current
substance abuse, psychiatric contraindications, and treatment refusal.
Given the high prevalence of illicit drug use and IDU among HCV‐positive individuals,
several potential barriers arise from the impact of these behaviors on patient lifestyle. In a study
of 4318 HCV‐positive patients in the Veteran’s Administration system, 2611 (61%) were former
PWID, although former IDU was not associated with candidacy for HCV treatment or efficacy of
treatment (Seal, Currie et al. 2007). Nonetheless, among physicians managing the care of active
drug users in particular, many potentially valid arguments against treatment initiation are
frequently cited, including: poor adherence to long and demanding treatment regimes; high
burden of adverse effects, particularly with regard to interferon use among patients with
comorbid psychiatric conditions such as major depressive disorder, and concerns of HCV
reinfection among active PWID following SVR (Edlin, Seal et al. 2001).
Some researchers have argued that current the treatment eligibility criteria remain too
restrictive, despite a relaxing of rules to permit treatment of active people who use and even
inject drugs on a “case‐by‐case” basis with careful monitoring and concomitant substance abuse
treatment (Ghany, Strader et al. 2009). A study of 404 HCV‐infected PWID aged 18‐35 found that
96% exhibited conditions that could exclude them from treatment on the basis of eligibility
criteria that were argued by the authors to be overly stringent in many cases (Hagan, Latka et al.
2006). Indeed, many studies have demonstrated that PWID can achieve rates SVR comparable
to non‐drug‐using samples if treatment is delivered in the right setting (Birkhead, Klein et al.
2007; Grebely, Knight et al. 2010; Aspinall, Corson et al. 2013). Nonetheless, the probability of
achieving SVR when treating people who are actively using or injecting drugs is highly context‐
dependent and must be considered individually in light of the standard eligibility criteria,
including individual housing situation, psychiatric health, alcohol consumption habits, and
presence of a social support network, in addition to access to ancillary PWID‐specific services
such as substance abuse treatment, opioid substitution therapy, and even clean syringes in
some situations (Birkhead, Klein et al. 2007). At one extreme, delaying therapy has been
suggested to be ethical as a patient care decision only in certain stages of HCV infection and if an
achievable plan is proposed to address a patient’s illicit drug use issues (Edlin, Seal et al. 2001).
Lastly, in light of substantial concerns of HCV reinfection following SVR, rates of reinfection are
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generally low (Micallef, Macdonald et al. 2007; Grebely, Knight et al. 2010; Grebely, Prins et al.
2012; Grady, Schinkel et al. 2013), and treatment of active PWID has been modeled to be cost‐
effective in populations with HCV prevalence below 60% (Martin, Vickerman et al. 2012).
Unfortunately, these studies do not address system‐level barriers such as the high cost of
treatment, restrictive coverage from insurers, and regional scarcity of harm reduction programs
as outlined in the following section, particularly in countries such as the United States that lack a
national healthcare system and comprehensive policy to manage the problem of widespread
HCV among PWID.

Healthcare system‐level and societal barriers
In a review by McGowan colleagues (2013), the most commonly cited barriers at the
level of the healthcare system or government included the high cost of HCV treatment,
restrictions on treatment as per government policy, insufficient public funding for HCV
management, and inadequate public promotion of treatment. In addition, numerous barriers
related to health insurance providers were reported, including: refusal to cover HCV treatment,
coverage limitations for HCV‐positive patients; refusal of plans to cover RNA quantification, HCV
genotyping, hepatic fibrosis testing, or medications to manage adverse effects; restrictions
regarding which physicians could treat HCV; requirement for liver biopsy to begin treatment;
and excessive paperwork (McGowan, Monis et al. 2013). Morrill and colleagues (2005) also
reported system delays in patient referral to HCV specialists as a common barrier to treatment
in their retrospective study. Another recent review by Harris and Rhodes (2013) of the most
significant social barriers to HCV care among PWID cited discrimination and stigma, housing
instability and homelessness, geographic access and localized resource deprivation problems,
criminalization of IDU lifestyle, health care system obstacles and government policy restrictions,
and gender‐related cultural issues. In an analysis of NHANES data from 2005‐2008, 54% HCV
RNA‐positive individuals had health insurance, but only 36% of HCV‐seropositive individuals
were both covered by health insurance and potentially eligible for treatment. Insurance status
was protective against being HCV RNA‐positive in a multivariate model (adjusted OR=0.4, 95%
CI: 0.2‐0.8) (Stepanova, Kanwal et al. 2011), suggesting that lack of universal healthcare in the
climate of increasingly costly treatments for HCV is likely to be an important factor in HCV
treatment uptake in the United States. What effect the Affordable Care Act may have health
insurance coverage expands to previously uninsured individuals remains to be seen.
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Two additional societal factors may play a role with regard to the treatment of actively
injecting individuals with CHC: size of the community in which physicians practice and social
stigma. Myles and colleagues (2011) found that size of the population in which Canadian
physicians practice was a robust predictor of whether or not HCV therapy was initiated, with
specialists in communities with a population of 500,000 or greater having nearly 4 times the
odds of treating current PWID relative to those practicing in smaller communities (OR 3.89, 95%
CI [1.06, 14.26]). This finding has obvious implications for the rural Appalachian study population
examined in the following chapter using data collected in the setting of Perry County (pop.
28,241) in Eastern Kentucky. Finally, HCV‐positive individuals and PWID frequently cite social
stigmatization as a major barrier to seeking treatment for their infection‐related and substance
abuse problems (Zickmund, Ho et al. 2003; Zacks, Beavers et al. 2006; Janke, McGraw et al.
2008; Treloar, Rance et al. 2013), which in turn acts as a barrier to both treatment initiation as
well as medication adherence among patients with CHC (Modabbernia, Poustchi et al. 2013).
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Chapter 5
Barriers to Care:
HCV treatment uptake and predictors of healthcare engagement among
rural Appalachian people who use drugs

5.1 Introduction
As previously described, HCV is a major source of morbidity and mortality worldwide,
estimated to cause more than 483,000 deaths globally in 2010 (Lim, Vos et al. 2012) and over
16,000 in the United States in 2011 (Centers for Disease Control and Prevention 2011), with a
U.S. a mortality rate exceeding that of HIV since 2007 (Ly, Xing et al. 2012). The virus
hyperendemic among people who inject drugs, with a midpoint seroprevalence of 73%
worldwide (Nelson, Mathers et al. 2011), and efforts to enhance primary prevention among
PWID have been met with mixed results (Page, Morris et al. 2013). In a study reporting no
impact of HCV‐positive status awareness on transmission risk behavior, Hagan and colleagues
(2006) commented that perhaps the most pragmatic benefit of HCV screening is “to facilitate
access to medical monitoring and treatment of HCV infection.” Indeed, although HCV screening
and post‐test counseling alone have been generally insufficient to reduce transmission risk
among seropositive PWID, increased screening retains important potential applications to
secondary disease prevention among high‐risk individuals. While other modifiable factors
related to HCV disease progression, particularly reducing or eliminating alcohol consumption,
are vital in the management of individuals with CHC, pharmacotherapy for HCV continues to
advance rapidly, offering the promise of decreased toxicity and contraindications, and of
particular relevance among PWID, shortened treatment durations and the imminent availability
of all‐oral, interferon‐ and even ribavirin‐free options achieving sustained virologic response
(SVR) in more than 98% of genotype 1 patients, whether treatment‐naïve or experienced
(Afdhal, Reddy et al. 2014; Afdhal, Zeuzem et al. 2014). Moreover, beyond individual‐level
benefits, treatment also represents another potential form of primary prevention in itself by
reducing the pool of viremic individuals able transmit the virus to others (Martin, Vickerman et
al. 2011; Hagan, Wolpe et al. 2013; Grebely and Dore 2014). However, despite being the crucial
first step in CHC care among seropositive individuals, medical follow‐up with HCV RNA
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quantification to assess for active infection is frequently not undertaken, even in the general
population (Spradling, Tong et al. 2014). Therefore, understanding factors impacting the
decision to see a healthcare provider after receiving a positive serotest and counseling are vitally
important, particularly in medically underserved populations such as PWID (Grebely, Genoway
et al. 2008) and individuals living in rural Central Appalachia (Stensland, Mueller et al. 2002).
Several studies have addressed the question of factors associated with seeing a
healthcare provider and seeking treatment for HCV, but few have specifically assessed recently‐
diagnosed seropositive individuals or drug‐using populations. Moreover, there are no prior
studies focused specifically on the resource‐deprived setting of rural Appalachia. In a sample
taken from four major U.S. healthcare organizations, Spradling and colleagues (2014) found that
just over half (61%) of 5,860 seropositive individuals had received follow‐up RNA testing within 6
months of serotesting, with a significantly increasing trend from 2003 to 2010 (p<0.001). Men,
patients with lower income, those born between 1945 and 1965 were less likely to receive and
RNA test within 6 months of serotesting (Spradling, Tong et al. 2014). Similarly, in a study of 245
seropositive patients sampled from medical facilities, detoxification programs, jails, and prisons,
McGibbon et al. (2013) reported that 164 individuals (67%) received follow‐up testing, although
21% of these tests were administered at the request of the investigators. Missed follow‐up
appointments, unavailability of RNA testing, and patient incarceration were the commonly cited
reasons for lack of follow‐up testing. The researchers concluded that HCV management
guidelines should be amended to recommend routine RNA testing after a positive serotest,
similar to confirmatory Western blot following a positive screening test for HIV (McGibbon,
Bornschlegel et al. 2013).
In population‐based NHANES data collected from 2001 to 2008, lack of HCV status
awareness was the most common barrier to treatment among HCV‐exposed individuals, with
only 84 of 169 individuals (49.7%) aware of their HCV‐seropositive status prior to NHANES
testing and just 3 (3.6%) of previously aware individuals reporting that their doctor had tested
them because of perceived HCV risk (Denniston, Klevens et al. 2012). Having health insurance
(p<0.001), a regular source of healthcare (p<0.001), and being aged 40‐59 (p<0.05) were
significant predictors of HCV‐positive status awareness in bivariate analyses. With regard to
medical follow‐up among HCV‐seropositive individuals, 131 (77.1%) had seen a doctor or
healthcare provider following their positive serotest result. Health insurance status (80.6%
versus 64.9%; p=0.04) and having a regular source of healthcare (91.6% versus 76.3%; p=0.01)
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were associated with receiving medical follow‐up following positive serostatus disclosure.
Among individuals seeing a healthcare professional following HCV‐positive status disclosure,
51.6% were told they needed regular medical care for HCV, while 31.2% were told they did not
need to do anything now with regard to HCV, and 9.4% reported being advised against starting
treatment for HCV. Of the individuals who were told they needed regular care for HCV, 61.8%
received medical treatment for HCV, representing 12.9% of the original 170 HCV‐seropositive
individuals responding to the survey. Finally, an 11 ‐item survey was given to assess HCV
knowledge level. Correct responses to two disease progression‐related questions and one
transmission‐related question were associated with following up with a healthcare provider
following HCV‐seropositive status disclosure (Denniston, Klevens et al. 2012).
In a related study of HCV‐positive secondary survey responders recruited via NHANES
between 2002 and 2007, status awareness emerged the largest barrier to treatment, with 69
out of 133 individuals (estimated 49% with adjustment for sampling) previously unaware of their
status (Volk, Tocco et al. 2009). Just 12 (adjusted 9%) did not follow‐up with a physician from
this subsample of survey respondents, although non‐response bias was a potential limitation. 33
respondents (adjusted 24%) were advised by their physician not to be treated, and 8 (adjusted
6%) refused treatment. 11 respondents (adjusted 12%) received treatment (Volz and
Heckathorn 2012). In related retrospective analysis of treatment uptake among patients
screened for HCV, 24% of 681 treatment‐eligible (RNA‐positive) patients in the U.S. Veterans
Affairs (VA) hospitals received treatment (Groom, Dieperink et al. 2008), whereas just 15% of
122 recently diagnosed viremic patients in a similar retrospective analysis, despite cost of
treatment not being a significant barrier among patients in the VA system. However, population‐
based NHANES and VA patient samples differ substantially from individuals engaging in active
drug use, so these findings are not directly applicable to the setting of rural Appalachia or to
active drug users and PWID, who as outlined below are typically characterized by lower levels
medical care and treatment initiation for HCV.
In a community‐based study specific to people reporting current illicit drug use,
Strathdee and colleagues (2005) reported that just 59 of 216 (27%) treatment‐naïve PWID age
18‐35 in Baltimore, Seattle, and New York City obtained medical follow‐up following disclosure
of HCV‐seropositive status, although 81.5% reported interest in receiving treatment. Interest in
treatment was associated with reporting greater than 50% perceived risk of cirrhosis or HCC in
the next 20 years (adjusted OR=3.7, 95% CI: 1.1‐12.7), having a usual source of care (aOR=6.0,
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95% CI: 1.8‐19.4), lack of alcohol dependency as determined by an AUDIT score ≥ 8 (aOR=0.2,
95% CI: 0.1‐0.6), and reporting higher readiness to stop illicit drug use (aOR=7.5, 95% CI: 1.8‐
32.3) (Strathdee, Latka et al. 2005). Mehta and colleagues (2008) also investigated treatment
uptake among 597 urban PWID with HCV antibodies, finding that 86 (21%) had been evaluated
for HCV treatment by a healthcare provider and just 36 (6%) had initiated treatment. 70% of
participants knew that HCV treatment was available, but only 22% were aware than HCV was a
potentially curable. Commonly reported barriers to HCV treatment were perceptions of severe
adverse effects, low treatment efficacy, and low priority of treatment due to the absence of
symptoms (Mehta, Genberg et al. 2008).
In another study of treatment willingness, Stein et al. (2001) reported that 162 of 306
(53%) former PWID who were HCV‐seropositive were “definitely” or “probably” interested in
initiating HCV treatment, but there was considerable disparity in knowledge levels with regard
to HCV natural history and management. In addition, 82% of individuals who did not know their
HCV status or had never received an HCV serotest were HCV‐seropositive, again suggesting
status awareness is a significant barrier to HCV treatment among PWID (Stein, Maksad et al.
2001). In a study of 2913 PWID in Vancouver, Canada between 2003 and 2004, HCV treatment
was reported in just 15 of 1360 seropositive individuals (1.1%), among which just 4 completed
treatment and 3 achieved SVR. Strikingly, incident HCV seroconversions occurred at a rate 25
times greater than the rate of HCV treatment (Grebely, Raffa et al. 2009); unfortunately,
predictors of treatment uptake were not reported in this study. With regard to the impact of
current IDU on receiving specialist care and initiating treatment for HCV, Stoove and colleagues
(2005) reported that in a sample of 690 Australian PWID, current and former PWID were less
likely to be referred to an HCV specialist than patients with no history of IDU (adjusted OR=3.4,
95% CI: 1.8‐6.2). In addition, current PWID were significantly less likely to initiate treatment for
HCV (p<0.001) (Stoove, Gifford et al. 2005). A review of HCV care uptake among PWID cited
PWID‐specific healthcare barriers on multiple levels commonly associated with low levels of
HCV‐related healthcare uptake. In addition to an array of issues and biases both among
providers and endemic to overall healthcare systems, prominent barriers among patients
included lifestyle instability and poor social functioning, psychiatric comorbidity (particularly
depression), HIV co‐infection, low HCV knowledge level, lack of status awareness, fear of
diagnosis and medical procedures, concerns regarding drug toxicity and low efficacy, and
problems related to finances and transportation (Mravcik, Strada et al. 2013). Finally, as
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mentioned in chapter 4, both shorter travel distance from clinic (Monnet, Collin‐Naudet et al.
2006; Monnet, Ramee et al. 2008) and greater community size quantified as population (Astell‐
Burt, Flowerdew et al. 2011) have been reported as predictors of increased access to HCV‐
related healthcare among HCV‐seropositive PWID.
Given the many barriers to HCV care among people who use drugs, understanding
factors impacting treatment‐seeking after positive serotesting and counseling are vital to
enhancing the effectiveness of HCV screening and targeting individuals at highest risk for severe
liver disease. This is particularly true in medically underserved regions such as rural Appalachia,
where access to harm reduction, substance abuse programs, and integrated disease
management recommended to address widespread HCV among people who use and inject
drugs (Birkhead, Klein et al. 2007; Grebely, Knight et al. 2010) is often limited. By contrast, these
programs are often accessible to PWID in urban centers and in national healthcare systems with
comprehensive HCV intervention policies in place, and the majority of prior research on HCV
care initiation has occurred in this context. Past research has revealed several factors associated
with HCV healthcare engagement, but as yet there is little consensus with regard to which are
most relevant with regard to targeting public health intervention, and many predictors are likely
to be highly population‐ and context‐specific. Moreover, few studies have addressed the
question longitudinally in the period just after serostatus disclosure, and no studies have
addressed the question in the context of rural Appalachia. Thus, the purpose of this study is to
describe HCV care engagement, treatment seeking and uptake in Central Appalachia, and to
identify predictors of receiving secondary medical assessment from a healthcare provider
following a positive HCV serotest and counseling.
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5.2 Methods
Sampling
As described in chapter 3, data analyzed here were collected at the first four study
occasions (baseline, 6‐months, 12‐months, and 18‐months) during the ongoing longitudinal
cohort study, Social Networks among Appalachian People (SNAP; R01DA024598 and
R01DA033862), the purpose of which was to describe epidemiology and risk factors of HCV, HIV,
and herpes simplex virus type 2 (HSV‐2) among people who use illicit drugs in the Central
Appalachian region of Eastern Kentucky. A baseline sample of 503 study participants was
recruited between November 2008 and August 2010 using respondent‐driven sampling (RDS) as
described in detail in chapter 3. Participants were 18 years of age or older, not currently in
substance use treatment, and must have used prescription opioids, heroin, crack/cocaine, or
methamphetamine in the last 6 months. For this analysis, participants testing HCV‐seropositive
at baseline, 6‐month, or 12‐month study occasions and receiving test results and counseling at
least 30 days prior to subsequent interviewing were included. Participants testing “reactive”
were counseled as if HCV‐seropositive and included as well; reactive participants who received a
definitive seronegative test upon subsequent testing were censored from analysis at that point
in time. Participants receiving HCV‐positive T&C at baseline (n0=226), six months (n6=21), or
twelve months (n12=8) were followed through 18‐month interviews. Participants who did not
return for at least one follow‐up interview following their first positive serotest were excluded;
there were no significant sociodemographic differences with regard to these participants. All
participants gave informed consent and were compensated for their time in completing
questionnaires, serotesting, and returning for test results. All study procedures were approved
by the University of Kentucky Institutional Review Board, and a Certificate of Confidentiality was
obtained.

HCV serotesting and data collection
HCV screening was completed at each interview session using the Home Access®
Hepatitis C Check serum antibody test with standard pre‐test counseling given to all
participants. This test uses dried blood spot specimens obtained by finger‐stick and 3rd‐
generation enzyme immunoassay (EIA) to detect HCV serum antibodies. Sensitivity and
specificity of this test are 98.2% and 99.6%, respectively (US Food and Drug Administration
1999), and accuracy exceeds 99% (O'Brien, Kruzel et al. 2001). Post‐test counseling given to
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participants testing seropositive was tailored to their result as detailed in Chapter 3, including
specific recommendations to seek further medical assessment from a healthcare provider and
contact information provided for Appalachian Regional Health Center hospital in Hazard and
four other nearby clinics offering HCV‐related assessment.
The dependent variable of interest was following up with a healthcare professional for
medical assessment following receipt of a positive HCV serotest and post‐test counseling
obtained at baseline, 6‐month, or 12‐month study occasions. Numbers of participants reporting
seeking and receiving treatment for HCV were also collected. To adjust appropriately for
potential bias introduced by non‐randomness inherent to respondent‐driven sampling (Volz,
Wejnert et al. 2012), individualized sampling weights were calculated using RDSAT software,
version 7.1 (Ithaca, NY) for the dichotomous medical follow‐up variable described above and
applied to all bivariate and multivariate analyses.
Sociodemographic and behavioral data were collected via interviewer‐administered
questionnaires using computer‐assisting personal interviewing (CAPI) software. Standard
sociodemographic measures including sex, race, age, education level (including
classroom/academic settings and technical training), income (with illegal sources specified),
marital status, sexuality, and religion were collected. In addition, medical insurance (including
private insurance, Medicaid or Medicare), transportation (access to vehicle and possession of
driver’s license), access to the internet, pattern of employment history were collected at
baseline, and participant responses to the MINI neuropsychiatric interview, version 5.0.31
(Sheehan, Lecrubier et al. 1998), to assess for symptoms of psychiatric disorders including major
depressive disorder (MDD), generalized anxiety disorder (GAD), post‐traumatic stress disorder
(PTSD), and antisocial personality disorder (ASPD) were also collected. Participants meeting the
criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM‐IV) for
any psychiatric conditions were given a standardized information sheet with detailed
information on mental health resources available in the region. Recent (last 6 month) and
lifetime non‐medical use of the following substances was collected at each interview: heroin,
OxyContin® (including old and newer abuse‐deterrent formulations as these entered the
market), other forms of oxycodone, all other prescription opioids, illicit methadone and
buprenorphine, cocaine, crack, methamphetamine, barbiturate, sedatives (including hypnotics
and tranquilizer), hallucinogens, marijuana, and simultaneous use of multiple substances.
Recent and lifetime use of alcohol, alcohol to intoxication, legal methadone, and legal
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buprenorphine were also collected, along with lifetime and recent (past 6‐month and 30‐day)
history of substance use treatment, drug overdose, and incarceration. In addition, shortest
driving distance from each study participant’s addresses to the nearest infectious disease
specialist offering HCV treatment (located at Appalachian Regional Health Center hospital in
Hazard KY, as listed in the HCV post‐test counseling materials) was computed at each study
occasion using geocoded North American Street Map data (Environmental Systems Research
Institute 2010) and the Network Analyst tool in ArcGIS, version 10.2 (Redlands, CA). Participants
who moved away from the area over the course of the study were excluded from analysis of this
measure. HCV knowledge level was assessed using the 6 true‐false questions described in
chapter 3, including participant awareness of HCV treatment availability.
In addition, given the importance of social support in seeking and adhering to HCV
treatment, number of named members offering support in each participant’s social support
network was also calculated from social network data at each time point. Study participants
reported the first name, surname initial, gender, and approximate age of other individuals (or
“alters”) from whom they had received social support. Named alters were later cross‐referenced
with existing demographic information from SNAP baseline data to determine if these
individuals were also enrolled in the study and thus a member of the sociometric network, or
individuals outside of the study. From the network representing social support, total number of
individuals from which the participant received social support (“social support network out‐
degree”) was calculated from time‐varying data reported at each interview. Finally, previous
receipt of a positive test for HCV, hepatitis B virus, HIV, or HSV‐2 from a healthcare professional
was also asked of study participants at each interview.

Analysis
Given the large number of covariates with potential to impact HCV care engagement, a
bivariate screening step was used to select variables for multivariate model‐building.
Longitudinal bivariate odds ratios were calculated in discrete time as described below; analyses
were conducted controlling for the main effect of time with individualized weights to adjust for
RDS. Independent variables with a significance level of p<0.10 were considered for potential
inclusion in the multivariate model. In addition, standard sociodemographic measures (sex, race,
age, education, and income) were considered for inclusion in the multivariate model regardless
of significance in bivariate analysis and retained in the model if their inclusion changed
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coefficient estimates for other independent measures by more than 10% (Hosmer and
Lemeshow 1989). Likewise, previously reported factors impacting healthcare access in drug‐
using populations were also considered in the final model, including current injection drug use,
recent substance abuse and opioid substitution therapy (methadone or buprenorphine), and
DSM‐IV psychiatric measures.
All bivariate and multivariate analyses utilized discrete‐time survival analysis (DTSA).
DTSA was developed for dichotomous dependent variables that are “interval‐censored” in
nature, meaning that the outcome of interest either occurs or does not occur during discrete
intervals defined by two points in time, with no information as to precisely when an event
occurs during each interval (Allison 1982; Singer and Willett 1993; Singer and Willett 2003). In
effect, DTSA is a modified form of survival analysis techniques adapted for the study of interval‐
censored outcomes. Moreover, DTSA yields a familiar odds ratio (OR) measure of association
that is interpretable by a researchers and clinicians across a broad array of scientific and
biomedical disciplines. This approach is ideally suited to non‐repeatable dichotomous outcomes,
such as the outcome primary outcome described here, receiving initial medical assessment from
a healthcare provider after a positive a serotest, a non‐repeatable event that could occur at any
time during the course of the study after testing HCV‐antibody positive: baseline to 6 months, 6
to 12 months, and 12 to 18 months. As serotest results and counseling, if appropriate, were not
received by participants in a homogenous fashion, some individuals were not eligible to obtain
medical follow‐up until after 6‐month interviewing had passed. Similarly, 21 individuals
seroconverted by 6 months and received test results and counseling after that time, followed by
another 8 participants after 12 months. DTSA is ideally suited to leveraging information from
such study designs featuring “staggered” study entry, as well as utilizing the data from
individuals who may have returned for an interview following a positive test result and reported
behavioral data, but were censored from the study because of a missed a subsequent interview.
DTSA approaches interval‐censored data much like a conventional survival analysis,
utilizing life‐tables to calculate hazard probabilities for the dependent measure during each time
interval, conditional on the outcome event not having occurred during a previous interval. From
this, a discrete‐time hazard function can be derived depicting the set of hazard probabilities
observed during each time interval. Discrete‐time hazard functions can then be assessed for
dependence on predictor variables using a series of “dummy” time period indicators (Singer and
Willett 1993). Unlike conventional logistic regression models, there is no single intercept term,
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but instead multiple α parameters serving as intercepts for each respective time interval
observed. Together, these interval‐specific α coefficients represent the baseline logit‐hazard
function subject to the main effect of time for the entire sample assuming a homogenous
population of individuals. For this analysis, More parsimonious approximations of the main
effect of time (constant and linear hazard in this case, as just three time intervals were assessed)
on hazard were assessed in a hierarchical fashion as described by Singer and Willet (2003).
Reduced models were compared to the fully discrete “general“ model for significant changes in
goodness‐of‐fit by assessing change in deviance (‐2[log likelihood]) on a chi‐square distribution
with N – k (number of time parameters in the fully‐discrete minus parameters in the compared
model) degrees of freedom and a critical value 3.84 (p<0.05). Nested time parameterizations
that did not differ significantly from the fully discrete model were then compared on 1 degree of
freedom (as there is a one unit difference in number of time parameters) using the same
distribution and critical value (3.84), along with two likelihood‐based measures of goodness‐of‐
fit, Akaike and Bayesian Information Criteria (AIC and BIC).
In order to capture heterogeneity between participants, time‐invariant and time‐varying
independent measures were considered using a manual forward‐selection process assessing
significance of additional covariates via Wald testing on a chi‐squared distribution with a
significance level of p<0.05. Because DTA employs maximum‐likelihood estimation, conventional
hierarchical methods can be used to compare proposed models with the iterative addition of
covariates, including evaluation of goodness‐of‐fit using AIC and BIC. As with conventional
logistic and other generalized linear models, odds ratios for particular covariates were
calculated by taking the anti‐log of the respective β coefficient. Finally, there are assumptions
inherent to DTSA, summarized as follows: 1. Censoring of participants is independent of the
dependent variable of interest; 2. Relationship between predictors and logit‐hazard is linear,
which can be explored graphically and addressed via transformation, categorical re‐
representation, or dichotomization of independent variables; 3. No unobserved heterogeneity,
as DTSA models have no error term (i.e., multivariate model are assumed to be acceptably
“complete” as specified); 4. Odds are proportional across time for a given predictor, similar to
the proportional hazards assumption of conventional survival analysis‐based Cox regression
(Singer and Willett 2003). Of note, interactions between significant independent variables and
time were assessed in order to test the latter assumption with a p<0.05 level of significance.
Finally, DTSA also assumes homogeneity in interval length between and within individuals.
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Therefore, for fully discrete and linear time specifications, models adjusted for individual
number of eligible days for follow‐up during each interval were also considered using the
following ratio: participant’s number of days eligible for follow‐up / mean number of days for
follow‐up for the overall sample. This ratio then served as time‐weighted indicator and was
compared to discrete‐time and linear‐time models using likelihood‐based goodness‐of‐fit
statistics as described above.

5.3 Results
254 of the 503 participants enrolled at baseline (50.5%) received a positive HCV serotest
and counseling at baseline, 6, or 12‐month study visits. As summarized in Table 5.4, these
individuals were predominantly male (60%), white (95%), and single (76%), with a mean age of
33 years. 95% reported a lifetime history of injection drug use. 98% reported ever having used
OxyContin® non‐medically, whereas 94% and 95% reported a lifetime history of illicit use of
sedatives and cocaine, respectively. 87% had ever been incarcerated, and 28% reported ever
having experienced a drug overdose. For these longitudinal data, dichotomous time‐variant
measures are summarized as any reporting of the respective characteristic between baseline
and 18 month interviews, whereas continuous measures are reported as means during the
study period. 80 participants (32%) reported having any form of health insurance over the
course of data collection between baseline and 12 months, and just 42 (17%) received substance
abuse treatment during the 18 months of data collection.
Table 5.1 below summarizes sample and estimated population proportions of HCV‐
related healthcare events reported at any study interview between 6 and 18 months among
these individuals receiving a positive serotest result and post‐test counseling. 150 participants
(59.1%) reported seeing a healthcare professional after receiving their positive test result, as
advised during informational counseling; adjusting for RDS, these individuals represent an
Table 5.1
Medical follow‐up, treatment seeking, and treatment receipt after HCV‐positive serotest and
counseling (n=254)
Aspect of HCV Care
Sample Total
Population Estimate
n (%)
% (95% CI)
Followed up with provider for medical assessment
150 (59.1)
51.8 (44.5 – 58.9)
Sought treatment for HCV
35 (13.8)
12.4 (8.4 – 18.1)
Received treatment for HCV
21 (8.3)
7.8 (4.5 – 13.1)
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Table 5.2
Life table with sample hazard and survival probabilities for receiving medical follow‐up after
HCV+ testing and counseling

1

Study
intervals1

Time since HCV+
T&C

HCV+ T&C
before
interval

Followed
up with
provider

Censored
at end of
interval

Proportion
following up
with provider
p(Hazard)

Proportion
remaining with
no follow‐up
p(Survival)

1
2
3

0 ‐ 6 months
6 ‐ 12 months
12 ‐ 18 months

254
137
95

97
31
22

20
11
73

0.382
0.226
0.232

0.618
0.478
0.367

Since HCV+ test and counseling

estimated 51.8% of the sampled population. Of these 150 participants, 35 (13.8%) described
themselves as “seeking treatment” following HCV‐positive T&C (12.4% estimated population
proportion). 21 of these participants (8.3% of sample; 7.8% estimated population proportion)
reported receiving treatment for HCV between 6 and 12 months. To illustrate the longitudinal
course of obtaining medical follow‐up in discrete time, life tables, hazard and survivor functions
for these 150 individuals obtaining medical assessment after testing seropositive are presented
in Table 5.2. The conditional probability (hazard) of seeing a clinician for medical assessment in
this rural sample was greatest in the 6 months immediately following HCV‐positive T&C (0.38),
followed by nearly uniform lower values after 12 (0.23) and 18 months (0.23).
Table 5.3 below presents RDS‐adjusted estimates for hazard and survival probability in
the sampled population. As with sample values, conditional probability of obtaining medical
assessment for HCV decreased after 6 months (0.37) to lower values of reported follow‐up at 12
(0.18) and 18 months (0.16), when examined in the context of fully discrete time presented in
the table below. Other parameterizations for the main effect of time were also considered in the
interest of improving statistical efficiency, including models specifying the main effect of time as
constant and linear functions. A quadratic time model was also assessed for pedagogical
purposes only, as with three data collection occasions the quadratic specification provides no
statistical advantage in terms of total parameters estimated and can only diminish precision
relative to the fully discrete model (3 degrees of freedom in both cases). Table A5.1 in the
Appendix summarizes goodness‐of‐fit statistics used to evaluate these four candidate models of
time. Deviance of the constant time model increased significantly from the fully discrete model
(p=0.002), so this model was rejected. Deviance for the linear time model did not significantly
increase relative to the discrete model (p=0.158) and dropped significantly from the constant
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Table 5.3. RDS‐adjusted population estimates for hazard and survival probabilities of receiving
medical follow‐up after HCV+ testing and counseling
Months
p(Hazard) SE
95% CI
p(Survival) SE
95% CI
since testing
0
1
0
1–1
6
0.366
0.036 0.296 – 0.436 0.634
0.036
0.563 – 0.704
12
0.177
0.033 0.112 – 0.242 0.522
0.036
0.451 – 0.592
18
0.161
0.035 0.092 – 0.230 0.438
0.035
0.368 – 0.507
model (p<0.0001). In addition, AIC and BIC goodness‐of‐fit measures in the linear specification
were at least as low or lower than all other candidate models (558.0 and 566.4, respectively),
suggesting the optimal balance of model fit and parsimony. Deviance statistics for the quadratic
time model did not significantly differ from the linear specification (p=0.331), suggesting no
improvement in fit, and as expected, AIC and BIC values were inferior to the fully discrete
general model (AIC: 559.1 versus 558.0; BIC: 571.6 versus 570.6, respectively). Finally, discrete‐
time and linear time models weighted for number of eligible days in each interval relative to
mean interval length exhibited inferior goodness‐of‐fit statistics compared to unweighted
discrete and linear model specifications and were dropped from consideration. In light of these
analyses, the linear parameterization of time was selected for final multivariate modeling and all
statistical inferences presented henceforth. Hazard functions for the general discrete and linear
time parameterizations are depicted graphically in Figure 5.1 below.
0.4

Discrete Time
AIC=558.0
BIC=570.6

0.35

Conditional Probability

0.3

Linear Time
AIC=558.0
BIC=566.4

0.25
0.2
0.15
0.1
0.05
0
6

12

18

Months since HCV+ T&C
Figure 5.1
RDS‐adjusted population hazard functions of following up with a healthcare provider after HCV‐
positive testing and counseling
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Table 5.4
Description of sample and bivariate associations with receiving medical follow‐up after HCV‐
positive test and counseling (n=254)1
Characteristic

Sample total
n (%)

Odds
Ratio

95% CI

p‐value

152 (59.8)
241 (94.9)
33.1 (8.0)
71 (28.0)
23 (9.1)
60 (23.6)
0.9 (1.4)
137.3 (29.3)
1283.6 (1949.6)
93 .8 (19.8)
78 (30.7)
92 (36.2)
68 (26.8)
73 (28.7)
76 (29.9)
35 (13.8)
30 (11.8)
68 (26.8)
234 (92.1)
218 (85.8)

0.73
0.92
0.99
1.39
0.58
0.73
1.03
1.00
1.01
0.98
0.95
0.98
0.95
1.78
0.86
0.89
0.88
1.45
1.56
1.22

0.44 – 1.20
0.32 – 2.66
0.96 – 1.02
0.83 – 2.35
0.32 – 2.66
0.42 – 1.27
0.86 – 1.25
0.99 – 1.01
0.99 – 1.01
0.97 – 1.00
0.56 – 1.59
0.58 – 1.64
0.55 – 1.62
1.04 – 3.05
0.51 – 1.47
0.44 – 1.83
0.37 – 2.08
0.84 – 2.50
0.62 – 3.94
0.63 – 2.36

0.209
0.874
0.213
0.255
0.198
0.270
0.716
0.454
0.284
0.036
0.832
0.930
0.839
0.036
0.589
0.754
0.770
0.185
0.343
0.558

80 (31.5)
164 (64.6)
5.7 (8.9)

1.97
0.90
0.99

1.19 – 3.27
0.56 – 1.56
0.97 – 1.01

0.008
0.679
0.470

106 (41.7)
86 (33.9)
36 (14.2)
151 (59.5)
68 (26.8)
11.3 (10.2)
135 (53.2)
2.0 (1.2)

1.11
1.44
1.97
1.88
1.18
0.99
1.77
1.12

0.67 – 1.83
0.81 – 2.56
0.99 – 3.92
1.19 – 2.97
0.66 – 2.11
0.96 – 1.01
1.12 – 2.78
0.93 – 1.34

0.691
0.216
0.055
0.007
0.574
0.246
0.014
0.222

Lifetime behavior (reported at time of initial HCV+ test)
Received substance abuse treatment
152 (59.8)
Incarceration
222 (87.4)
Drug overdose
72 (28.4)
Injection drug use
240 (94.5)
Heroin use
107 (42.1)
Illicit methadone use
240 (94.5)
Legal methadone use
63 (24.8)
Illicit buprenophine use
183 (72.1)
Legal buprenorphine use
30 (11.8)
Illicit OxyContin® use
249 (98.0)
Any other illicit oxycodone use
245 (96.5)

1.96
1.35
1.55
1.88
1.13
0.32
0.91
1.05
1.53
2.44
0.81

1.20 – 3.20
0.62 – 2.94
0.89 – 2.67
0.60 – 6.11
0.70 – 1.83
0.13 – 0.76
0.53 – 1.56
0.62 – 1.76
0.69 – 3.41
0.34 – 17.42
0.29 – 2.32

0.008
0.450
0.119
0.293
0.621
0.010
0.733
0.868
0.295
0.374
0.701

Time‐invariant
Male
White
Age (years) ‐ mean (SD)
Any religious affiliation reported
Heterosexual
Married
Number of dependents ‐ mean (SD)
Education (months) ‐ mean (SD)
Monthly income (US $) ‐ mean (SD)
% of income legal ‐ mean (SD)
Most often unemployed (last 3 years)
Transportation
Major depressive disorder
Generalized anxiety disorder
Antisocial personality disorder
Post‐traumatic stress disorder
Incident HCV during SNAP
Previous HCV+ test outside of study2
≥5 of 6 general HCV questions correct
Aware of HCV treatment
Time‐varying
Health insurance coverage3
“Good” to “excellent” health status
Days w/medical probs (last 30d) ‐
mean(SD)
Chronic medical condition
Taking legally prescribed medication
Receiving physical disability pension
Access to internet
Incarceration (last 30d)
Distance to hospital (km) ‐ mean (SD)
Moved to new address
Social support out‐degree ‐ mean (SD)
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Any other prescription opioid use
Sedative, hypnotic, or tranquilizer use
Barbiturate use
Crack use
Cocaine use
Methamphetamine use
Oral amphetamine use
Marijuana use
Hallucinogen use
Multiple substance use

245 (96.5)
238 (93.7)
43 (16.9)
197 (77.6)
240 (94.5)
113 (44.5)
86 (33.9)
247 (97.2)
139 (54.7)
246 (96.9)

0.31
0.58
0.83
0.92
0.64
0.87
0.83
0.34
1.01
0.84

Recent behavior (last 6 months)
Substance abuse treatment
42 (16.5)
1.01
Drug overdose
10 (3.9)
1.63
Alcohol use to intoxication
128 (50.4)
1.02
Injection drug use
170 (66.9)
0.95
Shared any IDU equipment
72 (28.4)
1.08
Shared any IDU or snorting equipment
165 (65.0)
1.25
Heroin use
12 (4.7)
2.19
Illicit methadone use
144 (56.7)
1.48
Legal methadone use
9 (3.5)
0.44
Illicit buprenorphine use
130 (51.2)
1.55
Legal buprenorphine use
23 (9.1)
1.69
4
194 (76.4)
1.35
OxyContin® use
Any other oxycodone use
219 (86.2)
1.08
Any other prescription opioid use
201 (79.1)
1.22
Sedative, hypnotic or tranquilizer use
195 (76.8)
1.43
Barbiturate use
8 (3.2)
2.89
Crack use
40 (15.8)
1.67
Cocaine use
80 (31.5)
1.05
Methamphetamine use
20 (7.9)
1.60
Oral amphetamine use
38 (15.0)
1.51
Marijuana use
170 (66.9)
1.72
Hallucinogen use
5 (2.0)
1.38
Multiple substance use
225 (88.6)
1.35
1
Discrete‐time survival analysis adjusted for respondent‐driven sampling
2
At time of HCV+ serotest
3
Private insurance, Medicaid, or Medicare
4
Includes original and abuse‐deterrent formulations of OxyContin®

0.06 – 1.67
0.26 – 1.33
0.45 – 1.51
0.47 – 1.82
0.23 – 1.82
0.54 – 1.44
0.49 – 1.40
0.08 – 1.39
0.62 – 1.65
0.14 – 4.92

0.172
0.199
0.537
0.819
0.405
0.630
0.480
0.133
0.954
0.845

0.59 – 1.74
0.46 – 5.74
0.63 – 1.64
0.59 – 1.52
0.59 – 1.98
0.78 – 2.00
0.65 – 7.43
0.93 – 2.35
0.10 – 1.95
0.97 – 2.50
0.66 – 4.34
0.80 – 2.28
0.62 – 1.88
0.75 – 1.98
0.86 – 2.39
0.93 – 8.99
0.85 – 3.26
0.61 – 1.82
0.62 – 4.15
0.74 – 3.05
1.07 – 2.78
0.18 – 10.70
0.76 – 2.40

0.973
0.446
0.946
0.818
0.803
0.355
0.208
0.100
0.277
0.068
0.275
0.258
0.793
0.431
0.166
0.066
0.134
0.849
0.329
0.257
0.026
0.756
0.310

Table 5.4 summarizes RDS‐adjusted bivariate analyses used to select potential
covariates considered in multivariate modeling. No sociodemographic measures were
associated with medical follow‐up except the percentage of reported monthly income derived
from legal sources (OR=0.98, 95% CI: 0.97‐1.00). Meeting the DSM‐IV criteria for generalized
anxiety disorder (GAD) was associated with increased odds of medical follow‐up (OR=1.8, 95%
CI: 1.0‐3.1), as was having health insurance coverage (OR=2.0, 95% CI: 1.2‐3.3) and access to the
internet (OR=1.9, 95% CI: 1.2‐3.0) at the onset of the study interval during which follow‐up was
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obtained. Lifetime behaviors associated with medical follow‐up included substance abuse
treatment (OR=2.0, 95% CI: 1.2‐3.2) and illicit methadone use (OR=0.3, 95% CI: 0.1‐0.8). The only
recent behavior significantly associated with medical follow‐up was illicit use of marijuana in the
last 6 months (OR=1.7, 95% CI: 1.1‐2.8).

Table 5.5
Predictors of medical follow‐up after HCV‐positive test and counseling: Linear time model
(n=254)1
Variable
Adjusted
95% CI
p‐value
Odds Ratio
Time (per study interval)
0.59
0.43 – 0.80
0.001
Previous HCV+ status awareness
1.70
0.93 – 3.08
0.083
Health insurance2
2.06
1.20 – 3.53
0.009
Access to internet
1.83
1.15 – 2.92
0.011
Major depressive disorder
0.47
0.23 – 0.96
0.039
Generalized anxiety disorder
2.63
1.33 – 5.18
0.005
Ever received substance abuse treatment
1.67
1.01 – 2.75
0.045
Ever used illicit methadone
0.33
0.14 – 0.82
0.016
Legal methadone use (last 6 months)
0.21
0.05 – 0.90
0.035
Marijuana use (last 6 months)
1.76
1.09 – 2.84
0.021
1
2

Discrete‐time survival analysis adjusted for RDS
Includes private insurance, Medicaid, or Medicare reported at onset of study interval

Independent associations with visiting a healthcare provider following an HCV‐
seropositive test and counseling are presented above in Table 5.5. The main effect of the linear
time parameter independently predicted 40% decreased odds of receiving medical follow‐up for
each 6‐month study interval elapsed since positive testing and counseling (95% CI: 0.4‐0.8).
Having any form of health insurance at the onset of study interval more than doubled the odds
of receiving medical assessment during the interval (adjusted OR=2.1, 95% CI: 1.2‐3.5), and
meeting the DSM‐IV criteria for generalized anxiety disorder at baseline interviewing exhibited a
similar strong positive association (aOR=2.6, 95% CI: 1.3‐5.2). By contrast, major depression
more than halved the odds of medical follow‐up (aOR=0.5, 95% CI: 0.2‐1.0). Interestingly, two
measures methadone use conferred decreased odds of follow‐up, whether use was legal and
recent (aOR=0.2, 95% CI: 0.1‐0.9) or illegal and at any previous time (aOR=0.3, 95% CI: 0.1‐0.8).
By contrast, recent marijuana use was associated with 1.7‐fold increase in odds of receiving
medical assessment following HCV‐positive T&C (95% CI: 1.1‐2.8). Lastly, previous HCV‐positive
status awareness (aOR=1.7, 95% CI: 0.9‐3.1) was retained in the model, despite marginal
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statistical significance (p<0.10), due to meaningful impact on other coefficients of other
significant covariates (>10% change) and improvements in goodness‐of‐fit suggested by
decreased AIC and BIC. Finally, no evidence of significant interactions with time was detected in
assessment of all final independent covariates, suggesting the proportional odds assumption
was not violated.

5.4 Discussion
This is the first report of HCV medical follow‐up, treatment seeking, and treatment
uptake in a rural drug‐using population and one of the few observational studies to assess
factors impacting initiation of HCV medical management in a longitudinal context. Nearly 60% of
this rural sample visited a healthcare professional for medical assessment after receiving an
HCV‐positive serotest and standard counseling. After adjustment for respondent‐driven
sampling, this represents an estimated 51% of HCV‐seropositive individuals in the sampled
population. This is unexpectedly higher than medical follow‐up proportions reported in most
other studies of urban drug‐using populations, which have ranged from 21% among PWID in
Baltimore (Mehta, Genberg et al. 2008) to 27% among young PWID in thre3 US cities (Strathdee,
Latka et al. 2005). These proportions offer stark contrast with the 75% OST participants
following up in Australia (Treloar, Hull et al. 2012), a nation offering relatively accessible
treatment programs for people who use drugs and government‐subsidized HCV treatment
options. In a large clinic‐based sample in the U.S., reported proportions range from 45% in 2003
up to 57% in 2010 in a significant upward trend (Spradling, Tong et al. 2014), and similar to the
level of follow‐up observed in this sample. Another study of 245 seropositive patients sampled
from the New York City health department reported that 67% obtained RNA testing, although
this number was artificially inflated by investigator requests (McGibbon, Bornschlegel et al.
2013).
By contrast, 80% of a population‐based sample had seen a clinician in a secondary
survey of NHANES participants (Denniston, Klevens et al. 2012). However, among individuals
receiving medical assessment, just 13% described themselves as “seeking treatment.” This
finding suggests markedly lower HCV treatment willingness among rural people who use drugs
relative to other prior studies, despite above‐average medical follow‐up rates among samples
reporting active drug use. However, it is important to consider that the two most relevant
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studies above were cross‐sectional in nature and sampling occurred in an urban setting (Mehta,
2008, and Strathdee et al., 2005), limiting direct comparison to the patterns observed in the
rural sample presented here. Nonetheless, while the proportion reporting receipt of medical
follow‐up in this study exceeded that in most urban drug‐using samples, proportion actually
seeking treatment lagged far behind. Finally, the proportion ultimately receiving treatment in
this rural population (8%) was comparable to other prior studies, with reported levels between
3% and 10% (Cullen, Stanley et al. 2007; Trepka, Zhang et al. 2007; Mehta, Genberg et al. 2008)
and higher uptake reported in community clinic‐based (Morrill, Shrestha et al. 2005) and
Australian (Grebely, Genoway et al. 2008) studies.
Several sociodemographic and behavioral factors independently predicted following up
with a healthcare professional in this rural drug‐using population. As with previous study of this
public health problem (Stepanova, Kanwal et al. 2011; Denniston, Klevens et al. 2012), health
insurance coverage was a robust predictor of healthcare system engagement in this rural drug‐
using population. Unfortunately, nearly 70% of this sample cohort was uninsured throughout
the study period, suggesting that lack of insurance coverage and likely healthcare costs are
major barriers to HCV care among rural Appalachians who use drugs. However, in light of early
reports of expanding insurance coverage in the United States (Gallup Well‐Being 2014; U.S.
Department of Health and Human Services 2014) and Kentucky in particular (Brammer 2014)
since implementation of the Affordable Care Act, there is reason for hope that the barriers
erected by issues related to insurance coverage and treatment cost may diminish.
Concordant with previously reported associations between readiness to cease illicit drug
use and interest in HCV treatment initiation (Strathdee, Latka et al. 2005), a lifetime history of
substance abuse treatment improved the chance of receiving post‐screening medical evaluation
in this population. Recent substance abuse treatment, however, was not significantly associated
with medical follow‐up, and surprisingly, recent legal methadone use actually decreased the
odds of seeing a healthcare professional. This negative association suggests that while past
treatment for addiction issues may boost health system engagement after screening,
contemporaneous substance abuse treatment and especially opioid substitution therapy do not
appear conducive to HCV medical care in the rural setting. Moreover, despite the small sample
of recent legal methadone recipients, the negative association of recent legal methadone use is
of particular interest, implying that what few harm reduction and IDU cessation services that are
available in Central Appalachia may actually deter HCV clinical assessment among seropositive
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individuals. Echoing previous research (Morrill, Shrestha et al. 2005; Treloar, Newland et al.
2010; McGibbon, Bornschlegel et al. 2013; McGowan, Monis et al. 2013), there may be a
potential provider‐ or system‐lever bias against simultaneously management of opioid addiction
and HCV at play. Furthermore, in terms of public health policy, this finding implies,
unsurprisingly, that harm reduction, substance abuse treatment, and HCV medical management
are not well integrated in the Appalachian region and may even be working antagonistically,
despite evidence that the benefits of such programs are maximized if implemented with an
integrated, “one‐stop‐shopping” approach (Grebely, Genoway et al. 2007; Grebely, Knight et al.
2010; Masson, Delucchi et al. 2013).
Two characteristics promoting HCV follow‐up in this sample have not been reported in
previous research. First, reporting access to the internet nearly doubled the likelihood of
medical follow‐up during the subsequent study interval. This association could suggest that
there is a protective benefit in the ability to access information regarding the potential health
consequences of CHC or to investigate current options for HCV care and treatment. In light of
past research describing the potential of internet access to increase patient knowledge level,
facilitate dissemination of health information, and promote “patient activism” (Stevenson, Kerr
et al. 2007; Pew Internet & American Life Project 2010; Magnezi, Grosberg et al. 2014),
particularly among patients with HIV (Kalichman, Weinhardt et al. 2002) and other chronic
diseases such as cancer (Basch, Thaler et al. 2004), it is reasonable that similar mechanisms
would be relevant to individuals testing positive for HCV. Furthermore, an innovative
“telemedicine” program has leveraged the internet to improve access to HCV‐related healthcare
among prisoners and rural residents in New Mexico with considerable success (Arora, Thornton
et al. 2007), suggesting a potential direction for interventional study of HCV management in
medically underserved Central Appalachia.
Another unexpected positive association was observed among recent marijuana users in
this rural cohort, who were nearly twice as likely to obtain medical follow‐up following an HCV‐
positive test and counseling. As one might expect, few studies have examined the impact of
recent cannabis use on outcomes related to HCV treatment uptake, although a major study
from the interferon/ribavirin era reported significant improvements in both treatment retention
and efficacy among patients reporting recent use of marijuana (Sylvestre 2002; Sylvestre,
Clements et al. 2006). However, no other studies have reported other “protective” associations
with regard to marijuana use and uptake of medical care or related outcomes. One hypothesis
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would be that rural PWID with high interest in quitting IDU but poor access to addiction
treatment options might substitute marijuana for prescription opioids and other preferred drugs
of injection, but in lieu of related research, further investigation of marijuana’s influence on
healthcare decisions among rural HCV‐seropositive PWID is necessary. Regardless, in light of
daily cannabis smoking being a potential risk factor for accelerated disease progression among
individuals with CHC (Hezode, Zafrani et al. 2008; Mallat, Hezode et al. 2008) and the scarcity of
other mechanisms promoting HCV‐related care in Central Appalachia, this tendency among
recent marijuana users is fortuitous at worst.
Finally, the two psychiatric measures independently associated with medical follow‐up
are of particular interest given the central role of psychiatric comorbidity in the determining
HCV treatment eligibility (American Association for the Study of Liver Diseases 2014) and high
prevalence of psychosocial impairment among CHC patients (Fireman, Indest et al. 2005;
Modabbernia, Poustchi et al. 2013). In addition to being a major contraindication to treatment,
unmanaged depression and related social isolation is a common barriers to healthcare
engagement among individuals with CHC in particular (Nguyen, Dore et al. 2007; Treloar,
Newland et al. 2010). Moreover, depression is frequently comorbid with HCV, and depressed
individuals are more likely to report symptoms, fatigue, and other adverse impacts on lifestyle
resulting from chronic infection (Dwight, Kowdley et al. 2000; Golden, O'Dwyer et al. 2005).
Interestingly, individuals meeting the DSM‐IV criteria for generalized anxiety disorder (GAD)
displayed a strong positive association with obtaining medical care, suggesting that individuals
more likely to experience anxiety after HCV status disclosure and counseling are also more
inclined to seek medical care. In one of the few prior studies to investigate anxiety and HCV, no
differences in adverse impacts of illness were reported among patients with CHC (Golden,
O'Dwyer et al. 2005), despite frequent associations between anxiety disorders and chronic
hepatitis C (el‐Serag, Kunik et al. 2002). While no previous studies have reported associations
between GAD and care initiation or uptake of treatment for HCV, the notion that a
predisposition for anxiety might promote initiation of medical care for a potentially fatal
infection is reasonable from an intuitive standpoint.
While this study provides important insight into factors impacting the initiation of HCV
medical management in a vulnerable population, there are some limitations to consider. First,
due to practical limitations on size of the study survey instrument, some variables were
reported only at baseline and thus analyzed as time‐invariant measures, although they may
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have in fact changed over time. This includes the DSM‐IV psychiatric measures, income, and
access to transportation and possession of a driver’s license. Next, a common predictor of HCV
care engagement and treatment uptake is having a regular physician, but this characteristic was
not assessed in the study questionnaire. However, several time‐varying proxy measures for
health management status were considered in analysis, including having a chronic medical
condition and regularly taking legally prescribed medication. Another potential limitation is the
unbalanced nature of data collection occasions, although in this analysis mean interval length
between baseline, 6, 12, and 18 months was relatively homogeneous. However, there were
substantial between‐subject differences in interval length and “eligible” days for seeking care
following HCV‐positive status disclosure and the subsequent interview. Thus, the time‐weighted
model presented in the Appendix adjusted for this potential source of variability; likelihood‐
based goodness‐of‐fit statistics (AIC/BIC) suggested model performance after adjusting for
heterogeneous interval length, so the final model was fit assuming uniform interval length (bin
width) between and within participants. Finally, as with results presented in chapter 3, these
analyses relied on self‐reported data, which can be subject to social desirability and recall
biases. Again, recall bias is expected to be minimized by the primary use of time‐variant
measures pertaining to the last 6 months or less, and previous studies have suggested self‐
reported data from people who use and inject drugs to be reliable (Kokkevi, Richardson et al.
1997; Darke 1998).
In this sample of rural PWID, the proportion obtaining medical follow‐up after positive
serotesting and counseling was above average, self‐reported “treatment seeking” behavior was
low, and HCV treatment uptake over the 18‐month study period was average to above average
relative to other observational studies of drug‐using populations. This pattern seems to suggest
that barriers on the individual level may be more significant than those among physicians, given
that 21 of the 35 (60%) participants who reported seeking treatment from a healthcare provider
also reported receiving treatment for HCV. Along with typical measures promoting healthcare
engagement such as having health insurance coverage and a history of substance abuse
treatment, there were some unexpected associations such as generalized anxiety disorder,
internet access, and recent marijuana use. Surprisingly, lower income level, recent IDU, and
other illicit drug use measures did not seem to inhibit medical follow‐up as reported in other
studies. The characteristics associated with decreased likelihood of medical follow‐up, including
legal or illicit methadone use and major depression, indicate substantial but potentially
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modifiable barriers to the initiation of care for HCV. Furthermore, these inhibitory factors
suggest a need to couple mental health services, substance abuse treatment, and opioid
substitution therapy with more accessible HCV medical care services in this high‐prevalence
population. This is especially true with regard to methadone recipients, who have an
opportunity to be linked with medical care at what may be one of the few points of health
system contact rural PWID with HCV may experience. Integrated programs combining HCV
management with other services such as psychiatric care, peer support and counseling, and
substance abuse treatment have been demonstrated to be effective with regard to promotion
of primary (Sacks‐Davis, Horyniak et al. 2012) as well as secondary (Birkhead, Klein et al. 2007)
prevention of HCV. Multidisciplinary HCV and addiction services targeted to PWID in the
Netherlands, for example, reported secondary medical assessment among 76% of study
participants, and 33% initiated treatment (Lindenburg, Lambers et al. 2011), proportions
comparable to clinic‐ and population‐based studies. Such findings reinforce the effectiveness of
integrated approaches to address both IDU and HCV simultaneously among people with a
history of injecting drugs. Interventional research targeted to rural individuals least likely to
seek care for HCV would be of considerable value, particularly programs offering combined care
for psychiatric, substance abuse, and infectious disease comorbidity.

5.5 Conclusions
These findings offer valuable insight into the potential public health impact of screening
on primary and secondary prevention of HCV among rural Appalachian people who use and
inject drugs. Despite overall declines in IDU and IDU sharing and some indication of transient
positive effects on risk behavior, the longitudinal patterns observed over two years of study are
generally in agreement with previous studies indicating that HCV screening and counseling alone
are not sufficient to make meaningful impact on HCV transmission risk in most high‐risk
populations. In this cohort, apparent preventive benefit was observed simply from being
enrolled in a structured longitudinal study and receiving health‐related informational materials
among all PWID regardless of serostatus. Substantial declines in reported IDU frequency and
sharing of IDU paraphernalia were observed over time in the overall sample, particularly in the
first 18 months of the study. However, with some exceptions, this protective trend occurred
mostly independent of serotest results and post‐test counseling, and there were indications of
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leveling off and even potential increases in IDU sharing reported at the final study visit after
more than 24 months.
On balance, this trajectory concurs with the conclusions of Page (2007) and other
researchers (Aspinall, Weir et al. 2014) that screening and counseling along are not sufficient to
effect lasting gains with regard to the primary prevention of HCV, and integrated
multidisciplinary approaches are required to make meaningful impact on HCV incidence in high‐
prevalence populations (Hagan and Schinazi 2013; Grebely and Dore 2014). However, it is worth
noting that the modest preventive gains discussed in Chapter 2 indicate that PWID in resource‐
deprived rural areas may in fact be somewhat more responsive to HCV screening and counseling
than has generally been reported among their urban counterparts. This may be particularly true
among women with regard to reducing the frequency of sharing syringes and other equipment
used during IDU. However, much of this gender‐specific benefit is apparently offset by engaging
in risky sexual relationships with other PWID, a characteristic emerging as a major deterrent to
primary prevention across several measures of IDU risk. In addition, affirming prior findings in
this study cohort (Havens, Lofwall et al. 2013), frequent injection of prescription opioids was a
robust predictor of elevated IDU risk in multiple models. In light of dense risk network structure
and its value in predicting HIV risk behavior in rural Appalachia (Havens, Oser et al. 2010), these
consistent associations indicate that network‐oriented analysis of the interplay between IDU risk
and the characteristics of sexual dyads is likely to be a productive avenue of research with
regard to preventing the transmission of bloodborne viruses such as HCV and HIV in this
population.
As for secondary prevention modalities after positive serotesting, descriptive
proportions in this study sample reflect encouraging levels of medical follow‐up and treatment
uptake, but a far less treatment‐seeking behavior relative to other studies. While this could
reflect differences in question format related to the semantics of “treatment willingness” versus
“treatment seeking,” it is also possible that seeking HCV treatment is simply not normative
behavior among PWID in rural Appalachia. Negative perceptions and peer anecdotes regarding
HCV treatment have been reported in previous studies (Swan, Long et al. 2010; Treloar,
Newland et al. 2010), and qualitative study of attitudes towards HCV treatment in a social
network context would shed fascinating light on individual and community‐level barriers to care
in this cohort. As for the significant predictors of healthcare engagement, possession of health
insurance stands out. In light of dramatic increases in access to care and sweeping system‐level
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changes to American healthcare under the Affordable Care Act, expansion of health insurance
coverage likely offers the greatest potential to impact uptake of care and treatment for HCV in
the immediate future. In addition, in the resource‐deprived context of Central Appalachia, the
gradual expansion of internet access in rural Eastern Kentucky (Cheves 2014) and the potential
of scaled‐up substance abuse treatment services could also have substantial impact on the
hepatitis C landscape in the recently diagnosed drug‐using population.
Finally, widespread treatment of active PWID was modeled to be cost‐effective in
populations with “moderate” HCV prevalence, or approximately 40% (Martin, Vickerman et al.
2012). Based on the implications of this model, the cost‐benefit ratio with regard to population‐
level primary prevention via HCV treatment may have substantially deteriorated in this cohort
during the course of data collection. Sample HCV prevalence was 54% among PWID at baseline
(Havens, Lofwall et al. 2013), but after 6 months it exceeded 60% and had surpassed 65% by 24
months. Unfortunately, this suggests the window of opportunity to leverage the HCV
“treatment‐as‐prevention” approach (Hagan, Wolpe et al. 2013) may be distressingly narrow in
rural Appalachia, and it may have been abruptly shut by potentially high seroincidence in this
cohort. Regardless, beyond cost‐effectiveness arguments, secondary prevention of CHC disease
manifestations carries substantial value in terms of both long‐term public health benefit and
bioethical considerations concerning allocation of care (Edlin, Seal et al. 2001). Moreover, recent
clinical trial data indicate that imminently available drug treatment agents may be even more
efficacious and less toxic than previously predicted (Doyle, Aspinall et al. 2013; Afdhal, Reddy et
al. 2014; Afdhal, Zeuzem et al. 2014). Such a trend will no doubt necessitate reevaluation of
previous cost‐effectiveness estimates, particularly once the cost of HCV treatment begins to
decline. At the present time, it appears clinical factors such as middling efficacy and high toxicity
will soon fade as prohibitive concerns with regard to the initiation of HCV treatment. In the
immediate future, however, the astronomical price tag will undoubtedly restrict many eligible
patients from receiving curative treatment, raising new, difficult questions with regard to the
allocation of care for chronic hepatitis C worldwide.
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Appendix

Table A3.1
Predictors of decreased IDU sharing among recent PWID (n=203): Autoregressive covariance
Characteristic
Adjusted
95% CI
p‐value
Odds Ratio
Male
0.32
0.15 – 0.67
0.002
Number of dependents (per individual)
0.67
0.50 – 0.90
0.008
Any religious affiliation reported
2.54
1.24 – 5.21
0.011
HCV+ test & counseling: 3 study intervals previously 1.20
0.99 – 1.43
0.068
Unprotected sex (last 30 days)
0.74
0.60 – 0.92
0.007
Prescription opioid IDU (last 6 months)
0.79
0.63 – 0.98
0.031
1

Population‐averaged GEE estimates adjusted for RDS

Table A3.2
Description of sample and population‐averaged bivariate associations with increased IDU
sharing among recent PWID with no previous HCV+ test (n=283)1
Characteristic
Time‐invariant
Received HCV+ test prior to study
Male
White
Age (per year) ‐ mean (SD)
Any religious affiliation reported
Married
Bisexual or homosexual
Number of dependents ‐ mean (SD)
Education (per year)
Monthly income (per $100 US) ‐ mean (SD)
Most often unemployed (last 3 years)
Driver’s license and vehicle
Major Depressive Disorder
Generalized Anxiety Disorder
Antisocial Personality Disorder
Post‐Traumatic Stress Disorder
≥5 of 6 general HCV questions correct
3 of 3 HCV transmission questions correct
Time‐varying
HCV+ T&C at any study visit (0‐18m)
Study occasions since HCV+ T&C:
1
2
3
4
Followed up with clinician after HCV+ test
Sought treatment after HCV+ test
Received HCV treatment after HCV+ test

Sample total

Odds
Ratio

95% CI

p‐value

63 (22.3)
167 (59.0)
265 (93.6)
32.7 (7.9)
81 (28.6)
68 (24.0)
27 (9.5)
1.0 (1.4)
11.7 (2.4)
1340.5 (2014.0)
84 (29.7)
93 (32.9)
77 (27.2)
84 (29.0)
97 (34.3)
39 (13.8)
257 (90.8)
271 (95.8)

1.10
0.72
4.11
0.96
1.05
1.40
1.24
0.95
0.91
0.98
2.18
0.73
0.95
0.58
0.93
0.33
2.83
2.98

0.39 – 3.08
0.34 – 1.52
0.56 – 30.13
0.92 – 1.00
0.52 – 2.14
0.61 – 3.18
0.60 – 2.54
0.81 – 1.12
0.81 – 1.03
0.95 – 1.00
1.01 – 4.68
0.36 – 1.48
0.47 – 1.91
0.27– 1.23
0.44 – 1.96
0.10 – 1.13
0.79 – 10.21
0.43 – 20.69

0.853
0.389
0.164
0.031
0.890
0.426
0.561
0.507
0.120
0.092
0.046
0.379
0.886
0.156
0.839
0.077
0.111
0.269

192 (67.8)
151 (53.4)
177 (62.5)
186 (65.7)
192 (67.8)
116 (41.0)
28 (9.9)
17 (6.0)

1.73
2.15
0.93
0.48
0.97
1.47
2.66
3.33

0.79 – 3.76
1.33 – 3.47
0.54 – 1.60
0.20 – 1.18
0.42 – 2.20
0.75 – 2.90
0.89 – 7.99
0.89 – 12.48

0.169
0.002
0.782
0.109
0.934
0.260
0.081
0.074
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Health insurance coverage
“Poor” to “fair” health status
Days with health problems2 ‐ mean (SD)
Reported chronic medical condition
Taking legally prescribed medication
Receiving physical disability pension
Substance use treatment (last 6m)
Legal methadone use (last 6m)
Legal buprenorphine use (last 6m)
Incarceration2
Lifetime behavior
Incarceration
Substance abuse treatment
Drug overdose
Years of IDU ‐ mean (SD)
Heroin use
Illicit methadone use
Legal methadone use
Illicit buprenophine use
Legal buprenorphine use
Illicit OxyContin® use
Other illicit oxycodone use
Any other prescription opioid use
Sedative, hypnotic, or tranquilizer use
Barbiturate use
Crack use
Cocaine use
Methamphetamine use
Prescription stimulant use
Marijuana use
Hallucinogen use
Inhalant use
Multiple substance use
Recent risk behavior (last 6m unless indicated)
Recent unprotected sex2
Recent unprotected sex with PWID2
Recent unprotected transactional sex2
Drug overdose
Alcohol use to intoxication
Daily or greater IDU frequency
Days of IDU2 ‐ mean (SD)
Heroin use
Heroin IDU
Illicit methadone use
Illicit buprenorphine use
OxyContin® use3
Any other oxycodone use
Any other prescription opioid use
Any prescription opioid IDU4
Days of Rx opioid IDU2 ‐ mean (SD)
Sedative, hypnotic or tranquilizer use
Sedative, hypnotic or tranquilizer IDU
Barbiturate use

140 (49.5)
168 (59.4)
5.0 (7.6)
141 (49.8)
139 (49.1)
64 (22.6)
87 (30.7)
32(11.3)
48 (17.0)
121 (42.8)

0.65
1.44
0.96
0.53
0.52
0.32
0.39
0.40
2.09
0.28

0.34 – 1.24
0.96 – 2.18
0.93 – 1.00
0.28 – 1.01
0.27 – 1.01
0.15 – 0.67
0.15 – 1.01
0.04 – 3.83
1.06 – 4.15
0.10 – 0.79

0.194
0.080
0.025
0.053
0.053
0.002
0.052
0.424
0.034
0.015

241 (85.2)
186 (65.7)
104 (36.8)
8.0 (7.0)
123 (43.5)
261 (92.2)
45 (15.9)
201 (71.0)
41 (14.5)
272 (96.1)
273 (96.5)
231 (81.6)
246 (86.9)
31 (11.0)
212 (74.9)
267 (94.4)
128 (45.2)
110 (38.9)
276 (97.5)
142 (50.2)
59 (20.9)
264 (93.3)

0.58
1.61
0.86
0.93
0.78
0.62
1.35
1.64
1.81
3.86
0.36
1.36
0.70
0.59
0.72
2.66
0.97
0.78
0.14
1.03
0.52
9.89

0.19 – 1.79
0.70 – 3.71
0.42 – 1.72
0.88 – 1.00
0.37 – 1.62
0.23 – 1.69
0.60 – 3.04
0.76 – 3.54
0.52 – 6.35
0.51 – 29.14
0.10 – 1.34
0.58 – 3.20
0.30 – 1.64
0.23 – 1.50
0.27 – 1.91
0.62 – 11.49
0.48 – 1.94
0.40 – 1.54
0.02 – 0.84
0.48 – 2.20
0.23 – 1.16
1.39 – 70.09

0.344
0.260
0.662
0.034
0.504
0.352
0.463
0.208
0.354
0.191
0.128
0.481
0.408
0.268
0.511
0.190
0.928
0.476
0.031
0.938
0.110
0.022

252 (89.1)
110 (38.9)
10 (3.5)
18 (6.4)
174 (61.5)
144 (50.9)
11.9 (10.3)
39 (13.8)
25 (8.8)
214 (75.6)
208 (73.5)
248 (87.6)
270 (95.4)
252 (89.1)
219 (77.4)
7.2 (8.8)
246 (86.9)
6 (2.1)
23 (8.1)

5.67
10.80
1.20
1.87
1.48
7.84
1.10
2.03
3.30
1.29
1.95
2.04
4.04
2.13
n/a
1.10
2.25
1.87
1.51

2.85 – 11.25
5.96 – 19.58
0.17 – 8.64
0.57 – 6.13
0.83 – 2.65
4.16 – 14.78
1.08 – 1.13
0.63 – 6.61
0.93 – 11.75
0.81 – 2.05
0.99 – 3.86
1.13 – 3.66
1.86 – 8.76
1.28 – 3.54
n/a
1.08 – 1.13
1.25 – 4.07
0.11 – 31.14
0.52 – 4.38

<0.0001
<0.0001
0.858
0.303
0.192
<0.0001
<0.0001
0.238
0.065
0.286
0.055
0.017
<0.0001
0.003
<0.0001
<0.0001
0.007
0.662
0.444
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Crack use
70 (24.7)
1.06
0.49 – 2.29
0.875
0.030
Cocaine use
135 (47.7)
2.23
1.08 – 4.57
0.152
Cocaine IDU
76 (26.9)
0.57
0.26 – 1.23
0.608
Methamphetamine use
49 (17.3)
0.71
0.19 – 2.66
0.436
Methamphetamine IDU
14 (5.0)
1.88
0.39 – 9.14
0.008
Prescription stimulant use
79 (27.9)
2.35
1.25 – 4.43
Prescription stimulant IDU
5 (1.8)
8.05
1.46 – 44.31 0.017
0.386
Marijuana use
223 (78.8)
1.30
0.72 – 2.37
0.067
Hallucinogen use
18 (6.4
0.47
0.21 – 1.05
0.665
Multiple substance use
263 (92.9)
1.11
0.70 – 1.76
1
GEE population‐averaged estimates adjusted for RDS
2
Last 30 days
3
Includes original and abuse‐deterrent formulations of OxyContin®
4
GEE did not converge; 100% of participants with any increased IDU sharing also reported recent
prescription
opioid IDU (p‐value via Fisher’s exact test)

Table A3.3
Predictors of increased IDU sharing among recent PWID (n=264)1: Autoregressive covariance
Characteristic
Adjusted
95% CI
p‐value
Odds Ratio
Time elapsed since study enrollment (per month)
1.04
1.01 – 1.07 0.013
Monthly income (per $100)
0.97
0.95 – 1.00 0.029
0.54 – 3.39 0.515
1.36
Study intervals since HCV+ test & counseling: 1
0.43 – 2.54 0.918
1.05
2
0.16 – 1.10 0.078
0.42
3
0.08 – 1.10 0.070
0.30
4
Unprotected sex with PWID (last 30 days)
5.77
3.05 – 10.91 <0.0001
Ever used marijuana (lifetime)
0.34
0.17 – 0.65 0.001
Prescription stimulant use (last 6m)
3.18
1.28 – 7.87 0.012
Days of prescription opioid IDU in last 30d (per day)
1.09
1.06 – 1.11 <0.0001
1

GEE population‐averaged estimates adjusted for RDS
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Table A3.4
Bivariate population‐averaged associations with IDU cessation in the last 6 months (n=220)1
Characteristic
Time‐invariant
Received HCV+ test prior to study2
Male
White
Age (per year) ‐ mean (SD)
Any religious affiliation reported
Married
Bisexual or homosexual
Number of dependents ‐ mean (SD)
Education (per year) ‐ mean (SD)
Monthly income (per $100 US) ‐ mean (SD)
Most often unemployed (last 3 years)
Driver’s license and vehicle
Major Depressive Disorder
Generalized Anxiety Disorder
Antisocial Personality Disorder
Post‐Traumatic Stress Disorder
≥5 of 6 general HCV questions correct
3 of 3 HCV transmission questions correct
Time‐varying
HCV+ T&C at any study visit (0‐18m)
Study occasions since HCV+ T&C:
1
2
3
4
Followed up with clinician after HCV+ test
Sought treatment after HCV+ test
Received HCV treatment after HCV+ test
Health insurance coverage
“Poor” to “fair” health status
Days with health problems3 ‐ mean (SD)
Reported chronic medical condition
Taking legally prescribed medication
Receiving physical disability pension
Substance use treatment (last 6m)
Legal methadone use (last 6m)
Legal buprenorphine use (last 6m)
Incarceration3
Lifetime behavior
Incarceration
Substance abuse treatment
Drug overdose
Years of IDU ‐ mean (SD)
Heroin use
Illicit methadone use
Legal methadone use
Illicit buprenophine use
Legal buprenorphine use

Sample total

Odds
Ratio

95% CI

p‐value

63 (22.3)
134 (60.9)
205 (93.2)
32.5 (8.2)
55 (25.0)
74 (25.4)
20 (9.1)
0.9 (1.3)
11.7 (2.5)
1250.4 (1832.9)
63 (28.6)
70 (31.8)
57 (25.9)
57 (25.9)
78 (35.5)
33 (15.0)
196 (89.1)
209 (95.0)

0.54
0.65
0.48
1.03
1.22
0.95
1.33
1.26
1.08
0.99
0.80
1.06
0.89
1.08
0.74
1.46
0.54
0.47

0.33 – 0.88
0.41 – 1.03
0.20 – 1.13
1.00 – 1.06
0.77 – 1.95
0.58 – 1.58
0.74 – 2.39
1.04 – 1.53
0.98 – 1.19
0.98 – 1.01
0.50 – 1.29
0.64 – 1.74
0.55 – 1.46
0.63 – 1.83
0.45 – 1.21
0.82 – 2.61
0.27 – 1.08
0.13 – 1.71

0.014
0.066
0.094
0.031
0.393
0.853
0.343
0.021
0.109
0.306
0.364
0.826
0.650
0.781
0.228
0.195
0.080
0.250

134 (60.9)
107 (48.6)
120 (54.6)
128 (58.2)
134 (60.9)
74 (33.6)
11 (5.0)
8 (3.6)
109 (49.6)
127 (57.7)
5.1 (7.9)
109 (49.6)
104 (47.3)
59 (26.8)
64 (29.1)
24 (10.9)
31 (14.1)
87 (39.6)

0.49
0.37
1.28
1.08
1.21
0.87
1.02
1.06
1.30
0.87
1.01
1.24
1.58
2.01
1.75
1.68
0.67
1.06

0.32 – 0.75
0.25 – 0.54
0.96 – 1.69
0.79 – 1.48
0.86 – 1.70
0.59 – 1.29
0.55 – 1.90
0.51 – 2.20
0.91 – 1.87
0.66 – 1.13
0.99 – 1.02
0.89 – 1.71
1.11 – 2.26
1.31 – 3.07
1.06 – 2.88
0.90 – 3.10
0.35 – 1.30
0.71 – 1.59

0.001
<0.0001
0.088
0.624
0.265
0.491
0.957
0.868
0.155
0.295
0.246
0.202
0.012
0.001
0.029
0.101
0.239
0.764

184 (83.6)
141 (64.1)
73 (33.2)
7.6 (7.0)
89 (40.5)
201 (91.3)
32 (14.6)
153 (69.6)
25 (11.4)

0.37
0.72
0.89
1.00
0.58
1.17
1.42
0.88
0.53

0.20 – 0.67
0.44 – 1.19
0.54 – 1.46
0.97 – 1.03
0.37 – 0.93
0.55 – 2.48
0.77 – 2.62
0.53 – 1.45
0.27 – 1.04

0.001
0.200
0.644
0.872
0.023
0.685
0.261
0.608
0.064
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Illicit OxyContin® use
209 (95.0)
0.17
0.06 – 0.50 0.001
Other illicit oxycodone use
211 (95.9)
6.01
1.16 – 31.22 0.033
Any other prescription opioid use
180 (81.8)
0.78
0.42 – 1.43 0.419
Sedative, hypnotic, or tranquilizer use
187 (85.0)
1.81
0.93 – 3.53 0.080
Barbiturate use
21(9.6)
1.56
0.77 – 3.15 0.220
Crack use
159 (72.3)
0.89
0.55 – 1.44 0.641
Cocaine use
205 (93.2)
0.86
0.39 – 1.91 0.713
Methamphetamine use
93 (42.3)
0.60
0.38 – 0.94 0.027
Prescription stimulant use
85 (38.6)
0.97
0.59 – 1.57 0.891
Marijuana use
215 (97.7)
0.14
0.03 – 0.49 0.003
Hallucinogen use
110 (50.0)
0.90
0.57 – 1.41 0.637
Inhalant use
47 (21.4)
1.21
0.73 – 1.99 0.462
Multiple substance use
202 (91.8)
0.59
0.27 – 1.28 0.184
Recent risk behavior (last 6m unless indicated)
Recent unprotected sex3
200 (90.9)
0.86
0.64 – 1.16 0.323
82 (37.3)
0.21
0.13 – 0.35 <0.0001
Recent unprotected sex with PWID3
7 (3.2)
0.85
0.22 – 3.36 0.825
Recent unprotected transactional sex3
Drug overdose
14 (6.4)
0.57
0.28 – 1.15 0.117
Alcohol use to intoxication
142 (64.6)
0.64
0.47 – 0.87 0.005
69 (31.4)
0.38
0.24 – 0.63 <0.0001
Daily or greater IDU frequency5
Heroin use
25 (11.4)
0.48
0.20 – 1.13 0.093
28 (12.7)
1.07
0.51 – 2.24 0.852
Heroin IDU5
Illicit methadone use
172 (78.2)
0.71
0.52 – 0.99 0.043
Illicit buprenorphine use
159 (72.3)
0.61
0.45 – 0.84 0.002
189 (85.9)
0.27
0.19 – 0.38 <0.0001
OxyContin® use4
Any other oxycodone use
208 (94.6)
0.32
0.21 – 0.50 <0.0001
Any other prescription opioid use
192 (87.3)
0.68
0.52 – 0.88 0.003
202 (91.8)
0.36
0.19 – 0.71 0.003
Any prescription opioid IDU5
10.8 (11.5)
0.93
0.91 – 0.95 <0.0001
Days of opioid IDU3,5 ‐ mean (SD)
Sedative, hypnotic or tranquilizer use
187 (85.0)
0.53
0.39 – 0.72 <0.0001
12 (5.5)
1.89
0.80 – 4.48 0.146
Sedative, hypnotic or tranquilizer IDU5
Barbiturate use
19 (8.6)
0.81
0.38 – 1.69 0.568
Crack use
57 (25.9)
0.50
0.29 – 0.87 0.014
Cocaine use
107 (48.6)
0.40
0.27 – 0.60 <0.0001
88 (40.0)
1.19
0.75 – 1.90 0.453
Cocaine IDU5
Methamphetamine use
36 (16.4)
0.50
0.29 – 0.87 0.014
7 (3.2)
3.42
1.11 – 10.53 0.032
Methamphetamine IDU5
Prescription stimulant use
67 (30.5)
0.65
0.43 – 1.00 0.050
9 (4.1)
0.56
0.21 – 1.48 0.244
Prescription stimulant IDU5
Marijuana use
181 (82.3)
0.66
0.49 – 0.89 0.006
Hallucinogen use
16 (7.7)
1.47
0.62 – 3.47 0.377
Multiple substance use
203 (92.3)
0.57
0.43 – 0.75 <0.0001
1
GEE population‐averaged estimates adjusted for RDS
2
n=283 (participants who reported IDU in the 6 months preceding baseline and returned after 6 months
3
Last 30 days
4
Includes original and abuse‐deterrent formulations of OxyContin®
5
Reported at baseline
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Table A3.5
Predictors of IDU cessation among recent PWID, excluding recent illicit drug use measures
(n=203)1: Autoregressive covariance
Characteristic
Adjusted
95% CI
p‐value
Odds Ratio
0.29 – 0.95 0.034
0.53
Study intervals since HCV+ test & counseling: 1
0.89 – 2.97 0.114
1.62
2
0.79 – 2.73 0.221
1.47
3
0.91 – 4.88 0.082
2.11
4
Number of dependents (per individual)
1.26
1.06 – 1.51 0.010
Lifetime history of incarceration
0.23
0.09 – 0.48 <0.0001
Currently receiving disability pension
2.72
1.52 – 4.87 0.001
Substance abuse treatment (last 6m)
2.41
1.32 – 4.42 0.004
Unprotected sex with PWID (last 30d)
0.16
0.08 – 0.32 <0.0001
Ever used illicit OxyContin® (lifetime)
0.21
0.09 – 0.48 <0.0001
Days of Rx opioid IDU in last 30d (per day)2
0.94
0.91 – 0.96 <0.0001
1
2

GEE population‐averaged estimates adjusted for RDS
At baseline

Table A3.6
Predictors of IDU cessation among recent PWID, with recent illicit drug use measures (n=203)1:
Autoregressive covariance
Characteristic
Adjusted
95% CI
p‐value
Odds Ratio
Time since study enrollment (per month)
0.97
0.95 – 1.00
0.056
0.003
0.18 – 0.70
0.36
Study intervals since HCV+ test & counseling: 1
0.832
0.56 – 2.04
1.07
2
0.833
0.54 – 2.19
1.08
3
0.660
0.53 – 2.76
1.20
4
Number of dependents (per individual)
1.25
1.02 – 1.53
0.031
Lifetime history of incarceration
0.21
0.10 – 0.46
<0.0001
Currently receiving disability pension
2.52
1.37 – 4.63
0.003
Unprotected sex with PWID (last 30d)
0.20
0.10 – 0.40
<0.0001
2
Days of Rx opioid IDU in last 30d (per day)
0.93
0.91 – 0.95
<0.0001
Illicit OxyContin® use (last 6m)
0.23
0.13 – 0.42
<0.0001
Other oxycodone use (last 6m)
0.34
0.21 – 0.56
<0.0001
Cocaine use (last 6m)
0.52
0.30 – 0.88
0.016
1
2

GEE population‐averaged estimates adjusted for RDS
At baseline
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Table A5.1
Goodness‐of‐fit statistics for various parameterizations of time
Time Model DF
Deviance ΔDeviance1 p‐value
3
552.01
‐
‐
Discrete
566.30
‐
‐
Adj. discrete3 3
Constant
1
569.29
‐
‐
2
557.98
11.31 (1)
0.0008
Adj. linear3
Linear
2
554.00
15.29 (1)
<0.0001
Quadratic
3
553.05
0.95 (1)
0.331
1
Versus preceding model with fewer parameters
2
Versus fully discrete time specification
3
Weighted to adjust for interval length

ΔDeviance2
‐
14.29 (0)
17.28 (2)
5.97 (1)
1.99 (1)
1.04 (0)

p‐value
‐
‐
0.0002
0.015
0.158
‐

AIC
558.01
572.30
571.29
561.98
558.00
559.05

BIC
570.56
584.85
575.48
570.35
566.37
571.61

Table A5.2
Predictors of medical follow‐up after HCV‐positive T&C: Interval‐weighted linear time model1
Variable
Adjusted
95% CI
p‐value
Odds Ratio
Time (per study interval)
0.64
0.47 – 0.89
0.007
Aware of HCV+ status at time of serotest
1.73
0.94 – 3.16
0.076
Ever received substance abuse treatment
1.64
1.01 – 2.75
0.045
Percent of income legal
0.99
0.97 – 1.00
0.063
Health insurance
2.04
1.18 – 3.53
0.010
Access to internet
1.82
1.14 – 2.90
0.012
Major depressive disorder
0.46
0.22 – 0.96
0.038
Generalized anxiety disorder
2.68
1.34 – 5.35
0.005
Ever used illicit methadone
0.32
0.13 – 0.79
0.014
Legal methadone use (past 6 months)
0.20
0.05 – 0.91
0.037
Marijuana use (past 6 months)
1.77
1.09 – 2.87
0.021
1

Discrete‐time survival analysis adjusted for RDS

Table A5.3
Predictors of medical follow‐up after HCV‐positive test and counseling: Discrete‐time model1
Variable
Adjusted
95% CI
p‐value
Odds Ratio
Aware of HCV+ status at time of serotest
1.69
0.93 – 3.08
0.084
Ever received substance abuse treatment
1.66
1.01 – 2.73
0.047
Percent of income legal
0.99
0.97 – 1.00
0.069
Health insurance
2.07
1.21 – 3.56
0.008
Access to internet
1.82
1.14 – 2.90
0.012
Major depressive disorder
0.48
0.23 – 0.97
0.040
Generalized anxiety disorder
2.64
1.34 – 5.20
0.005
Ever used illicit methadone
0.32
0.13 – 0.79
0.013
Legal methadone use (past 6 months)
0.21
0.05 – 0.90
0.036
Marijuana use (past 6 months)
1.73
1.07 – 2.79
0.026
1

Discrete‐time survival analysis adjusted for RDS
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